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Preface to “Host-Directed Therapies for Tuberculosis”
TB is considered one of the oldest documented infectious diseases in the world and is believed
to be the leading cause of mortality due to a single infectious agent. Mtb, the causative agent
responsible for TB, continues to afflict millions of people worldwide. Furthermore, one-third of the
entire world’s population has latent TB. Consequently, there has been a worldwide effort to eradicate
and limit the spread of Mtb through the use of antibiotics. However, management of TB is becoming
more challenging with the emergence of drug-resistant and multi-drug resistant strains of Mtb.
Furthermore, when administered, many of the anti-TB drugs commonly present severe complications
and side effects. Novel approaches to enhance the host immune responses to completely eradicate
Mtb infection are urgently needed. This Special Issue will, therefore, cover recent advances in the area
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Abstract: Mycobacterium tuberculosis (M. tb) is the etiological agent that is responsible for causing
tuberculosis (TB). Although every year M. tb infection affects millions of people worldwide, the only
vaccine that is currently available is the Bacille Calmette–Guérin (BCG) vaccine. However, the BCG
vaccine has varying efficacy. Additionally, the first line antibiotics administered to patients with
active TB often cause severe complications and side effects. To improve upon the host response
mechanism in containing M. tb infection, our lab has previously shown that the addition of the
biological antioxidant glutathione (GSH) has profound antimycobacterial effects. The aim of this
study is to understand the additive effects of BCG vaccination and ex-vivo GSH enhancement in
improving the immune responses against M. tb in both groups; specifically, their ability to mount an
effective immune response against M. tb infection, maintain CD4+ and CD8+ T cells in the granulomas,
their response to liposomal glutathione (L-GSH), with varying suboptimal levels of the first line
antibiotics isoniazid (INH) and pyrazinamide (PZA), the expressions of programmed death receptor
1 (PD-1), and their ability to induce autophagy. Our results revealed that BCG vaccination, along with
GSH enhancement, can prevent the loss of CD4+ and CD8+ T cells in the granulomas and improve
the control of M. tb infection by decreasing the expressions of PD-1 and increasing autophagy and
production of the cytokines interferon gamma IFN-γ and tumor necrosis factor-α (TNF-α).
Keywords: M. tb; BCG vaccination; immune exhaustion; glutathione; cytokines; granulomas
1. Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis (M. tb), continues to afflict millions of
people worldwide. In 2017, approximately 10 million people suffered from active TB and 1.6 million
died from this disease [1]. Additionally, one third of the world’s population is latently infected with
M. tb. Individuals infected with M. tb have a 5–15% lifetime risk of developing an active disease;
however, immunocompromised patients, such as people living with diabetes, malnutrition, human
immunodeficiency virus (HIV), or those who use tobacco, have a higher risk of developing active TB [1].
Common symptoms of active pulmonary TB are coughs with a bloody sputum, chest pains, weakness,
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weight loss, fever, and night sweats, eventually resulting in death when untreated [1]. M. tb infection
occurs due to inhalation of infectious aerosolized droplets, and the bacteria become seeded in the lower
respiratory tract where there is an enrichment of alveolar macrophages.
M. tb infection is initiated when the inhaled organisms are phagocytosed by these alveolar
macrophages [2]. In an immune-competent individual, the immune system is able to mount a
formidable response against M. tb, resulting in the formation of a solid and robust granuloma.
Composed of a compact aggregate of immune cells [3]. Mature macrophages in the granuloma can
fuse into multinucleated giant cells or differentiate into foam cells and epithelioid cells [3]. Alongside
macrophages, other cells, such as neutrophils, dendritic cells, natural killer cells, fibroblasts, CD4+ T
cells, and cytotoxic CD8+ T cells, are also recruited into the granuloma via cytokine mediation, leading
to containment of the M. tb infection [3]. The effector responses inside the granulomas along with a lack
of nutrients and oxygen causes M. tb to become dormant and remain latent in a nonreplicating state.
The contained M. tb within a granuloma in the lungs is commonly referred to as latent tuberculosis
(LTBI). A breakdown of immune responses designed to contain the infection in immunocompromised
individuals can result in reactivation of M. tb [4]. This dysregulation promotes liquification of caseum
and replication of M. tb, thereby promoting cavity formation and the release of M. tb to the exterior
during coughing, ultimately spreading the infection to other parts of the lungs [5]. Active M. tb is able
to deflect many host defense mechanisms via the cord factor, preventing phagosome-lysosome fusion
and the degradation of the bacilli [6].
In order to effectively contain M. tb within the granuloma, proper cytokine-mediated signaling
is essential to promote the necessary aggregation of cells [7]. Cytokines, such as interferon gamma
(IFN-γ) and tumor necrosis factor-α (TNF-α), play a critical role in both the innate and adaptive
immune responses against M. tb infection [8]. TNF-α produced by macrophages induces the formation
and maintenance of the granuloma. The T-helper 1 (Th1) subset of CD4+ T cells releases IFN-γ to
activate effector mechanisms in macrophages to not only kill M. tb intracellularly but also enhance the
effector functions of natural killer cells and cytotoxic T lymphocytes (CD8+) T-cells [9].
Once activated, CD8+ T cells and natural killer cells will then produce antimicrobial peptides,
perforin and granulysin, to destroy intracellular M. tb and the host cells.
The programmed death receptor 1 (PD-1), a negative regulator of activated T cells, is markedly
upregulated on the surface of pathogen-specific CD8+ T cells in mice [10]. Blockage of this pathway
restores the CD8+ T cell function and reduces the microbial load [10]. PD-1 is also expressed on the
surface of CD4+ T cells, with a positive correlation in regard to the microbial load and an inverse
correlation with the CD4+ T cell count.
Although the immune system has a robust defense system in place to combat M. tb infection,
it cannot always contain the infection. For this reason, host directed therapy is often required.
The Center for Disease Control (CDC) recommends four anti-TB agents to form the core of the treatment
regimen for patients with active TB [11]. These drugs include isoniazid (INH), rifampicin (RIF), ethambutol
(EMB), and pyrazinamide (PZA). This extensive drug regimen often leads to noncompliance to the TB
treatment, leading to multidrug-resistant (MDR)-TB, which is typically resistant to both INH and RIF [12].
Although a myriad of antibiotics can be used to treat this mycobacterial infection, there is only one
vaccine available to prime the immune system against M. tb, and that is the Mycobacterium bovis bacille
Calmette–Guérin (BCG) vaccine [13]. BCG used in this vaccine is an attenuated strain of M. bovis [13].
The WHO recommends that infants in countries with a high risk of M. tb infection be immunized with
the BCG vaccine soon after birth [13]. Because the incidence of TB is low in the United States, it is not
recommended for infants to be administered this vaccination. Additionally, estimates of the protective
efficacy of the BCG vaccine against adult pulmonary TB very widely, ranging from 0 to 80% [13].
Glutathione (GSH), a tripeptide antioxidant composed of glutamine, cysteine, and glycine, is found
ubiquitously amongst all cell types. GSH prevents cellular damage by detoxifying reactive oxygen
species (ROS) [14]. GSH exists in both a reduced state (rGSH) and an oxidized form (GSSG) [14]. rGSH
contains the antioxidant properties, while GSSG is a simple byproduct of the oxidation of GSH and
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has no antioxidant effects [14]. When exposed to ROS, two molecules of rGSH are converted to GSSG
and water [14]. Mycobacteria possess an alternative thiol, mycothiol, rather than GSH, to regulate
their redox homeostasis [15]. Due to this property, the presence of millimolar concentrations of GSH
(physiological concentrations) inside infected macrophages can lead to inhibition in the growth of
M. tb [15]. Our laboratory has previously demonstrated that GSH-enhancement by N-acetyl cysteine
(NAC) supplementation resulted in a significant reduction of M. tb burden among both healthy and
diabetic individuals [15]. Additionally, enhancement of GSH by means of NAC has the potential
implications of not only reducing the toxicity of anti-TB medications through GSH’s redox potential
but may possibly permit lower antibiotic dosage to promote enhanced patient compliance [15]. For this
reason, our lab tested the effects of liposomal glutathione (L-GSH) in the presence and absence of
sub-optimal concentration of INH and PZA in improving the ability of immune cells isolated from
BCG-vaccinated and non-vaccinated individuals to control M. tb infection.
In this study, we determined the additive effects of BCG vaccination and in vitro GSH-enhancement
in improving the ability of immune cells to control M. tb infection by measuring the differences in
the immune responses between vaccinated and non-vaccinated individuals. Fluorescent staining and
other antibody assays were also performed to determine the underlying mechanistic differences in
the ability of immune cells from vaccinated and unvaccinated groups to respond to L-GSH, cytokine
production, the surface expression of CD4, CD8, PD-1, and their ability to induce autophagy.
2. Materials and Methods
2.1. Peripheral Blood Mononuclear Cell Isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from the whole blood of both
BCG-vaccinated and non-BCG-vaccinated participants. Whole blood was layered in a 1:1 ratio onto
ficoll histopaque (Sigma, St. Louis, MO, USA), a high density-pH neutral polysaccharide solution,
for density gradient centrifugation (1800 rpm for 30 min) [15]. The PBMCs at the interface were
aspirated, washed twice with sterile 1X PBS (Sigma, St. Louis, MO, USA), and resuspended in Roswell
Park Memorial Institute (RPMI) (Sigma, St Louis, MO, USA) with 5% human AB serum (Sigma,
St. Louis, MO, USA). PBMC counts were determined by trypan blue exclusion staining.
2.2. Generation of In Vitro Granulomas
Our laboratory had successfully established an in vitro human granuloma model using PBMCs,
isolated from healthy subjects and individuals with type 2 diabetes [15–18]. These granulomas [15–18]
exhibit a physically well-demarcated aggregation of mononuclear cells with a denser central core
descending towards the periphery, which can be seen in the in vitro granulomas. Multi-nucleated
giant cells (MNGs hallmark of granulomas), T cells, and activated macrophages were also seen.
These features are reminiscent of early stage, cellular lung granulomas in experimental animal models
of TB, including rabbits and non-human primates. Such granulomas are also noted in the lungs
of mice during chronic M. tb infection. Using our previously published protocol, we developed
in vitro granulomas for the current study. Isolated PBMCs from the two study groups resuspended
in RPMI were infected with the Erdman strain of M. tb at a multiplicity of infection (MOI) of 0.1:1
cell ratio. 500 μL of the cell suspension containing PBMCs and M. tb were added to the 24-well
plates. To ensure proper adhesion of isolated immune cells, 24-well plates (Corning, Corning, NY,
USA) were coated with 0.001% poly-lysine (Sigma, St. Louis, MO, USA) overnight [15,16]. PBMCs
(6 × 105 cells/well) were distributed into the poly-lysine coated 24-well plates [15,16]. PBMCs in
the wells were either sham-treated or treated with the minimum inhibitory concentration (MIC), a
1.10 dilution, and a 1.100 dilution of two first-line antibiotics with and without 120 μM of liposomal
glutathione (L-GSH (Your Energy Systems)). This comprised INH (0.125 micrograms/mL) standalone,
120 μM of L-GSH, 1/10 INH (0.0125 micrograms/mL) standalone, 120 μM of L-GSH, 1/100 INH (0.00125
micrograms/mL) standalone, 120 μM of L-GSH, PZA (50 micrograms/mL), 120 μM of L-GSH, 1/10 PZA
3
J. Clin. Med. 2019, 8, 1556
(5 micrograms/mL) standalone, or 120 μM of L-GSH and 1/100 PZA (0.5 micrograms/mL) standalone
or 120 μM of L-GSH. All tissue culture plates with infected PBMCs were maintained at 37 ◦C with 5%
CO2 until they were terminated at 8 days post infection.
2.3. Termination of Granulomas
Following 8 days post infection, the minimum time needed for granuloma formation, in vitro granulomas
were terminated to determine the intracellular survival of M. tb [15,16]. To terminate, the supernatants of
each category were aspirated and collected into eppendorf tubes separated by a treatment group, and 250
μL of ice cold, sterile 1× PBS was replaced in lieu of the supernatants followed by gentle scraping of the
wells [15,16]. Scraping was done to ensure maximum recovery of granuloma lysates from the wells.
2.4. Colony Forming Units
Collected supernatants and lysates from termination were plated on 7H11 agar media (Hi Media,
Santa Maria, CA, USA) enriched with Albumin Dextrose Complex (ADC) (GEMINI, Calabasas, CA,
US). They were incubated for a minimum of 3 weeks and 3 days to evaluate the mycobacterial survival
under the different treatment conditions by counting the colony forming units (CFUs).
2.5. Cytokine Measurements
To measure cytokine levels, the sandwich enzyme-linked immunosorbent assay (ELISA) technique
was used. The assay was performed via the manufacturer’s protocol (Invitrogen, Carlsbad, CA,
USA). The cytokines measured were IFN-γ and TNF-α in the supernatants at 8 days post-infection
to determine the effects of the antibiotics with and without L-GSH treatments on cytokine levels in
BCG-vaccinated and non-vaccinated individuals.
2.6. Glutathione Measurements
Levels of GSH from the granulomas of non-vaccinated and BCG-vaccinated subjects were
measured by the colorimetric method using an assay kit from Arbor Assay (K006-H1). Granuloma
lysates were mixed in a 1:1 ratio with cold 5% sulfosalicylic acid (SSA), incubated for 10 min at 4 ◦C,
followed by centrifugation at 14,000 rpm for 10 min. The GSH was measured in the lysates following
the manufacturer’s instructions. The reduced GSH (rGSH) was calculated by subtracting the oxidized
glutathione (GSSG) from the total GSH.
2.7. Staining and Imaging Techniques
Each trial contained designated wells for fluorescent and light microscopic studies. Cover glasses
were allotted into 24-well plates for granuloma formation observation. The cover glasses were fixed with
4% paraformaldehyde (PFA) for 1 h at room temperature and washed three times with 1× PBS for 5 min
to remove cell debris. Fixed granulomas were then stained with Hematoxylin and Eosin (H&E) (Poly
Scientific, Bay Shore, NY, USA) for 2 min at room temperature and destained with deionized water. The
granuloma-stained cover glasses were mounted onto glass slides with HistoChoice mounting media.
Fixed granulomas on cover glasses were also permeabilized with Triton X for 2 min and stained overnight
with antibodies conjugated with fluorescent markers (CD4-PE, CD8-PE, and LC3B-PE). Cover glasses
were washed with phosphate buffer saline (PBS) and mounted on clean glass slides with mounting media
containing 4’,6-diamidino-2-phenylindole DAPI For PD1 staining, fixed granulomas on cover glasses
were permeabilized with Triton X for 2 min and incubated overnight with anti-PD1 (Pro-Sci), followed
by incubation for another 2 h with c-Myc. Cover glasses were then incubated overnight with secondary
antibodies (mouse anti-human) and conjugated with fluorescein isothiocyanate (FITC). Cover glasses
were mounted using a mounting media containing DAPI. Slides were observed under the fluorescent
microscope. Fluorescent images were captured, and the fluorescent intensity was quantified using the
ImageJ software (version 8, GraphPad, San Diego, CA, USA).
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2.8. Statistical Analysis
Statistical data analysis was performed using GraphPad Prism Software 8 using the unpaired t-test
with Welch correction for two sampled graphs. A one-way ANOVA (analysis of variance) was performed
for samples with greater than two categories with Tukey corrections. Reported values are the means with
each respective category. A p < 0.05 was considered significant. The p value style consisted of 0.1234 as
not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks (***),
and less than 0.0001 with four asterisks (****). A hash mark (#) indicates categories compared to control,
and an asterisk indicates categories compared to the previous category directly before it.
3. Results
3.1. Survival of the Erdman Strain of M. tb in the In Vitro Granulomas
We first tested the effects of L-GSH in controlling the growth of M. tb inside in vitro granulomas
derived from non-vaccinated and BCG-vaccinated subjects. Approximately, 25 μL of granuloma lysates
were plated on 7H11 growth media and incubated for four weeks to allow adequate time for M. tb
growth. In both non-vaccinated and BCG-vaccinated individuals, there was a significant reduction in
the bacterial load when standalone L-GSH was added (Figure 1A,B). We then measured the effects of
PZA added at various concentrations in the presence and absence of L-GSH in altering the viability of
M. tb. In the non-vaccinated group, there was a significant reduction in the viability of M. tb when
PZA was added at MIC and at the 1/10 lower dilution in the presence and absence of L-GSH when
compared to the untreated control (Figure 1C). In the BCG-vaccinated group, there was a significant
reduction in the viability of M. tb with the addition of L-GSH at all tested concentrations of PZA when
compared to the untreated control category and to the PZA-alone treated groups (MIC, 10 and 100
times lower than MIC concentrations). Notably, in the BCG-vaccinated group, PZA + L-GSH 120
resulted in complete clearance of M. tb (Figure 1D). Hematoxylin and Eosin staining was performed to
observe the morphology of the granuloma-like structures. Not surprisingly, we witnessed more solid
and robust granulomas when the bacterial load was higher. Correspondingly, the aggregation of the
granuloma was not as dense when the infection was cleared (Figure 1A,B). Additionally, we compiled
the results from the M. tb survival assays from the non-vaccinated and BCG-vaccinated individuals to
compare the same treatment categories. The BCG-vaccinated subjects displayed a significantly greater
ability to kill M. tb and/or containment potential than the non-vaccinated control. L-GSH treatment
resulted in a similar trend, exhibiting improved killing of M. tb in the granulomas from BCG-vaccinated
individuals when compared to the non-vaccinated subjects (Figure 1E). In regard to the comparison of
the PZA treated granulomas from non-vaccinated and BCG-vaccinated subjects, there was a significant
reduction in the viability of M. tb in all categories of the BCG-vaccinated individuals when compared
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Figure 1. Survival of the Erdman strain of Mycobacterium tuberculosis treated with Pyrazinamide and
Isoniazid in media. (A) M. tb growth in 7H11 agar media from non-vaccinated subjects with liposomal
glutathione (L-GSH) treatment along with Hematoxylin and Eosin (H&E) images of granuloma
like structures from eight-day terminated samples; (B) M. tb growth in 7H11 agar media from
Bacille Calmette–Guérin (BCG) vaccinated subjects with L-GSH treatment along with H&E images of
granuloma-like structures from eight-day terminated samples; (C) M. tb growth in 7H11 agar media
with pyrazinamide (PZA), 1/10 PZA, and 1/100 PZA treatment in the presence or absence of L-GSH
in non-vaccinated subjects; (D) M. tb growth in 7H11 agar media with PZA, 1/10 PZA, and 1/100
PZA treatment in the presence or absence of L-GSH in BCG-vaccinated subjects. (E) M. tb growth
in 7H11 agar media from non-vaccinated (white bar) and BCG-vaccinated (black bar) groups with
sham treatment and L-GSH treatment; (F) M. tb growth in 7H11 agar media in non-vaccinated and
BCG-vaccinated groups with PZA treatment. Data represents ± SE(standard error) rom experiments
performed from 14 different subjects. An unpaired t-test with Welch corrections was used in Figure (A).
Analysis of Figures B–F utilized a one-way ANOVA (analysis of variance) with Tukey test. The p value
style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**),
0.0002 with three asterisks (***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates
categories compared to control, and an asterisk indicates categories compared to the previous category
directly before it. (G) M. tb growth in 7H11 agar media with isoniazid (INH), 1/10 INH, and 1/100
INH treatment in the presence or absence of L-GSH in non-vaccinated subject; (H) M. tb growth in
7H11 agar media with INH, 1/10 INH, and 1/100 INH treatment in the presence or absence of L-GSH in
BCG-vaccinated subjects; (I) M. tb growth in 7H11 agar media in non-vaccinated and BCG-vaccinated
groups with INH treatment. Data represents ± SE from experiments performed from 14 different
subjects. Analysis of figures utilized a one-way ANOVA with Tukey test. The p value style consisted of
0.1234 as not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three
asterisks (***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates categories
compared to control, and an asterisk indicates categories compared to the previous category directly
before it.
The effects of INH in altering the viability of M. tb in the granulomas of non-vaccinated and
BCG-vaccinated subjects was also tested. In the non-vaccinated group, there was a significant reduction
in the viability of M. tb (almost undetectable colonies) when INH was added at MIC. There was
a significant reduction in CFUs in all categories, excluding the 1/100 INH category (Figure 1G).
In the BCG-vaccinated group, there was a significant reduction in the viability of M. tb at MIC
and in all categories (Figure 1H). When comparing INH treated granulomas in non-vaccinated and
BCG-vaccinated subjects, granulomas from BCG-vaccinated subjects controlled the M. tb infection
more effectively compared to the non-vaccinated groups in the presence and absence of INH and/or
L-GSH (Figure 1I).
7
J. Clin. Med. 2019, 8, 1556
3.2. Levels of the Reduced Form of GSH in the In Vitro Treated Granulomas
GSH levels were measured from the cellular lysates of the PBMCs using an assay kit from Arbor
Assays. The untreated granulomas from BCG-vaccinated individuals displayed higher levels of
the reduced form of GSH than non-vaccinated individuals. L-GSH treatment resulted in increased
levels of GSH in both the groups; however, there was a significant increase in the levels of GSH
from the granulomas of BCG-vaccinated individuals (Figure 2A). Treatment of granulomas from
BCG-vaccinated subjects with PZA in combination with L-GSH resulted in a significant increase in the
levels of GSH compared to the non-vaccinated group (Figure 2B). The levels of reduced forms of GSH
were also measured in the lysates of the eight-day terminated samples. In granulomas treated with
INH, BCG-vaccinated individuals had a significant increase in GSH in all categories in the presence
and absence of L-GSH (Figure 2C).
Figure 2. Levels of reduced GSH in PZA and INH treated granulomas. The GSH assay was performed
by the colorimetric method using an Arbor Assays kit. (A) Comparison of reduced GSH levels in
non-vaccinated and BCG-vaccinated groups; (B) GSH measurements in PZA treated granulomas from
non-vaccinated and BCG-vaccinated subjects. Data represents ±SE from experiments performed from
14 different subjects. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*),
0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four asterisks
(****). (C) The GSH assay was performed by the colorimetric method using an Arbor Assays kit.
GSH measurements in INH treated granulomas from non-vaccinated and BCG-vaccinated subjects.
Data represents ± SE from experiments performed from 14 different subjects. Analysis of figures
utilized a one-way ANOVA with Tukey test. The p value style consisted of 0.1234 as not significant,
0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than
0.0001 with four asterisks (****).
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3.3. Expression of CD4 in the In Vitro Granulomas
CD4 T cell expression was measured with an anti-CD4 antibody, conjugated with
Phycoerythrin-Cy5 (PE-Cy5). Analysis of CD4 T cells were corrected with the average mean fluorescence
of 4’,6-diamidino-2-phenylindole (DAPI). The addition of standalone L-GSH resulted in a significant
increase of the CD4 mean fluorescence in both vaccinated and non-vaccinated groups (Figure 3A,B).
CD4 expression levels were then measured from the pyrazinamide treatment categories in the presence
and absence of L-GSH, both in the non-vaccinated group and the BCG-vaccinated group. In the
non-vaccinated group, there was a significant increase in CD4 expression with L-GSH addition when
compared to both the control group and the standalone PZA. A dilution of 1/100 PZA standalone
treatment resulted in a significant increase in CD4 expression when compared to the control (Figure 3C).
In the BCG-vaccinated group, L-GSH addition resulted in a significant increase in CD4 expression when
compared to the sham treated group. The categories of standalone MIC PZA and 1/10 PZA resulted
in a significant increase in CD4 expression when compared to the control. Additionally, there was
a significant increase in the expression of CD4 in PZA + L-GSH and 1/10PZA + L-GSH categories
when compared to their standalone counterparts (Figure 3D). The compiled graph comparing the
sham treated versus L-GSH treated granulomas from non-vaccinated and BCG-vaccinated subjects
demonstrated a significant increase in the mean fluorescent intensity of CD4 in BCG-vaccinated subjects
with the addition of L-GSH (Figure 3E). In comparison to the non-vaccinated group, PZA treatment
resulted in a significant increase in CD4 expression in the granulomas from BCG-vaccinated groups
(Figure 3F). L-GSH + PZA treatment resulted in a further increase in the expression of CD4 in the
granulomas from BCG-vaccinated subjects compared to the non-vaccinated group (Figure 3F).
There is an increase in the viability potential of CD4 when L-GSH adjunctive treatment is added.
In the compiled data comparing the non-vaccinated group to the BCG-vaccinated group, in INH
treated granulomas, there was a significant increase in CD4 expression in the BCG-vaccinated groups
in most categories, except for MIC and 1/10 INH + L-GSH (Figure 3G,H).
Figure 3. Cont.
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Figure 3. Expression of CD4 in PZA and INH treated granulomas. CD4 T cells were measured with
an anti-CD4 antibody conjugated with (Phycoerythrin-Cy5) PE-Cy5. The nuclei of cells were stained
with (4’,6-diamidino-2-phenylindole) DAPI. The mean fluorescence of CD4 was corrected with the
mean DAPI fluorescence. (A) CD4 mean fluorescence from non-vaccinated subjects with L-GSH
treatment along with CD4 fluorescent images; (B) CD4 mean fluorescence from BCG vaccinated subjects
with L-GSH treatment along with CD4 fluorescent images; (C) CD4 mean fluorescence with PZA,
1/10 PZA, and 1/100 PZA treatment in the presence or absence of L-GSH in non-vaccinated subjects;
(D) CD4 mean fluorescence with PZA, 1/10 PZA, and 1/100 PZA treatment in the presence or absence of
L-GSH in BCG-vaccinated subjects; (E) CD4 mean fluorescence in non-vaccinated and BCG-vaccinated
groups with sham treatment and L-GSH treatment; (F) CD4 mean fluorescence in non-vaccinated and
BCG-vaccinated groups with PZA treatment. Data represents ± SE from experiments performed from
14 different subjects. An unpaired t-test with Welch corrections was used in Figure (A). Analysis of
Figures B–F utilized a one-way ANOVA with Tukey test. The p value style consisted of 0.1234 as
not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks
(***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates categories compared
to control, and an asterisk indicates categories compared to the previous category directly before it.
(G) CD4 mean fluorescence with INH, 1/10 INH, and 1/100 INH treatment in the presence or absence of
L-GSH in non-vaccinated subjects; (H) CD4 mean fluorescence with INH, 1/10 INH, and 1/100 INH
treatment in the presence or absence of L-GSH in BCG-vaccinated subjects; (I) CD4 mean fluorescence
in non-vaccinated and BCG-vaccinated groups with INH treatment. Data represents ± SE from
experiments performed from 14 different subjects. The analysis of figures utilized a one-way ANOVA
with Tukey test. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*),
0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four asterisks
(****). A hash mark (#) indicates categories compared to the control, and an asterisk indicates categories
compared to the previous category directly before it.
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3.4. Expression of CD8 in the In Vitro Granulomas
CD8 T cell expression was measured with an anti-CD8 antibody, conjugated with PE-Cy5. Analysis
of CD8 expression was corrected with the average mean fluorescence of DAPI. Individuals vaccinated
with BCG displayed the ability to maintain an elevated number of CD8 T cells in the granulomas
compared to the non-vaccinated individuals. The addition of L-GSH significantly increased the already
high levels of CD8 expression in the granulomas from BCG-vaccinated subjects (Figure 4A,B). A similar
trend was found with the PZA treatment groups. Among the non-vaccinated group, the addition
of L-GSH + PZA also significantly increased the levels of CD8 expression when compared to the
control group and to its counterpart with standalone antibiotics, with the exception of 1/100 PZA
+ L-GSH (Figure 4C). However, in the BCG-vaccinated group, there was a significant increase in
CD8 expression in all the PZA + L-GSH treatment groups (Figure 4D). This can be explained due to
the restorative effects L-GSH exhibits to diminish T cell exhaustion. When directly comparing the
non-vaccinated to BCG-vaccinated groups, there was no significance between the two sham-treated
and L-GSH-treated categories (Figure 4E). The general trend with PZA treatment demonstrates that,
on average, BCG-vaccinated subjects possess higher levels of CD8 expression, with significance found










Figure 4. Expression of CD8 in PZA and INH treated granulomas. CD8 T cells were measured with an
anti-CD8 antibody conjugated with PE-Cy5. The nuclei of cells were stained with DAPI. The mean
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fluorescence of CD8 was corrected with the mean DAPI fluorescence. (A) CD8 mean fluorescence from
non-vaccinated subjects with L-GSH treatment along with CD4 fluorescent images; (B) CD8 mean
fluorescence from BCG-vaccinated subjects with L-GSH treatment along with CD8 fluorescent images;
(C) CD8 mean fluorescence with PZA, 1/10 PZA, and 1/100 PZA treatment in the presence or absence of
L-GSH in non-vaccinated subjects; (D) CD8 mean fluorescence with PZA, 1/10 PZA, and 1/100 PZA
treatment in the presence or absence of L-GSH in BCG-vaccinated subjects; (E) CD8 mean fluorescence
in non-vaccinated and BCG-vaccinated groups with sham treatment and L-GSH treatment; (F) CD8
mean fluorescence in non-vaccinated and BCG-vaccinated groups with PZA treatment. Data represents
± SE from experiments performed from 14 different subjects. An unpaired t-test with Welch corrections
was used in Figure (A). Analysis of Figures B–F utilized a one-way ANOVA with Tukey test. The p value
style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**),
0.0002 with three asterisks (***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates
categories compared to the control, and an asterisk indicates categories compared to the previous
category directly before it. (G) CD8 mean fluorescence with INH, 1/10 INH, and 1/100 INH treatment
in the presence or absence of L-GSH in non-vaccinated subjects; (H) CD8 mean fluorescence with
INH, 1/10 INH, and 1/100 INH treatment in the presence or absence of L-GSH in BCG-vaccinated
subjects; (I) CD8 mean fluorescence in non-vaccinated and BCG-vaccinated groups with INH treatment.
Data represents ± SE from experiments performed from 14 different subjects. Analysis of figures
utilized a one-way ANOVA with Tukey test. The p value style consisted of 0.1234 as not significant,
0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than
0.0001 with four asterisks (****). A hash mark (#) indicates categories compared to the control, and an
asterisk indicates categories compared to the previous category directly before it.
In the presence of L-GSH, there was a significant increase in the levels of CD8 T cells compared
to the sham-treated and INH alone treated groups in the non-vaccinated group (Figure 4G). In the
BCG-vaccinated group, there was a significant increase in CD8 expression in all categories when
compared to the control group. Additionally, in the INH + L-GSH and 1/10 INH + L-GSH treatment
groups, there was a significant increase when compared to their standalone antibiotic counterparts
(Figure 4H). The mean fluorescence of CD8 in INH-treated granulomas showed a significant increase
in BCG-vaccinated subjects compared to non-vaccinated subjects in the presence and absence of INH
and/or L-GSH treatment (Figure 4I).
3.5. Expression of PD-1 in the In Vitro Granulomas
Programmed death 1 markers were measured with a conjugated horseradish peroxidase (HRP)
anti-PD1 antibody with an anti-mouse FITC secondary antibody. Analysis of PD-1 expression was
corrected with the average mean fluorescence of DAPI. Our lab observed a significant decrease in
the expression of PD-1 in response to L-GSH treatment in both non-vaccinated and BCG-vaccinated
subjects when compared to the sham-treated category (Figure 5A,B). When the granulomas were
treated with PZA, there was a significant decrease in PD-1 expression in the non-vaccinated group
among all categories when compared to the control group. Additionally, in response to L-GSH,
there was a significant decrease in PD-1 expression to the 1/10 PZA + LGSH and 1/100 PZA + L-GSH
when compared to their counterparts without L-GSH treatment (Figure 5C). In the BCG-vaccinated
group, there was a decrease in PD-1 expression across all categories when compared to the control,
and the addition of L-GSH further significantly reduced PD-1 expression when compared to the
antibiotics without L-GSH (Figure 5D). Between the non-vaccinated and BCG-vaccinated sham-treated
and L-GSH-treated groups, the BCG-vaccinated group had significantly less PD-1 expression in the
sham-treated control (Figure 5E). When treated with PZA, the granulomas from BCG-vaccinated
subjects demonstrated a significant decrease in PD-1 expression when compared to the non-vaccinated
subjects, with the exception of 1/10 PZA + L-GSH and 1/100 PZA + L-GSH (Figure 5F). We observed an
overall decreased expression of PD-1 from the granulomas of BCG-vaccinated subjects compared to
the non-vaccinated group. The levels of PD-1 were measured in granulomas treated with INH in the
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presence and absence of L-GSH. In the non-vaccinated group, the addition of L-GSH leads to a significant
decrease in PD-1 expression when compared to standalone antibiotics and the control. Additionally,
there was a significant decrease of PD-1 expression in the 1/10 INH and 1/100 INH categories when
compared to the control (Figure 5G). Similar to the non-vaccinated group, in the BCG-vaccinated
group, L-GSH addition to the INH treatment groups leads to a significant decrease in PD-1 expression
compared to the sham-treated and standalone antibiotic-treated categories. Additionally, there was
a significant decrease of PD-1 in the MIC INH and 1/100 INH categories (Figure 5H). Importantly,
the BCG-vaccinated group had significantly lower PD-1 levels at every category (INH treatment group









Figure 5. Expression of programmed death receptor 1 (PD-1) in PZA treated granulomas. PD-1 T cells
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were measured with an anti-PD1 primary monoclonal antibody conjugated with HRP. A secondary
anti-mouse PE-Cy5 antibody was added after blocking with 0.1% Triton X for 1 h. The nuclei of
cells were stained with DAPI. The mean fluorescence of PD-1 was corrected with the mean DAPI
fluorescence. (A) PD-1 mean fluorescence from non-vaccinated subjects with L-GSH treatment along
with PD-1 fluorescent images; (B) PD-1 mean fluorescence from BCG vaccinated subjects with L-GSH
treatment along with PD-1 fluorescent images; (C) PD-1 mean fluorescence with PZA, 1/10 PZA,
and 1/100 PZA treatment in the presence or absence of L-GSH in non-vaccinated subjects; (D) PD-1
mean fluorescence with PZA, 1/10 PZA, and 1/100 PZA treatment in the presence or absence of
L-GSH in BCG-vaccinated subjects; (E) PD-1 mean fluorescence in non-vaccinated and BCG-vaccinated
groups with sham treatment and L-GSH treatment; (F) PD-1 mean fluorescence in non-vaccinated
and BCG-vaccinated groups with PZA treatment. Data represents ± SE from experiments performed
from 14 different subjects. An unpaired t-test with Welch corrections was used in Figure (A). Analysis
of Figures B–F utilized a one-way ANOVA with Tukey test. The p value style consisted of 0.1234 as
not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks
(***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates categories compared
to the control, and an asterisk indicates categories compared to the previous category directly before
it. (G) PD-1 mean fluorescence with INH, 1/10 INH, and 1/100 INH treatment in the presence or
absence of L-GSH in non-vaccinated subjects; (H) PD-1 mean fluorescence with INH, 1/10 INH, and
1/100 INH treatment in the presence or absence of L-GSH in BCG-vaccinated subjects; (I) PD-1 mean
fluorescence in non-vaccinated and BCG-vaccinated groups with INH treatment. Data represents ± SE
from experiments performed from 14 different subjects. Analysis of figures utilized a one-way ANOVA
with Tukey test. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*),
0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four asterisks
(****). A hash mark (#) indicates categories compared to the control, and an asterisk indicates categories
compared to the previous category directly before it.
3.6. Cytokine Responses in the In Vitro Granulomas
Using the sandwich Enzyme-linked Immune Sorbent Assay (ELISA) method, we measured the
levels of TNF-α, a cytokine that causes the recruitment of other cells to form a granuloma, and IFN-γ,
which enhances the effector functions of macrophages to control intracellular M. tb infection. These
cytokines were measured from the supernatants of the terminated samples. TNF-α expression was
significantly increased in the control and L-GSH treatment categories of the BCG-vaccinated group
(Figure 6A). When the granulomas were treated with PZA, there was a general upwards trend in TNF-α
production from the BCG vaccinated categories, especially in the lower concentrations (Figure 6B).
However, due to complete bacterial clearance of the MIC treated categories, no further immunological
responses were needed, which is why we ascertain that the TNF-α levels at the lower concentrations
were low. There was a significant increase in IFN-γ in the BCG-vaccinated L-GSH treatment group
(Figure 6C). PZA treatment in the presence and absence of L-GSH resulted in a significant increase of
IFN-γ in the BCG-vaccinated group when compared to the non-vaccinated group (Figure 6D). Increased
production of IFN-γ may be the mechanism by which BCG-vaccinated subjects display enhanced
control over the bacteria. TNF-α and IFN-γ levels were measured in the supernatants of INH-treated
granulomas. TNF-α production was significantly elevated in the control category and in the lower
1/10 INH + L-GSH and 1/100 INH + L-GSH120 categories in BCG vaccinated groups. Treatment with
INH at MIC in the presence and absence of L-GSH resulted in complete inhibition in the growth of M.
tb, leading to homeostasis in the immune response, therefore resulting in significantly lower TNF-α
production in BCG-vaccinated subjects (Figure 6E). INH treatment of BCG-vaccinated granulomas in
the presence or absence of L-GSH resulted in significantly higher levels of IFN-γ when compared to
the non-vaccinated group (Figure 6F). This follows the same trend as those treated with PZA.
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Figure 6. Cytokine responses in PZA and INH treated granulomas. (A) Tumor necrosis factor-α (TNF-α)
levels from the supernatants of non-vaccinated and BCG-vaccinated sham-treated and L-GSH-treated
granulomas at eight days post-infection; (B) TNF-α levels from the supernatants of non-vaccinated and
BCG-vaccinated PZA treated granulomas at eight days post-infection; (C) interferon gamma (IFN-γ)
levels from the supernatants of non-vaccinated and BCG-vaccinated sham-treated and L-GSH-treated
granulomas at eight days post-infection; (D) IFN-γ levels from the supernatants of non-vaccinated
and BCG-vaccinated PZA treated granulomas at eight days post-infection. Data represents ± SE from
experiments performed from 14 different subjects. Analysis of figures utilized a one-way ANOVA
with Tukey test. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*),
0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four asterisks
(****). (E) TNF-α levels from the supernatants of non-vaccinated and BCG-vaccinated INH-treated
granulomas at eight days post-infection; (F) IFN-γ levels from the supernatants of non-vaccinated
and BCG-vaccinated INH-treated granulomas at eight days post-infection. Data represents ± SE from
experiments performed from 14 different subjects. Analysis of figures utilized a one-way ANOVA
with Tukey test. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk
(*), 0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four
asterisks (****).
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3.7. Autophagy Levels in the In Vitro Granulomas
Most assays for autophagy modulators use the autophagy marker protein LC3B as the readout
for autophagic activity. LC3B is a mammalian homolog of the yeast ATG8 protein, a ubiquitin-like
protein that becomes lipidated and tightly associated with the autophagosomal membranes [19].
Autophagy levels were therefore measured by LC3B detection, a key marker for the autophagosome
membrane structure. Increased levels of autophagy were observed in non-vaccinated individuals
(Figure 7A). L-GSH treatment enhanced the levels of autophagy in BCG-vaccinated subjects (Figure 7B).
In the granulomas of non-vaccinated subjects treated with PZA in the presence or absence of L-GSH,
there was a significant increase of LC3B levels in all categories treated with L-GSH compared to the
control and the categories without L-GSH treatment (Figure 7C). The same trend was found in the
BCG-vaccinated subjects, with the exception of 1/10 PZA + L-GSH, with the only significant increase
found when compared to the sham-treated group (Figure 7D). When comparing the non-vaccinated and
BCG-vaccinated individuals directly, the BCG-vaccinated individuals showed a significant decrease in
autophagy when compared to non-vaccinated individuals (Figure 7E). In response to PZA treatment
with L-GSH, the LC3B levels were higher in the non-vaccinated group than the BCG-vaccinated group
(Figure 7F). This may be a cell death mechanism to compensate for the low CD4 and high PD-1 in
non-vaccinated subjects. In INH-treated granulomas, the presence of L-GSH lead to a significant
increase in LC3B levels in the non-vaccinated group when compared to the sham-treated and the
lone antibiotic-treated groups (Figure 7G). In BCG-vaccinated individuals, the MIC standalone INH
showed a significant increase in autophagy compared to the control, and the addition of L-GSH to
this category lead to a significant increase compared to the sham-treated and MIC standalone-treated
groups (Figure 7H). When compared to the non-vaccinated group, there is less expression of LC3B
in BCG-vaccinated individuals (Figure 7I). L-GSH treatment of granulomas from BCG-vaccinated
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Figure 7. Autophagy levels in PZA- and INH-treated granulomas. Autophagy was measured with an
anti-LC3B antibody, conjugated with PE-Cy5. The nuclei of cells were stained with DAPI. The mean
fluorescence of LC3B was corrected with the mean DAPI fluorescence. (A) LC3B mean fluorescence
from non-vaccinated subjects with L-GSH treatment, alongside LC3B fluorescent images; (B) LC3B
mean fluorescence from BCG-vaccinated subjects with L-GSH treatment, alongside LC3B fluorescent
images; (C) LC3B mean fluorescence with PZA, 1/10 PZA, and 1/100 PZA treatment in the presence
or absence of L-GSH in non-vaccinated subjects; (D) LC3B mean fluorescence with PZA, 1/10 PZA,
and 1/100 PZA treatment in the presence or absence of L-GSH in BCG-vaccinated subjects; (E) LC3B
mean fluorescence in non-vaccinated and BCG-vaccinated groups with sham treatment and L-GSH
treatment; (F) LC3B mean fluorescence in non-vaccinated and BCG-vaccinated groups with PZA
treatment. Data represents ± SE from experiments performed from 14 different subjects. An unpaired
t-test with Welch corrections was used in Figure (A). Analysis of Figures B–F utilized a one-way ANOVA
with Tukey test. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*),
0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four asterisks
(****). A hash mark (#) indicates categories compared to the control, and an asterisk indicates categories
compared to the previous category directly before it. (G) LC3B mean fluorescence with INH, 1/10 INH,
and 1/100 INH treatment in the presence or absence of L-GSH in non-vaccinated subjects; (H) LC3B
mean fluorescence with INH, 1/10 INH, and 1/100 INH treatment in the presence or absence of L-GSH
in BCG-vaccinated subjects; (I) LC3B mean fluorescence in non-vaccinated and BCG-vaccinated groups
with INH treatment. Data represents ± SE from experiments performed from 14 different subjects.
Analysis of figures utilized a one-way ANOVA with Tukey test. The p value style consisted of 0.1234 as
not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks
(***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates categories compared to
the control, and an asterisk indicates categories compared to the previous category directly before it.
4. Discussion
Using in vitro granulomas derived from PBMCs, this study compares the differences in the
immune responses against M. tb in both BCG-vaccinated and non-vaccinated subjects. The effects
of GSH enhancement and the first line antibiotics (INH and PZA) in further enhancing the ability
of immune cells to control M. tb infection in both the groups was also evaluated. This study also
focuses on the mechanistic actions of PBMC-derived in vitro granuloma-like structures infected with
the Erdman strain of M. tb from non-vaccinated subjects and BCG-vaccinated subjects to illustrate their
immune response in a regulated environment. Our in vitro granulomas constituted cell types, such as
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macrophages, monocytes, and CD4 and CD8 T cells, all of which contribute to the immune responses
necessary for granuloma formation.
We observed an active replication of M. tb to in the sham-treated granulomas, from the
non-vaccinated group (Figure 1A). Furthermore, the addition of L-GSH led to a significant reduction
in the viability of M. tb (Figure 1A). This confirms previous findings that indicate that L-GSH possesses
antimycobacterial and immune-enhancing abilities. Furthermore, H&E staining was performed on
these granuloma-like structures to visualize the morphology of these structures. The absence of L-GSH
in the sham-treated category led to a formation of a sparse array of a granuloma, while L-GSH addition
to this sample formed a larger, more robust granuloma-like structure (Figure 1A). This demonstrates
the M. tb containment ability of L-GSH (Figure 1A). A similar trend was found in the BCG-vaccinated
subjects. Notably, the mycobacterial count in the sham-treated control of the BCG-vaccinated group
was 50% lower than the non-vaccinated subjects, and the addition of L-GSH lead to a further significant
reduction in the bacterial load (Figure 1B). H&E staining demonstrated that the sham-treated and
L-GSH-treated categories resulted in dense, robust granuloma-like structures, indicating the ability of
BCG-vaccinated individuals to mount a robust immune response to hinder M. tb growth.
Findings from our study indicate that treatment of in vitro granulomas with PZA + L-GSH and
INH+L-GSH resulted in a significant reduction in the bacterial load in the BCG-vaccinated samples
compared to the non-vaccinated samples (Figure 1F,I). This evidence suggests that BCG vaccination
enhances the ability of immune cells to effectively respond to GSH, PZA, and INH treatments, leading
to containment and killing of M. tb (Figure 1E,F,I).
Our results also indicate that BCG-vaccinated individuals innately had higher levels of GSH
when compared to the non-vaccinated group. Furthermore, L-GSH treatment resulted in a significant
three log increase in the levels of GSH in BCG-vaccinated subjects when compared to non-vaccinated
subjects (Figure 2A). PZA or INH treatments resulted in a significant increase in the levels of GSH in the
granulomas from the BCG-vaccinated group when compared to the non-vaccinated group (Figure 2).
Increased levels of GSH in the in vitro granulomas of BCG-vaccinated subjects further illustrate GSH’s
antimycobacterial activity, as indicated by low M. tb numbers in the CFU assays in the BCG-vaccinated
group in comparison to the non-vaccinated group.
Macrophages, CD4 and CD8 T cells play an important role in the control of M. tb infection.
Cytokines, such as TNF-α, interleukin-2 (IL-2), and IFN-γ, produced by macrophages and T cells
can enhance the effector responses against M. tb infection. In order to understand the immune
effector mechanisms, by which BCG-vaccinated versus non-vaccinated subjects contain M. tb infection,
we first measured the expression levels of CD4 in the granulomas. We initially observed the mean
fluorescence of CD4 in the granulomas cultured in the presence and/or absence of L-GSH, PZA and
PZA. We observed a dramatic, significant increase in the expression of CD4 in the granulomas from the
BCG-vaccinated group with L-GSH addition (Figure 3E), PZA addition at every concentration of the
antibiotic in the presence and absence of L-GSH, and INH + L-GSH treatment at every concentration
of the antibiotic (Figure 3F,I), indicating the efficacy of L-GSH, PZA, and INH to maintain the viability
CD4 T cells (Figure 3). This evidence also demonstrates that there is less CD4 T cell exhaustion in
BCG-vaccinated subjects.
CD8+ T cells have also been shown to produce IFN-γ that can augment effector functions to
control M. tb infection [20,21]. Importantly, CD8+ T cells possess cytolytic and cytotoxic functions to
kill M. tb infected cells via a granule-mediated function (using perforin, granzymes, and granulysin).
CD8 expression was determined in the granulomas of non-vaccinated and BCG-vaccinated subjects.
Higher CD8 expression was observed following L-GSH treatment in the granulomas from both
non-vaccinated and BCG-vaccinated subjects (Figure 4E). The addition of the PZA and INH in the
presence or absence of L-GSH resulted in an increase in the expression of CD8 in the BCG-vaccinated
category when compared to the non-vaccinated group (Figure 4F,I). Based on this general upward
trend in the expression of CD8 in BCG-vaccinated subjects, we conclude that individuals who have
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been vaccinated with BCG have not only higher CD4 T cells in the presence of L-GSH, but also elevated
levels of CD8 T cells.
A programmed death receptor 1 (PD-1) is a type I transmembrane protein expressed in immune
cells, such as T, B, and NK cells [22,23]. When it binds to its receptor, PD-L1, PD-1 strongly interferes
with T cell receptor (TCR) signal transduction [22,23]. PD-1 is a negative regulator of activated T
cells, and blockage of this path restores T cell functions [10,24]. For this reason, our lab quantified the
levels of PD-1 in non-vaccinated and BCG-vaccinated subjects. We observed a significant decrease
in the expression of PD1 in the sham control, PZA-treated, and INH-treated granulomas from
BCG-vaccinated individuals when compared to the same categories in the non-vaccinated group
(Figure 5F,I). The addition of L-GSH significantly reduced PD-1 expression in both non-vaccinated
and BCG-vaccinated groups (Figure 5A,B). These results indicate that low PD-1 expression in
BCG-vaccinated individuals leads to less T cell exhaustion during M. tb infection. Decreased PD-1
expression in BCG-vaccinated subjects, along with increased CD4 and CD8 expressions, resulted in
improved killing and containment of M. tb.
Cytokine production is a key determinate in the containment of a mycobacterial infection.
TNF-α released during initiation of host immune response against M. tb infection causes recruitment
of immune cells to form a granuloma while IFN-γ enhances effector functions of macrophages
to control an intracellular M. tb infection. While TNF-α is a vital cytokine in containing M. tb,
overexpression of TNF-α has been connected to multiple autoimmune inflammatory diseases [24–26].
Hence modulation of this cytokine is necessary. BCG-vaccinated individuals had higher levels of
TNF-α in the sham-treated category (Figure 6A). L-GSH has a modulatory effect on the production of
TNF-α in the BCG-vaccinated subjects (Figure 6A). Treatment of granulomas from BCG-vaccinated
subjects with lower concentrations of PZA and INH in the presence or absence of L-GSH led to higher
TNF-α production (Figure 6C,E). In the MIC concentration for both PZA and INH, TNF-α levels were
diminished in the BCG-vaccinated categories. This is because at MIC, the CFUs were undetectable and,
hence, there is restoration of homeostasis in the immune responses. L-GSH, PZA, and INH treatments
also significantly increased the production of IFN-γ in granulomas from BCG-vaccinated subjects
when compared to the non-vaccinated subjects (Figure 6D,F). This increased production of IFN-γ may
be the mechanism by which BCG-vaccinated subjects can control M. tb infection.
Recently, autophagy has also been recognized as an immune effector mechanism against
intracellular pathogens [27,28]. We observed that BCG-vaccinated individuals have a significant
decrease in the expression of LC3B when compared to non-vaccinated individuals in the presence
and absence of L-GSH, PZA and INH (Figure 7F,I). Our results indicate that autophagy could be a
compensatory mechanism by which non-vaccinated individuals combat an M. tb infection.
Our study findings illustrate that the addition of L-GSH to the antibiotic treatment elicited a
significant improvement in the granulomatous responses against M. tb infection. Our results indicate
that in non-vaccinated individuals there was increased survival of M. tb, low CD8 T cell counts,
and higher expression of PD-1. The addition of L-GSH to granulomas from non-vaccinated individuals
restored the viability of CD8 and CD4 T cells and promoted autophagy. In contrast to the non-vaccinated
subjects, BCG-vaccinated subjects innately able to kill M. tb more effectively, and this was accompanied
by increased levels of GSH, higher CD8 counts, and decreased expression of PD-1. The addition of
L-GSH to granulomas from BCG-vaccinated subjects lead to increased CD4 T cell viability, increased
TNF-α and IFN-γ production, decreased PD-1 expression, and diminished T cell exhaustion. Therefore,
we believe that enhancing GSH by means of L-GSH supplementation, along with anti-TB treatment,
would not only reduce toxicity and treatment duration, but can also enhance the host immune responses
to combat an active infection to promote enhanced treatment compliance.
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Abstract: The human response to Mycobacterium tuberculosis (Mtb) infection is affected by the
availability of iron (Fe), which is necessary for proper immune cell function and is essential for the
growth and virulence of bacteria. Increase in host Fe levels promotes Mtb growth and tuberculosis (TB)
pathogenesis, while Fe-supplementation to latently infected, asymptomatic individuals is a significant
risk factor for disease reactivation. However, the effect of Fe-supplementation on the host immunity
during latent Mtb infection remains unclear, due partly to the paucity in availability of animal models
that recapitulate key pathophysiological features seen in humans. We have demonstrated that rabbits
can develop non-progressive latency similar to infected humans. In this study, using this model
we have evaluated the effect of Fe-supplementation on the bacterial growth, disease pathology,
and immune response. Systemic and lung Fe parameters, gene expression profile, lung bacterial
burden, and disease pathology were determined in the Mtb-infected/Fe- or placebo-supplemented
rabbits. Results show that Fe-supplementation to Mtb-infected rabbits did not significantly change the
hematocrit and Hb levels, although it elevated total Fe in the lungs. Expression of selected host iron-
and immune-response genes in the blood and lungs was perturbed in Mtb-infected/Fe-supplemented
rabbits. Iron-supplementation during acute or chronic stages of Mtb infection did not significantly
affect the bacterial burden or disease pathology in the lungs. Data presented in this study is of
significant relevance for current public health policies on Fe-supplementation therapy given to anemic
patients with latent Mtb infection.
Keywords: tuberculosis; latent infection; pulmonary; rabbit; Mycobacterium tuberculosis; iron
supplementation; pathology; immune response; gene expression; Perls’ stain
1. Introduction
About a third of the world’s population is estimated to be infected with Mycobacterium tuberculosis
(Mtb), the etiological agent of tuberculosis (TB) [1,2]. In more than 90% of Mtb-infected individuals,
the immune response controls the infection, with Mtb persisting in a quiescent state [1]. These
latentlyinfected (LTBI) individuals can active Mtb replication and symptomatic disease upon host
immune compromising conditions [1]. Despite the role of host immunity in controlling Mtb infection,
the specific components that contribute to the establishment and/or reactivation of LTBI remain poorly
understood [3,4].
The human response to Mtb infection is affected by the availability of iron (Fe), which is necessary
for the proper function of the immune system [5]. About a quarter of the total Fe in the body is
present/stored in the hepatocytes and macrophages, while more than 60% is bound by hemoglobin,
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which is essential for the transfer and transport of oxygen [5]. About 5% of Fe in the body exist
in proteins involved in respiration and energy metabolism. Thus, Fe homeostasis is important
for normal cell growth and replication. In addition, several Fe-containing enzymes and proteins
such as myeloperoxidase, NADPH oxidase, nitric oxide synthase, indole-amine 2,3 dioxygenase and
lipoxygenase are directly involved in the host immune response to infection [5].
The World Health Organization (WHO) has identified Fe deficiency as the most common nutritional
disorder worldwide and has developed a strategy to eradicate anemia in TB-endemic countries that
includes increasing Fe intake through food fortification programs (https://www.who.int/nutrition/
publications/en/ida_assessment_prevention_control.pdf). However, this program does not screen
individuals for prior exposure to Mtb before starting therapy. This is a matter of concern because Fe
is also essential for the growth and virulence of Mtb. Since host Fe homeostasis is tightly regulated,
Mtb has to compete with the host cell to acquire Fe. As an intracellular pathogen, Mtb thrives mostly
in macrophages, which contain high levels of cytoplasmic Fe. First, the host produces Fe-binding
proteins, such as transferrin, ferritin and lactoferrin, in order to deprive invading pathogens of
Fe and macrophages sequester these host proteins [6,7]. Second, macrophages degrade senescent
erythrocytes, which release Fe-containing heme [8]. However, cytoplasmic Fe is not readily accessible
to the intracellular Mtb that survive in the phagosomes. To acquire host Fe, Mtb produces Fe-chelating
siderophores, which can scavenge Fe from non-heme host proteins and also facilitate the accumulation
of Fe within the phagosomes of infected macrophages [8]. In infected host cells, Mtb-containing
phagosomes can fuse with early endosomes, which contain transferrin, a protein that binds and
transports Fe in the blood, allowing Mtb to acquire transferrin-bound Fe [9]. Increases in host Fe
levels promote Mtb growth and TB pathogenesis [10–12]. This is evidenced by a recent study, which
showed that in Fe-deficient microenvironments, such as within hypoxic granulomas, Mtb adapts to a
non-replicating persistent state [13]. In addition, Esx-3, one of the type VII secretion systems of Mtb
that is involved in Fe-acquisition has also been suggested to interfere with the host functions that
restrict Fe-availability [14]. Moreover, Mtb mutant for esx3 was impaired for Fe-uptake [14]. Similarly,
Mtb mutant for mbtK, a mycobactin synthase gene involved in siderophore production, is defective
for Fe-acquisition and showed attenuated growth in vitro and in infected mouse lungs [15]. These
findings clearly show that Mtb utilizes several mechanisms to acquire Fe from the host and highlight
the importance of Fe acquisition for the growth and virulence of Mtb. Indeed, treatment of Mtb-infected
mice with Fe promoted bacterial growth in tissues and Fe-supplementation to anemic individuals has
been associated with reactivation of LTBI [16–18]. Thus, providing Fe-supplementation therapy to
asymptomatic LTBIs can be a significant risk factor for Mtb reactivation to symptomatic disease. In
order to develop new and/or better public health strategies to control TB in high-burden countries,
it is necessary to understand the role of host Fe homeostasis in host-pathogen interaction(s) during
Mtb infection.
Although Fe is known to promote Mtb growth, the effect of Fe-supplementation on the course of
initial Mtb infections and its influence on the host immunity to infection is unclear [10]. Commonly used
animal models, such as mice fail to recapitulate key pathophysiological features associated with LTBI.
Previously, we have demonstrated that Mtb CDC1551-infected rabbits can develop LTBI spontaneously,
as seen in humans [19]. In this study, we have used this LTBI rabbit model to investigate the effect of
moderate Fe-supplementation on the immune response and outcome of pulmonary Mtb infection.
2. Materials and Methods
2.1. Bacteria and Chemicals
Mycobacterium tuberculosis CDC1551 (Mtb CDC1551) strain was obtained from Dr. Thomas
Shinnick (Centers for Disease Control (CDC), Atlanta, GA), grown in Middlebrook 7H9 medium
supplemented with 10% OADC enrichment (Difco BD, Franklin Lakes, NJ, USA), aliquoted and stored
frozen at −80 ◦C. To prepare the inoculum for rabbit aerosol infection, stock vials were thawed and
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used as described previously [19]. All chemicals were purchased from Sigma (Sigma-Aldrich, St. Louis,
MO, USA), unless mentioned otherwise.
2.2. Experimental Design
Based on our previous experience with the rabbit model of LTBI and on the literature for
Fe-supplementation therapy, we set out to investigate: (a) The effect of Fe-supplementation during
“acute phase” of Mtb infection (i.e., from day 1 until 8 weeks post-infection) and (b). the effect
of Fe-supplementation of rabbits with a pre-established infection, i.e., starting at 8 until 16 weeks
post-infection, when untreated rabbits usually develop a non-progressive “chronic phase of infection”
that ultimately leads to LTBI [19].
2.3. Rabbit Infection and Treatment
Fifty-eight (n= 58) specific pathogen free, female New Zealand white rabbits (Oryctolagus cuniculus)
of ~2.5 kg body weight (Covance Research Products, Denver, PA, USA) were exposed to Mtb
CDC1551-containing aerosols using a “nose-only” delivery system to deliver ~3 log10 CFU into the
lungs, as described previously [19]. At 3 hours post-exposure (T = 0), six rabbits were euthanized,
lungs were harvested, and serial dilutions of the lung homogenates were plated on Middlebrook 7H11
agar media (Difco BD, Franklin Lakes, NJ, USA) to determine the number of bacterial colony-forming
units (CFU). Starting at day 1 or at 8 weeks post-infection, groups of rabbits (n = 6 per group
per time point) were randomly allocated and treated with 25 mg Fe-dextran (in 0.5 mL water) or
placebo (0.5 mL sterile dextran in water) injected intra-muscularly (biceps femoris), as described
previously [20]. Fe-supplementation was given 3 days a week for 8 weeks (i.e., either from day
1 until 8 weeks post-infection for acute infection, or from 8 to 16 weeks post-infection for chronic
infection) (Supplementary Figure S1). This dose of Fe-dextran III (75 mg/week) is equivalent to the
recommended pediatric human dose, which is non-toxic and well tolerated in rabbits [20]. The animals
were given food and water ad-libitum and, weighed periodically. At T = 0 (3 h), 4, 8, 12, and 16 weeks
post-infection, groups of rabbits (n = 6) were euthanized and organs were harvested to enumerate
Mtb CFU, histology and for total host RNA isolation. About 40% (by weight) of the lung was used for
preparing homogenates for Mtb CFU assays. Four animals were used as uninfected controls for Fe
estimation and gene expression analysis in the blood and lung tissues. Lung tissues for RNA isolation
were snap-frozen at −80 ◦C immediately after removal. Tissue sections for histology were fixed in
neutral formalin. Blood was collected in heparinized tubes and plasma was separated by centrifugation
and used in iron estimation assays. The blood pellet was used for total RNA isolation. All animal
procedures were performed as per the approved procedures of the Rutgers University Institutional
Animal Care and Use Committee.
2.4. Histology Staining
Formalin-fixed lung portions were paraffin embedded and cut into 5 μm sections for staining
with Hematoxylin–eosin (H&E) to visualize leukocytes, or Perls’ staining method for iron deposition
as reported previously [21]. The stained sections were analyzed using a Nikon Microphot DXM 1200C
microscope and photographed using NIS-Elements software (Nikon Instruments Inc., Melville, NY,
USA). Visualization of Mtb in infected rabbit lung sections was performed by immunohistochemistry
(IHC) using anti-Mtb antibody, as reported previously [22]. The IHC-stained sections were analyzed
and photographed using an EVOS FL fluorescence microscope (Thermo Fisher Scientific, Pittsburg,
PA, USA).
2.5. Measurement of Blood Parameters
Hematocrit was performed manually using heparinized capillary tubes (Fisher Scientific, Pittsburg,
PA, USA), as described previously [23]. Hemoglobin (Hb) was measured by using Hemoglobin Assay
Kit following the manufacturer’s instructions (Abnova, Walnut, CA, USA).
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2.6. Measurement of Plasma and Lung Tissue Iron
Total iron-binding capacity (TIBC), total iron, and percentage transferrin saturation (%Tf) in
plasma and lung homogenates of uninfected or Mtb CDC1551-infected rabbits with or without
Fe-treatment was determined using a colorimetric assay (TIBC and Serum Iron Assay Kit) following
the manufacturer’s instructions (BioVision, Milpitas, CA, USA). This experiment was performed in
duplicate with samples from three animals per time point per condition.
2.7. RNA Isolation from Rabbit Lung and Blood
Total host RNA was isolated as described earlier [24]. Briefly, lung tissue and whole blood
cell pellet were homogenized with 10× volume (wt/vol) of TRI reagent (Molecular Research Center,
Cincinatti, OH, USA). The homogenates were extracted with 0.3 volumes (vol/vol) of BCP solution
and the aqueous phase was mixed with an equal volume of 70% ethanol and passed through mini
spin columns (Qiagen Inc, Germantown, MD, USA). Following on-column digestion with DNaseI, and
subsequent washings, RNA was eluted with sterile water. The quality and quantity of the purified
RNA was assessed in a NanoDrop instrument (NanoDrop products, Wilmington, DE, USA).
2.8. Quantitative Real-Time PCR Analysis (qPCR)
Total RNA was reverse transcribed into cDNA using the AffinityScript QPCR cDNA Synthesis Kit
following instructions of the manufacturer (Agilent Technologies Inc., Santa Clara, CA). Quantitative
PCR (qPCR) experiments were performed on a Stratagene Mx3005p machine (Agilent Technologies,
Inc. Santa Clara, CA, USA) with cDNA and site-specific oligonucleotide primers of target genes, using
Brilliant III Ultra-Fast SYBR®Green QPCR Master Mix, according to the product instructions (Agilent
Technologies Inc., Santa Clara, CA, USA). No SYBR and no cDNA control samples were included
in one of the triplicate assays for each experimental time point. Housekeeping gene GAPDH was
included to normalize the levels of expression of test genes. Threshold cycle value (Ct) was determined
using MxPro4000 software and fold-change in gene expression was calculated from the formula 2–ΔΔCt,
where ΔCt is the difference in Ct between the test gene and GAPDH and ΔΔCt is the difference between
test and control conditions. Each experiment was repeated at least three times with cDNA from 3 to 6
animals per experimental time point per group. Supplementary Table S1 lists the description of tested
genes and primer sequences used in qPCR experiments.
2.9. Statistical Analysis
Statistical analysis was performed on data by one-way ANOVA followed by Tukey’s multiple test
comparison using GraphPad Prism-5 (GraphPad Software, La Jolla, CA, USA) and the mean ± standard
deviation values were plotted as graphs. For all the experimental data, p ≤ 0.05 was considered
statistically significant.
3. Results
3.1. Iron Parameters in Fe-Supplemented Rabbits during Acute or Chronic Mtb Infection
The effect of Fe-supplementation on the hematocrit and hemoglobin (Hb) content of rabbits
during Mtb-infection was measured at 4 and 8 weeks (acute) or 12 and 16 weeks (chronic) post-
infection/treatment.
An average hematocrit level of 42% and Hb content of ~14 g/L was observed at all time-points
(Supplementary Figure S2), and no significant difference in either the hematocrit or Hb levels was
observed in Mtb-infected rabbits with Fe- or placebo supplementation.
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3.2. Systemic and Lung Fe Levels in Mtb-Infected Rabbits with or without Fe-Supplementation
The total Fe binding capacity (TIBC), which is an indirect measure of free Fe, total Fe, and the
percent of Fe-saturated transferrin (%Tf) were measured in rabbit plasma and lung homogenate.
In the plasma, Mtb-infected rabbits with Fe-supplementation had significantly reduced TIBC,
accompanied by elevated total Fe and %Tf saturation, compared to placebo-treated animals at both
acute and chronic stages of infection (Figure 1A–C). In the lungs, no significant differences in TIBC
and %Tf saturation levels were observed between animals, irrespective of their Fe-supplementation
status during the acute phase of infection (Figure 2A,C). However, a higher Fe level was observed
in the lungs of Mtb-infected/Fe-supplemented animals, compared to placebo-treated animals during
acute (8 weeks) and chronic (16 weeks) post infection (Figure 2B). Fe-supplementation during chronic
Mtb infection significantly increased the lung TIBC only at 16 weeks, compared to the placebo-treated
rabbits (Figure 2A). Similarly, the Fe-supplemented rabbits also had a significantly higher Fe level in the
lungs at 4 and 12 weeks post infection, compared to the placebo-supplemented animals (Supplementary
Figure S3).
Figure 1. Effect of Fe-supplementation on plasma iron parameters of rabbits at 8 weeks (A,C,E) or
16 weeks (B,D,F) post-Mtb infection. Total iron binding capacity (TIBC) (top), total iron (middle),
and percent transferrin saturation (bottom) were determined in plasma samples of Mtb-infected and
placebo- or Fe-treated rabbits at the conclusion of treatment (i.e., 8 weeks or 16 weeks post-infection).
Data was analyzed by one-way Anova with Tukey’s multiple comparison test. Values plotted are mean
+/– sd with n = 4 per group per time point. * p < 0.05; ** p < 0.01.
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Figure 2. Effect of Fe-supplementation on the lung iron parameters of rabbits at 8 and 16 weeks post
infection. TIBC (top; A), total iron (middle; B) and percent transferrin saturation (bottom; C) were
determined in the homogenates of Mtb-infected and placebo (-) or Fe (+) treated rabbits. Data was
analyzed by one-way Anova with Tukey’s multiple comparison test. Values plotted are mean +/– sd
with n = 4 per group per time point. * p < 0.05.
3.3. Fe-Supplementation Does Not Affect Systemic Host Iron-Responsive Gene Expression during Mtb Infection
The effect of Fe-supplementation on the systemic expression of host iron-responsive genes,
including HFE1, HFE2 (HJV), HFE3 (TFR2), HAMP, SLC40A1 (FPN1), SLC11A2 (NRAMP2), HMOX1,
FTH1, LCN2, BMP6, and NFE2L2 (NRF2) was determined in Mtb-infected rabbit blood and lungs.
These genes are selected for their role in systemic Fe homeostasis as well as host response to Fe in
the system (Supplementary Table S2). Among these genes, HFE1 and HFE2 interact with the transferrin
receptor (TFR) and transferrin to modulate Fe transportation and availability. Transferrin also controls
expression of hepcidin (HAMP), the central regulator of systemic Fe [25,26]. Moreover, HFE2 is a
co-receptor for BMP, which drives HAMP expression through the SMAD signaling pathway [27]. The
Fe exporter, FPN, mediates export of Fe recycled in macrophages from erythrocytes and Fe absorbed
from the diet by enterocytes. HAMP binds to FPN and induces its internationalization and subsequent
degradation, thereby reducing Fe release from macrophages and enterocytes [28]. FTH1 is a subunit of
ferritin, an Fe-storage protein [29], and HMOX is an enzyme involved in heme catabolism, both of
which are regulated by host Fe status [30]. NRF2, a regulator of the antioxidant response, also regulates
FTH1 and FPN to maintain cellular Fe homeostasis [31]. LCN2 is an immune protein that sequesters
Fe-loaded siderophores and blocks bacterial Fe acquisition from infected host cells [32].
Consistent with activation of nutritional immunity, expression of all the tested Fe-responsive
genes was significantly up-regulated in the blood of Mtb-infected rabbits at 8 weeks (acute) (Figure 3A)
and 16 weeks (chronic) (Figure 3B) post infection, compared to the uninfected animals. Similar trend
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in the expression of these genes was noted in rabbit blood at 4 (acute) and 12 (chronic) weeks post
infection (Supplementary Figure S4). However, no significant differential expression was observed in
the blood between placebo- and Fe- supplemented Mtb-infected rabbits at any of the tested time points
(Figure 4A–D). These results suggest that Mtb infection induces the expression of host Fe-responsive
genes systemically and that Fe-supplementation does not lead to further up-regulation of these genes.
Figure 3. Expression of iron-responsive genes in Mycobacterium tuberculosis (Mtb)-infected rabbits at
4- and 12-weeks post infection. Data shown are expression of target genes in the blood (A,B) or lung
(C,D) during acute (8 weeks; A,C) or chronic (16 weeks; B,D) stages of infection. The gene expression
levels in Mtb-infected animals was calibrated with the corresponding levels in uninfected rabbits. Host
house-keeping gene (GAPDH) expression was used to normalize the level of target gene expression.
Data was analyzed by one-way Anova with Tukey’s multiple comparison test. Values plotted are mean
+/– sd with n = 4 per group per time point. All tested genes were statistically significant in Figure 3A–D.
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Figure 4. Effect of Fe-supplementation on the expression of host iron-responsive genes in Mtb-infected
rabbits. Heat map of selected immune response gene expression in the blood (A–D) or lung (E–H)
during acute (4 and 8 weeks; A,B,E,F) or chronic (12 and 16 weeks; C,D,G,H) stages of infection in
rabbits treated with Fe. The data from Fe-supplemented animals was calibrated with the corresponding
levels in placebo-treated animals. Host house-keeping gene (GAPDH) expression was used to normalize
target gene expression. Red color indicates up-regulation and blue color indicates down-regulation.
The gradient in color indicates the trend towards up- or down-regulation.
3.4. Fe-Supplementation Perturbs Expression of Host Iron-Responsive Genes in the Lungs of
Mtb-Infected Rabbits
The effect of Fe-supplementation on the expression of HFE1, HFE2, HFE3 (TFR2), BMP6, HAMP,
FPN1, NRAMP2, HMOX1, FTH1, NRF2, and LCN2 was assessed in rabbit lung homogenates. Expression
of all the tested genes was significantly up-regulated in the lungs of Mtb-infected/placebo treated
rabbits at 8 (acute) and 16 (chronic) weeks post-infection, compared to uninfected animals (Figure 3C,D).
A similar trend in the expression of these genes was noted in Mtb-infected rabbit lungs at 4 (acute)
and 12 (chronic) weeks post infection (Supplementary Figure S4). Fe-supplementation resulted in a
significant down-regulation of HFE3 (TFR2), HAMP, FPN1, and LCN2 while BMP6 and FTH1 were
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significantly up-regulated, compared to the placebo group, at 4 weeks post-infection (Figure 4E). At
8 weeks post-infection, expression of BMP6, HAMP, FPN1, FTH1, NRF2, and LCN2 was significantly
up-regulated, while HFE1 was significantly down-regulated by Fe-supplementation, compared to the
placebo group (Figure 4F). Expression of BMP6 and FTH1 were up-regulated by Fe-supplementation at
both, 4 and 8 weeks post-infection.
Among the tested Fe-responsive genes, expression of HFE1, BMP6, and HMOX1 at 12 weeks, and
HAMP at 16 weeks post-infection, was significantly up-regulated. At these later time points, expression
of HFE1, HFE3 (TFR2), and FPN1 was significantly down-regulated by Fe-treatment, compared to
the placebo group (Figure 4G,H). Taken together, these results indicate that Mtb infection induces
the expression of host Fe-responsive genes in rabbit lungs and that a subset of these genes were
differentially regulated by Fe-supplementation during acute and chronic stages of infection.
3.5. Fe-Supplementation Affects Systemic Expression of Host Immune Response Genes in Mtb-Infected Rabbits
To determine the association between host iron- and immune-response gene expression at
systemic level, we measured the expression of proinflammatory (IFNG, TNFA, IL1B, NOS2, and
IL6) and antiinflammatory (IL10, SMAD6, and SMAD7) genes in the blood of Mtb-infected and
placebo- or Fe-supplemented rabbits. While proinflammatory cytokines are involved in mounting a
protective immunity, anti-inflammatory molecules are involved in wound healing and dampening
of inflammatory response [10,19]. SMAD6 and SMAD7 are involved in HAMP expression through
BMP signaling [23] (Supplementary Table S2). In the blood and lung homogenates of Mtb-infected
rabbits, the level of expression of all tested genes was significantly up-regulated, at 8 (acute) and
16 (chronic) weeks post infection (Figure 5A–D). Similar trend in the expression of these genes was
noted in the blood and lungs at 4 (acute) and 12 (chronic) weeks post infection (Supplementary
Figure S5). In Mtb-infected/Fe-supplemented rabbits, expression of IFNG, TNFA, and IL1B was
significantly down-regulated, whereas expression of IL6 and SMAD6 was up-regulated, compared to
placebo-treated animals, at 4 weeks post-infection (Figure 6A). At 8 weeks post-infection, expression of
SMAD6 and SMAD7 was significantly up-regulated in the Mtb-infected/Fe-supplemented animals,
compared to placebo-treated rabbits (Figure 6B). Although expression of all the tested genes was
up-regulated in the blood at 12 and 16 weeks post-infection, Fe-supplementation did not significantly
alter the expression of any of the tested genes at these time points (Figure 6C,D).
These results suggest that expression of host immune-response genes was significantly
up-regulated systemically during acute and chronic stages of Mtb infection. Fe-supplementation
during acute, and not chronic stages of infection, reduced the expression of a subset of proinflammatory
genes while up-regulating antiinflammatory genes at the systemic level.
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Figure 5. Expression of host pro- and anti-inflammatory response genes in Mtb-infected rabbits at 8
and 16 weeks post infection. Data shown are expression of target genes in the blood (A,B) or lung
(C,D) during acute (8 weeks; A,C) or chronic (16 weeks; B,D) stages of infection. The gene expression
levels in Mtb-infected animals was calibrated with the corresponding levels in uninfected rabbits. Host
house-keeping gene (GAPDH) expression was used to normalize the level of target gene expression.
Data was analyzed by one-way Anova with Tukey’s multiple comparison test. Values plotted are
mean +/– sd with n = 4 per group per time point. All tested genes were statistically significant (p < 0.05)
in Figure 5A–D.
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Figure 6. Effect of Fe-supplementation on the expression of host immune response genes in Mtb-infected
rabbits. Heat map of selected immune response gene expression in the blood (A–D) or lung (E–H)
during acute (4 and 8 weeks; A,B,E,F) or chronic (12 and 16 weeks; C,D,G,H) stages of infection in
rabbits treated with Fe. The data from Fe-supplemented animals was calibrated with the corresponding
levels in placebo-treated animals. Host house-keeping gene (GAPDH) expression was used to normalize
target gene expression. Red color indicates up-regulation and blue color indicates down-regulation.
The gradient in color indicates the trend towards up- or down-regulation
3.6. Fe-Supplementation Perturbs Expression of Host Immune Response Genes in the Lungs of
Mtb-Infected Rabbits
Expression of IFNG, TNFA, IL1B, NOS2, IL6, IL10, NOS2, SMAD6, and SMAD7 was measured
at 4 and 8 (acute) or 12 and 16 (chronic) weeks post infection, using total RNA isolated from lung
homogenates of rabbits with placebo- or Fe-supplementation (Figure 6E–H). Compared to uninfected,
the level of expression of all tested genes were significantly up-regulated in the lungs during acute and
chronic stages of Mtb infection, irrespective of treatment status. In Mtb-infected/Fe- supplemented
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rabbits, expression of SMAD6 and SMAD7 was significantly down-regulated at 4 weeks, compared
to the placebo-treated animals (Figure 6E). At 8 weeks post-infection, expression of IL10, NOS2, and
SMAD7 was significantly up-regulated in the Fe-supplemented animals (Figure 6F).
Although the tested host immune response genes were highly up-regulated in the lungs at 12
and 16 weeks post-infection (Figure 5 D and Supplementary Figure S5), no significant difference
in the expression level was observed for any of the tested genes between Fe-supplemented and
placebo-treated rabbit lungs at these time points (Figure 6G,H).
These results suggest that Mtb infection up-regulates the expression of the tested host immune
response genes at the site of infection, and a subset of these genes were differentially regulated by
Fe-supplementation during acute infection.
3.7. Fe-Supplementation Did Not Affect the Lung Bacillary Load in Mtb-Infected Rabbits
To test whether Fe-supplementation affects the progression of initial infection to active disease
(acute phase), Mtb CFU was determined at 4 and 8 weeks in the lung homogenates of rabbits
with/without Fe-supplementation (Figure 7A). In Mtb-infected/placebo-treated animals, the lung
bacterial CFU increased significantly, reaching a peak load at 4 weeks (3log10 at T = 0 to 4.5 log10 CFU
at 4 weeks). A gradual reduction to 3.5 log10 CFU was seen at 8 weeks post-infection. Compared
to the placebo group, Fe-supplementation from day 1 onwards until 8 weeks post-infection, did not
significantly affect the bacterial CFU at both 4 and 8 weeks post-infection (Figure 7A). At these time
points, no significant difference in body weight was seen between Mtb-infected/Fe-supplemented and
placebo groups (Supplementary Figure S6).
Figure 7. Effect of Fe-supplementation on the lung bacillary load of Mtb-infected rabbits. Number of
bacterial colony-forming units (CFU) was determined in the lungs of rabbits supplemented with Fe or
placebo during acute (A) or chronic (B) stages of Mtb infection. Data was analyzed by one-way Anova
with Tukey’s multiple comparison test. Values plotted are mean +/– sd with n = 5 per group per time
point. Rx denotes treatment start time (day-1 or 8 weeks post-infection). The treatment was continued
for 8 weeks in both acute and chronic infection groups.
To test whether Fe-supplementation affects the pulmonary bacterial burden during the chronic
stage of infection, groups of Mtb-infected rabbits were supplemented with Fe or placebo for 8 weeks,
starting at 8-week post-infection (until 16-week post-infection) (Figure 7B). In the placebo-treated
animals, the lung bacillary load increased significantly with a peak burden of ~4.5 log10 CFU at four
weeks, followed by a gradual decrease in CFU until 16 weeks post-infection, when the mean bacterial
CFU was ~1.5 log10. Fe-supplementation of Mtb-infected rabbits from 8–16 weeks post-infection did
not significantly affect the net cultivable bacillary load in the lungs, compared to the placebo group.
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(Figure 7B). No significant difference in body weight was seen between Mtb-infected/Fe-supplemented
and placebo-treated rabbits at these time points (Supplementary Figure S6).
These results suggest that Fe-supplementation during acute or chronic stages of Mtb infection did
not significantly affect the bacterial burden in the lungs of infected rabbits.
3.8. Fe-Supplementation Did Not Affect Disease Pathology in Rabbit Lungs Infected with Mtb
To determine the effect of Fe-supplementation on TB immunopathology, we performed histologic
staining of lung, liver, and spleen tissues with H&E, Perls’ Fe-staining, or AFB staining to visualize
immune cells, Fe deposition, or Mtb, respectively (Figure 8).
Figure 8. Effect of Fe-supplementation on rabbit lung pathology at 8 weeks post Mtb infection.
Histopathology of rabbit lungs infected with Mtb CDC1551 at 8 weeks post infection with (A–C)
or without (D–F) Fe-supplementation showing disease pathology (H&E stain; A,D), iron deposition
(Perls’ iron stain; B,E) and Mtb (by immunohistochemistry; C,F). Dark arrows in (E) show cellular iron
deposition (blue color). White arrows in (C,F) show Mtb (purple color). The scale bar for all the images
is 50 μm. Sections were photographed at 400× (A,B,D,E) or 600× (C,F) of original magnification.
Analysis of the H&E-stained lung sections of Mtb-infected/placebo-treated rabbits at 4 and
8 weeks showed both histopathologic and disease manifestations, as described previously (Figure 8
and Supplementary Figure S7) [19]. No clearly visible, macroscopic sub-pleural granuloma was
seen in any of the infected rabbits at these time points. However, microscopic granulomas with
increased immune cell infiltration, including neutrophils and monocytes, were prominent at 4 and
8 weeks post-infection, although no central necrosis or caseation was noticed in the granulomas. The
granulomas in Mtb-infected/Fe-supplemented rabbit lungs at 4 and 8 weeks were very similar in size,
cellular architecture, and maturation state compared to Mtb-infected/placebo-treated animals (Figure 8
and Supplementary Figure S7).
Fe deposition in lung granulomas was evaluated by Perls’ staining method. Fe deposition was
observed in the histiocytes of lung lesions only in Fe-supplemented and not in placebo-treated rabbits
at 4 (Supplementary Figure S7) and 8 weeks post-infection/treatment (Figure 8B,E). At these time
points, the presence of Mtb was observed by immunohistochemistry using anti-Mtb antibody in the
lung lesions of both Fe-supplemented and placebo-treated, rabbits (Figure 8C, F and Supplementary
Figure S7).
Histologic analysis of the H&E-stained lung sections of Mtb-infected/placebo-treated rabbits
during chronic stages of infection (i.e, 12 and 16 weeks post infection) showed similar histopathology
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and disease manifestations, as described previously (Figure 9 and Supplementary Figure S8) [19].
No macroscopic sub-pleural lesions were observed in Mtb-infected rabbit lungs at these time points.
However, a small number of microscopic cellular aggregations, reminiscent of resorbing lesions, with
fewer immune cells present, were prominent at 12 weeks post-infection (Supplementary Figure S8). By
16 weeks, the lungs had a small number of cellular aggregates within the otherwise normal-looking lung
parenchyma, consistent with our previous report (Figure 9) [19]. The lung lesions of Fe-supplemented
rabbits at 12 and 16 weeks post-infection were very similar in size and cellular infiltration to the
placebo-treated animals at the same time points (Figure 9 and Supplementary Figure S8). Perls’ staining
method revealed Fe deposition in the lung cells at 12 and 16 weeks post-infection/treatment only in
the Fe-supplemented, and not in placebo-treated, rabbits (Figure 9B,E and Supplementary Figure S8).
At these time points, Mtb was present in the lung sections of Fe-supplemented and placebo-treated
animals (Figure 9C,F and Supplementary Figure S8).
These observations show that although elevated Fe was present in the lungs of Mtb-infected/
Fe-supplemented rabbits at both acute and chronic stages of infection, the course of infection and
disease pathology were not significantly altered by the supplementation.
Figure 9. Effect of Fe-supplementation on rabbit lung pathology at 16-weeks post Mtb infection.
Histopathology of rabbit lungs infected with Mtb CDC1551 at 16 weeks post infection with (A–C)
or without (D–F) Fe-supplementation showing disease pathology (H&E stain; A,D), iron deposition
(Perls’ iron stain; B,E) and Mtb (by immunohistochemistry; C,F). Dark arrows in (E) show cellular iron
deposition (blue color). White arrows in (C,F) show Mtb (purple color). The scale bar for all the images
is 50 μm. Sections were photographed at 400× (A,B,D,E) or 600× (C,F) of original magnification.
4. Discussion
Here, we have determined the effect of Fe-supplementation on the outcome of non-progressive,
pulmonary Mtb CDC1551 infection in a rabbit model. We show that Fe-supplementation alters
the level of TIBC, total Fe, and %Tf saturation, and expression of host iron- and immune-response
genes at the systemic and local levels during Mtb infection. Histologic examination of rabbit lungs
revealed accumulation of Fe in Mtb-infected/Fe-supplemented rabbits without significant change in
lung bacterial burden or disease pathology, compared to placebo-treated rabbits.
We observed significant up-regulation of Fe-responsive host gene expression in the lungs and in
the blood of rabbits during acute and chronic stages of Mtb infection. Our findings are consistent with,
and supported by previous reports in vitro and in mice, guinea pig, and non-human primate models of
pulmonary TB [33–36]. These studies have shown that during Mtb infection, Fe-responsive host genes,
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such as FPN1, FTH1, LCN2, HMOX1, and HAMP1, were differentially regulated as a host-protective
response against infecting bacteria. Some of these genes, such as HAMP1 and BMP6, were also
reported to be differentially expressed between lungs and liver of mycobacteria-infected mice [37].
Although gene expression in blood was not reported in these studies, we observed a differential
expression pattern of host iron-responsive genes between blood and lung cells in Mtb-infected rabbits.
We also observed differential TIBC, total Fe, and %Tf saturation levels between blood and lung
homogenate of Mtb-infected rabbits. The association between Fe parameters and host iron-responsive
gene expression in blood and lungs, and the relevance of this association to Mtb pathogenesis, requires
further investigation.
We observed that Fe-supplementation did not significantly alter the expression of host
iron-responsive genes that were up-regulated by Mtb infection in rabbit blood and lungs. The
up-regulation of these genes, including HAMP1, BMP6, and FTH1 in the lungs of Fe-supplemented
rabbits, is likely part of the host’s response to increased Fe accumulation. This is supported by histologic
examination, which revealed accumulation of Fe in the lungs of Mtb-infected/Fe-supplemented rabbits.
The induction of HAMP suggests down-regulation of Fe absorption and retention in macrophages;
increased HAMP expression through induction of BMP pathway has been reported in human immune
cells exposed to high Fe and in a mouse model of Mtb infection supplemented with Fe [38,39]. Taken
together, these results suggest that: (a) Mtb infection induces the expression of host iron-responsive
genes in rabbits—a subset of these genes were differentially regulated by Fe-supplementation and/or
by infection stage (acute versus chronic); and (b), host iron-responsive genes are differently regulated
in blood and lungs of Mtb-infected rabbits.
During the course of Mtb infection, expression levels of many host immune-response genes
were up-regulated both systemically (blood) and locally (lungs) in untreated rabbits. Most of these
genes, including TNFA, IL1B, IFNG, and IL10, were up-regulated during acute phase of infection and
their expression gradually declined, following immunological control the infection, at later stages
in Mtb-infected rabbits. These findings are consistent with our earlier reports on humans, and in
various animal models, that showed elevated expression of pro- and anti- inflammatory genes during
Mtb infection [19,40]. Fe-supplementation of Mtb-infected rabbits reduced the expression of these
host immune response genes systemically, particularly during acute phase of infection, but not in
the lungs. However, expression of IL6, IL10, SMAD6, and SMAD7 were up-regulated both in the
lungs and in blood of Mtb-infected/Fe-supplemented rabbits. This is consistent with previous findings
showing up-regulation of antiinflammatory cytokine genes, such as IL10, and down-regulation of the
proinflammatory Th1 response during Fe-supplementation [10]. Similarly, reduction of TNFA, IFNG,
and IL1B expression, with concomitant induction of IL10 expression, has been reported previously in
Fe-treated M. bovis BCG-infected mice, in Mtb-infected murine cell line J774, and in human mononuclear
phagocytes [37,41,42]. In addition, up-regulation of IL-6, as a consequence of an acute response due
to proinflammatory stimuli, has been shown to induce HAMP production in THP-1 cells, human
macrophages, and in a murine model [38,43,44]. Taken together, these findings are consistent with our
observations, and highlight the influence of Fe in the host immune response to Mtb infection.
We observed that perturbation of either the systemic or the local expression of host immune-
and iron-responsive genes during acute and chronic stages of Mtb infection did not affect the
outcome of infection. The organ bacillary loads, as well as disease pathology, were similar between
Fe-supplemented and placebo-treated Mtb-infected rabbits. This finding is consistent with the
data from recent studies in murine models of pulmonary TB with Fe-supplementation which
showed that neither Fe-supplementation nor Fe deficiency significantly altered TB susceptibility
and that Mtb load in infected organs was similar between Fe-supplemented/Fe-deficient and control
mice [15,34,37]. One possibility for this observation is that although elevated Fe accumulation was
noted in Mtb-infected/Fe-supplemented hosts, the Fe may not be available to infecting bacteria to
enhance their growth and/or to cause exacerbated disease [45]. Consistently, %Tf saturation levels
were significantly elevated in Fe-supplemented/Mtb-infected rabbits. Transferrin can sequester excess
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Fe in the host, thus restricting its availability to Mtb. In contrast, another study showed increased
Mtb growth upon Fe overload in a mouse model of pulmonary infection [46]. Similarly, exacerbated
disease burden was reported in a guinea pig model of Mtb infection with Fe overload [47]. One
reason for the discrepancy between these reports and our study on Mtb infection and Fe overload is
that most of the animal and human studies on Fe-supplementation were conducted in an active TB
condition, marked with progressive Mtb infection/disease, exacerbated inflammation, and bacillary
loads in affected tissues [46,47]. In contrast, the rabbit model of LTBI used in this study develops
non-progressive infection, with an initial protracted period of bacterial growth and a protracted
granulomatous response, followed by a gradual reduction in bacillary load and disease pathology,
both of which are efficiently controlled over time as the rabbits develop latency [19]. Therefore, the
impact of Fe-supplementation is likely affected by the model system, the nature of infecting Mtb strain,
and the subsequent host response.
The relationship between host Fe status and the outcome of Mtb infection is complex and not
yet fully understood [10,11,34,37,38]. Patients with active TB, and some animal models of Mtb
infection, have been shown to develop anemia, resulting from both Fe deficiency and/or chronic
inflammation [48–50]. However, the association between host susceptibility to mycobacterial infection
and host Fe status remains unclear [34,48–57]. A recent study showed that almost half of all patients
with active pulmonary TB had anemia due to Fe deficiency and/or inflammation, at the time of
diagnosis, and were recommended Fe supplementation as part of their therapy [57]. However, the
association between anemia and LTBI remains unclear, although anemia is considered as a major risk
factor for disease reactivation among these individuals [55–57]. Moreover, it has been reported that
Fe-supplementation is beneficial to the host in situations where Fe deficiency co-exists with active
disease showing exacerbated disease pathology [58]. In other conditions, where disease-associated
inflammation predominates without concurrent Fe deficiency, the overall benefit of Fe-supplementation
on the host is either negligible or insignificant [49]. In support of this notion, a study reported that
Fe-supplementation to 131 pulmonary TB patients did not influence Mtb growth or disease severity,
compared to the placebo group [49]. Similarly, reports on household contacts and LTBI individuals
showed no significant correlation between Fe parameters and progression of disease [56]. Thus, in
chronic, non-progressive Mtb infections, such as our study reported here, in which there was no
exacerbated inflammation and associated disease pathology, Fe-supplementation may not have a
significant influence on the outcome of Mtb infection.
In conclusion, our findings did not show a causal role for Fe supplementation and reactivation
of LTBI in terms of bacterial burden and tissue pathology, although we observed changes in host
gene expression associated with Fe-homeostasis and host immunity in Fe-supplemented animals,.
However, results from this study, which links moderate Fe-supplementation with the host immunity
during latent Mtb infection, should facilitate future investigations to determine the components of
immune system that modulate Fe-dependent responses and to identify Mtb factors that perturb host
Fe homeostasis.
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Abstract: While evidence is accumulating that platelets contribute to tissue destruction in tuberculosis
(TB) disease, it is still not known whether antiplatelet agents are beneficial to TB patients. We performed
this retrospective cohort study and identified incident TB cases in the Taiwan National Tuberculosis
Registry from 2008 to 2014. These cases were further classified into antiplatelet users and non-users
according to the use of antiplatelet agents prior to the TB diagnosis, and the cohorts were matched
using propensity scores (PSs). The primary outcome was survival after a TB diagnosis. In total,
74,753 incident TB cases were recruited; 9497 (12.7%) were antiplatelet users, and 7764 (10.4%)
were aspirin (ASA) users. A 1:1 PS-matched cohort with 8864 antiplatelet agent users and 8864
non-users was created. After PS matching, antiplatelet use remained associated with a longer survival
(adjusted hazard ratio (HR): 0.91, 95% confidence interval (CI): 0.88–0.95, p < 0.0001). The risk of
major bleeding was not elevated in antiplatelet users compared to non-users (p = 0.604). This study
shows that use of antiplatelet agents has been associated with improved survival in TB patients.
The immunomodulatory and anti-inflammatory effects of antiplatelet agents in TB disease warrant
further investigation. Antiplatelets are promising as an adjunct anti-TB therapy.
Keywords: tuberculosis; antiplatelet; aspirin; immunomodulation; survival; Taiwan
1. Introduction
Tuberculosis (TB) remains an important global infectious disease with an estimated 10 million
new cases and 1.6 million deaths in 2017 [1]. The World Health Organization (WHO) has set a goal of
eradicating TB as a public health problem, aiming to achieve 50% and 90% reductions in the global TB
incidence by 2025 and 2035, respectively [2]. TB remains an important infectious disease that causes
significant morbidity and mortality [3]. Though considered a treatable infectious disease, TB treatment
success rates and cure rates are still suboptimal [4]. The mortality rate from TB remains high, especially
in elderly populations, which can exceed 20% in patients older than 65 years [5]. Besides point-of-care
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diagnostic methods, the discovery of newer anti-TB agents and a more-thorough understanding of its
pathophysiology remain important clinical issues in combating this disease.
While the majority of TB studies regarding host immunity have focused on monocytes and
lymphocytes, several recent basic science studies have highlighted the role of platelets as a novel
participant in TB’s pathogenesis [6]. It was first observed that platelet activation status was correlated
with TB disease severity [7]. In active TB, a hypercoagulable state exists with an increased risk of
thrombosis, which improves after treatment [8]. Furthermore, it is now recognized that platelets play a
role in tissue destruction and pro-inflammation in TB disease [9]. In a recent study, active platelets
were present at sites of pulmonary TB, and a co-culture with platelets decreased the intracellular
killing of Mycobacterium tuberculosis and increased its replication [9]. Finally, another more recent
study further provided in vivo experimental evidence that infection-induced platelet activation is a
potential target for TB host directed therapy [10]. With accumulating evidence of platelet involvement
in TB’s pathophysiology, it was therefore intriguing to determine if the use of antiplatelet agents
would be beneficial for TB patients and could serve as a potential adjunct anti-TB agent. However,
no epidemiologic studies have examined this question.
We therefore initiated this population-based study to investigate the clinical impacts of antiplatelet
agents on the survival of TB patients. Through the linkage of the Taiwan National Tuberculosis Registry
(TNTR) database, the Taiwan National Health Insurance (NHI) database, and national mortality




The Institutional Review Board of Taipei Medical University approved the study (N201712019)
and waved the need for informed consent because this retrospective study used encrypted data and
presented no risk to participants.
2.2. Study Participants and Setting
This study was conducted by linking Taiwan NHI claims data, mortality data from the Department
of Statistics, Ministry of Health, and Welfare, and the TNTR [11]. The TNTR was established by the
Taiwan Centers for Disease Control (CDC) in 1996, and clinicians are obligated to report and register
every TB patient in Taiwan in the TNTR [12,13]. In addition, the registry system includes information
on TB characteristics, treatment courses, and clinical outcomes. Taiwan’s NHI is a universal healthcare
system that covers 96% of the residents of Taiwan (with a population of about 23 million) [14–17].
The inclusion criterion was incident TB cases who received anti-TB treatment identified from the
TNTR between 2008 and 2014. Patients with multidrug-resistant TB (MDRTB), with incomplete data,
or who were younger than 20 years were excluded.
2.3. Definitions and Data Collection
A diagnosis of TB and information regarding TB disease characteristics (smear positivity, culture
positivity, and a cavitation on chest radiography) were ascertained from the TNTR. In Taiwan,
a diagnosis of TB is made based on clinical symptoms, microbiological studies, radiographic findings,
and response to anti-TB treatment [18]. Comorbidities and clinical characteristics of TB patients were
extracted from the Taiwanese NHI claims database.
Antiplatelets were divided into aspirin (ASA, irreversible cyclooxygenase inhibitor) and non-ASA
antiplatelets, including adenosine diphosphate (ADP) receptor inhibitors, phosphodiesterase inhibitors,
glycoprotein IIB/IIIA inhibitors, and adenosine reuptake inhibitors (Supplementary Table S1).
Protease-activated receptor (PAR)-1 antagonists and thromboxane receptor antagonists were not
available in Taiwan during the study period and were therefore excluded from our study.
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Users of each category of drugs were defined as using more than 90 defined daily doses (DDDs)
of all drugs in the category within 180 days prior to the TB diagnosis. The calculation of DDD followed
its definition by the WHO, which is the assumed average maintenance dose per day for a drug used
for its main indication in adults [19].
We collected information (DDD) regarding the usage of statins, metformin, nonsteroidal
anti-inflammatory drugs (NSAIDs), and corticosteroids within 180 days prior to the TB diagnosis.
The definition of comorbidities is summarized in Supplementary Table S2. Immunocompromised
hosts were defined if they had either diabetes mellitus (DM), end-stage renal disease (ESRD), cancer,
cirrhosis of the liver, steroid use, a transplant, or acquired immunodeficiency syndrome (AIDS).
2.4. Outcomes
The primary outcome was patient survival after a TB diagnosis. Secondary outcomes were
mortality within 12 months after the diagnosis and major bleeding events after the diagnosis.
The definition of major bleeding was modified from the International Society on Thrombosis
and Haemostasis (ISTH) definition, and modifications were made due to the limitations of the claims
database [20,21]. The definition of major bleeding in our study was hospitalization after TB diagnosis
due to either an intracranial hemorrhage or a gastrointestinal hemorrhage necessitating a transfusion.
The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and
ICD-10-CM codes for defining major bleeding are described in Supplementary Table S3. The date of
hospitalization was the bleeding date.
All participants were followed up until end of the study period (31 December 2016).
2.5. Statistical Analysis
Proportions or means were used to describe the demographic, clinical, and radiographic
characteristics of TB patients. Inter-group differences were analyzed using an independent-sample
t-test for continuous variables and a chi-squared test for categorical variables. The propensity score (PS)
for the probability of being administered an antiplatelet agent was derived using a logistic regression
model including the potential confounders of age, sex, socioeconomic status, smear positivity, culture
positivity, cavitation, comorbidities, the Charlson comorbidity index (CCI) [22], coronary artery
disease, DM, ESRD, cancer, cirrhosis, ischemic stroke, chronic obstructive pulmonary disease, AIDS,
and hypertension.
A Cox proportional hazard regression model and logistic regression were, respectively, used to
analyze factors associated with patient survival and one-year mortality. PS-matching and PS-stratified
analysis were both performed. A cumulative incidence function was used to analyze major bleeding
events due to competing risks. Variables that remained significantly different after PS matching and
accounting for concomitant medications, including statins, steroids, metformin, and NSAIDs, were
further adjusted in the final model. We also performed survival and one-year mortality rate analyses
before PS matching, adjusted with variables used in the PS derivation. Subgroup analyses were
performed among immunocompromised TB patients, including DM, ESRD, psoriasis, cancer, and
steroids users. All data analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).
P < 0.05 of a two-sided test was considered statistically significant.
3. Results
3.1. Patients Identification
The patient recruitment process is illustrated in Figure 1. In total, 74,753 participants were
recruited for the study.
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Figure 1. Flowchart of patient recruitment.
3.2. Demographic Data
The clinical characteristics of identified participants are described in Table 1. Among 74,753 participants,
12.7% (n = 9497) were antiplatelet users, and 10.4% (n = 7764) were aspirin users. The mean age
was 63.6 years for all participants, and 69.8% were male. Compared to non-users, antiplatelet users
were older, more likely to be male, and had higher CCI scores. Antiplatelet users were also more
likely to have underlying comorbidities, except for AIDS, rheumatoid arthritis (RA), transplant, and
pneumoconiosis. Antiplatelet users were also more likely to be culture positive, but they were less
likely to be smear positive or have a cavitation on chest radiography. Antiplatelet users also took a
higher cumulative dose of statins, NSAIDs, metformin, and corticosteroids (Supplementary Table S4).
After PS matching, 8864 antiplatelet users, including 7281 ASA users and 1704 non-ASA antiplatelet
users, were matched with 8864 antiplatelet non-users. As for comorbidities, only the stroke incidence
significantly differed between the two groups (26.9% versus 24.5%, p < 0.001). Antiplatelet users also
took higher cumulative doses of statins and metformin (Supplementary Table S4).
For the subgroup analysis, a 1:1 comparison cohort was created for the ASA (7281 ASA users and
7281 matched antiplatelet non-users) and non-ASA antiplatelet (1704 non-ASA antiplatelet users and
1704 matched antiplatelet non-users) groups from the PS-matched population (Table 2). For the ASA
subgroup analysis, only the stroke incidence significantly differed between ASA users and matched
non-users (24.7% versus 22.6%, p = 0.003). ASA users also took higher cumulative doses of statins
and metformin and a lower dose of corticosteroids compared to non-users (Supplementary Table S5).
For the non-ASA antiplatelet subgroup analysis, only ESRD significantly differed between non-ASA
antiplatelet users and matched non-users (10.9% versus 8.0%, p = 0.005) (Table 2). Non-ASA antiplatelet
users also took a higher cumulative dose of statins compared to non-users (Supplementary Table S5).
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3.3. Survival Analysis
Before PS matching, antiplatelet use was associated with worse overall survival in the univariate
analysis (crude hazard ratio (HR): 1.88, 95% confidence interval (CI): 1.82–1.94, p < 0.0001) but better
overall survival in the multivariate analysis (adjusted HR: 0.90, 95% CI: 0.86–0.93, p < 0.0001). After PS
matching, antiplatelet use was associated with improved overall survival in the univariate (crude HR:
0.90, 95% CI: 0.87–0.93, p < 0.0001) and multivariate analyses (adjusted HR: 0.91, 95% CI: 0.88–0.95,
p < 0.0001). In the PS-stratified analysis, antiplatelet use was associated with improved overall survival
(adjusted HR: 0.91, 95% CI: 0.84–0.97, p < 0.0001).
After PS matching, non-ASA antiplatelet use was associated with worse overall survival compared
with ASA use (adjusted HR: 1.36, 95% CI: 1.26–1.46, p < 0.0001).
As for the comparison of survival between ASA users and antiplatelet non-users, ASA use was
associated with improved overall survival (adjusted HR: 0.90, 95% CI: 0.86–0.94, p < 0.0001) after
PS matching.
As for the comparison of survival between non-ASA antiplatelet users and antiplatelet non-users,
there was no association between non-ASA antiplatelet use and overall survival (HR: 1.00, 95% CI:
0.92–1.09, p = 0.996) after PS matching.
In the subgroup analysis, while immunocompromised patients had worse survival compared
with immunocompetent patients (adjusted HR: 1.47, 95% CI: 1.41–1.54, p < 0.0001), antiplatelet use
was associated with better survival among both immunocompromised patients (HR: 0.93, 95% CI:
0.89–0.98, p = 0.010) and immunocompetent patients (HR: 0.92, 95% CI: 0.86–0.97, p = 0.003). Results of
the subgroup analysis are illustrated in Figure 2.
 
Figure 2. Forest plot of the association between antiplatelet agent use and survival among different
groups of patients. Abbreviations: AIDS, acquired immunodeficiency syndrome; AS, ankylosing
spondylitis; DM, diabetes mellitus; ESRD, end-stage renal disease; and RA, rheumatoid arthritis
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3.4. One-Year Mortality Analysis
Before PS matching, antiplatelet use was associated with a higher one-year mortality rate (crude OR:
1.93, 95% CI: 1.83–2.03, p < 0.0001) in the univariate analysis but a lower one-year mortality rate
(adjusted OR: 0.91, 95% CI: 0.85–0.96, p = 0.0015) in the multivariate analysis. In the PS-stratified
analysis, antiplatelet use was also associated with a lower one-year mortality rate (adjusted OR: 0.90,
95% CI: 0.86–0.93, p < 0.0001).
After PS matching, antiplatelet use was also associated with a lower one-year mortality rate in
the univariate analysis (crude OR: 0.87, 95% CI: 0.82–0.93, p < 0.0001) and in the multivariate analysis
(adjusted OR: 0.91, 95% CI: 0.85–0.97, p = 0.004).
After PS matching, non-ASA antiplatelet use was associated with a higher one-year mortality rate
compared with ASA use (adjusted OR: 1.49, 95% CI: 1.32–1.69, p < 0.0001).
As for the comparison of survival between ASA users and antiplatelet non-users, ASA use was
associated with a lower one-year mortality rate (adjusted OR: 0.90, 95% CI: 0.83–0.97, p < 0.0001) after
PS matching.
As for the comparison of survival between non-ASA antiplatelet users and antiplatelet non-users,
there was no association between non-ASA antiplatelet use and the one-year mortality rate (OR: 0.94,
95% CI: 0.82–1.09, p = 0.439) after PS matching.
3.5. Major Bleeding Event Analysis
Incidences of major bleeding were 0.038, 0.035, 0.052, and 0.019 per person-year in antiplatelet
users, ASA users, non-ASA antiplatelet users, and antiplatelet non-users, respectively, in the study
population before PS matching.
Incidences of major bleeding were 0.037, 0.035, 0.052, and 0.040 per person-year in antiplatelet
users, ASA users, non-ASA antiplatelet users, and antiplatelet non-users, respectively, in the study
population after PS matching. There was no difference in the bleeding risk between antiplatelet users
and non-users in the cumulative incidence function analysis (subhazard ratio: 0.98, 95% CI: 0.90–1.06,
p = 0.604).
4. Discussion
In our population-based study, we found that antiplatelet use was associated with better overall
survival and lower 12-month mortality in pulmonary TB patients who received anti-TB treatment.
ASA, which constitutes the majority of antiplatelet agents, provided a survival advantage for TB
patients and may be a candidate for auxiliary anti-TB treatment. The safety profile of bleeding events
was tolerable among antiplatelet users.
The beneficial effects of antiplatelet agents may result from several mechanisms. First, platelets are
known to significantly upregulate monocyte matrix metalloproteinase (MMP)-1 expression, which is
associated with lung tissue destruction [10]. In another study, ASA also reduced MMP levels in diabetic
rats with induced coronary ischemia [23]. Second, platelets may also act through the modulation of
monocyte-derived chemokine and inflammasome activation, leading to a phenotype associated with
increased bacterial growth [9]. The increased lung destruction and unrestricted bacterial growth due to
platelet activation then leads to poor treatment responses and clinical outcomes. In another murine
model study, a low-dose of ASA in combination with other anti-TB agents had anti-inflammatory
effects and demonstrated a systemic decrease in neutrophilic recruitment and decreased levels of
acute-phase reaction cytokines in the late stage [24]. Interestingly, our study also found that TB
disease among antiplatelet users tended not to be cavitated on chest radiography and was also smear
negative. This supports antiplatelet agents having beneficial effects of controlling bacterial growth and
attenuating lung tissue destruction.
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Antiplatelet agents prevent platelet aggregation and are widely used in patients with coronary
heart diseases and cerebrovascular events [25]. Different antiplatelet agents inhibit platelet aggregation
through different mechanisms. ASA, the most common antiplatelet agent, mainly irreversibly blocks
the enzyme cyclooxygenase (COX)-1, thereby preventing the generation of thromboxane A2, a potent
platelet activator [26]. Adenosine diphosphate (ADP) antagonists, e.g., clopidogrel, inhibit platelet
aggregation by interacting with two purinergic receptors on platelets [27]. A survival advantage was
observed in ASA but not in non-ASA antiplatelets. Recently, purinergic pathways were implicated
in augmenting the response of killing intracellular pathogens, including M. tuberculosis, and also
controlling collateral damage [28]. Inhibiting purinergic pathways, as influenced by ADP receptor
antagonists, may have adverse impacts on TB treatment. This may explain why a survival benefit was
not observed in non-ASA antiplatelet groups. Another explanation may be that non-ASA antiplatelet
agents are usually second-line antiplatelets, indicating that non-ASA antiplatelet users may be more
disabled or morbid, thus diminishing the benefits of antiplatelet agents. In addition, interestingly,
while some basic scientific studies proposed the benefits of ASA, NSAIDs, and even cilostazol in TB
treatment, there are no such studies so far that highlighted ADP receptor antagonists as a potential
adjunct anti-TB treatment [29–31].
Another important and potential explanation for the finding that overall survival did not improve
in non-ASA antiplatelet users when compared to antiplatelet non-users may be that the survival benefit
was specific to ASA or NSAID effects but not to anti-platelet effects. ASA can modulate inflammatory
processes, such as neutrophil attraction and activation, through small lipid mediators such as thromboxane
A2 and prostaglandin E2 through COX pathways [32,33]. Interestingly, NSAIDs have been proposed as
an adjunct anti-TB treatment by modulating neutrophil recruitment [34,35]. ASA has also been shown
before to reduce neutrophil recruitment in active TB diseases [24]. The abovementioned mechanism may
also explain why ASA but not non-ASA antiplatelets were associated with improvement in TB survival.
There have been examples of antiplatelet agents being repurposed for other diseases [26,36,37].
An important instance is the use of antiplatelets in chemoprevention and the treatment of colorectal
cancer. It was hypothesized that activated platelets contribute to colorectal tumorigenesis and
metastatization via cell–cell interactions and release of tumor mediators [26,36]. A low-dose of ASA
therefore prevents tumor growth and metastasis by inhibiting platelet activation during different
stages of intestinal tumorigenesis [26,36]. As ASA is an old drug with a well-known safety profile,
so repurposing ASA use in anti-TB treatment is an attractive approach to improve TB control.
The TNTR is a web-based national TB notification system maintained by the Taiwanese CDC.
Since reporting suspected and confirmed TB diseases to the CDC is mandatory and demanded by
law in Taiwan, the completeness and timeliness of the TNTR are excellent. Additional patient and
disease characteristics, including smear and culture positivity, are available in the database [38].
Uncertain diagnoses of patients also undergo discussion in an expert meeting to ensure the quality of
the diagnoses. Linkage between the TNTR, NHI claims database, and mortality data therefore offered
the advantage of high diagnostic accuracy, data abundance, and longitudinal follow-ups [12,39].
Bleeding is a concern with use of antiplatelet agents. A low-dose ASA is defined as 75–325 mg
daily, and this is the most widely prescribed dosage of ASA used in cardiovascular diseases, but it still
carries an increased risk of bleeding [40]. While the vast majority of ASA tablets in Taiwan contain
75–100 mg of ASA, using a DDD of 90 within 180 days as a cutoff point correlated to a daily dose of
around 50–100 mg in our study. The bleeding risk in antiplatelet users was not increased in our study,
while the survival benefit remained. A low-dose of ASA may, therefore, be considered if ASA is to be
used as an auxiliary therapy for TB.
Other concerns remain regarding the use of antiplatelets in anti-TB regimens in addition to the
bleeding risk. Drug–drug interactions may also be another issue. For instance, ASA demonstrated
a modest antagonism against isoniazid [41,42]. Rifampicin increases the metabolite of clopidogrel,
augments antiplatelet activity, and could be associated with a higher bleeding risk [43]. These safety
and therapeutic issues should be taken into consideration and evaluated in future studies.
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In our study, the benefit of antiplatelet agents was evident among DM, ESRD, psoriasis, and
immunocompromised patients. Indeed, diabetes is associated with increased platelet reactivity, and
antiplatelet agents are commonly used for the primary and secondary prevention of cardiovascular
events [44,45]. ESRD is also associated with the prothrombotic status of platelet dysfunction [46].
In psoriatic patients, an enhanced cyclooxygenase activity with platelelet hyper-aggregation has been
observed [47]. In DM, psoriasis, and ESRD patients who develop active TB, the prothrombotic state
may be aggravated. In immunocompromised hosts, delayed and impaired innate immune responses to
invasion by M. tuberculosis are associated with disease status progression, as in the case of DM [48,49].
Furthermore, the treatment of TB patients with underlying comorbidities is a challenge, and treatment
outcomes are usually worse. The beneficial effects of antiplatelets in attenuating thrombosis and
immunomodulation in DM, psoriasis, ESRD, and immunocompromised patients may be more evident
and worthwhile.
Our study has some limitations. First, we were unable to exclude the possibility of unmeasured
confounders. For instance, antiplatelet users may have a higher socioeconomic status (Table 1) and tend
to be more health conscious. This may lead to the earlier detection of TB and better treatment outcomes.
We, however, included disease severity and a low income in our PS matching. Furthermore, while
antiplatelet agents are mainly used for the primary and secondary prevention of cardiovascular and
cerebrovascular diseases, which are usually the result of end organ damage of underlying diseases and
aging processes, antiplatelet users may be more fragile and disabled than non-users. Second, our study
was conducted in Taiwan, the population of which is of Asian ethnicity. Whether these findings can be
extrapolated to patients of other ethnicities remains unknown. In addition, this was a retrospective
study, and the conclusions drawn from our study can be speculative. Future interventional studies,
especially with a randomized design, should be conducted to prove this finding.
In conclusion, our study is the first population-based epidemiological study that has demonstrated
a survival benefit among active TB patients receiving antiplatelets. Our study points to a potential
direction for designing and discovering new anti-TB agents. Since ASA use was associated with better
overall survival and other antiplatelet drugs did not improve survival rates, this phenomenon may
suggest that the survival benefit may not be solely due to antiplatelet effects. Additional studies
investigating the underlying mechanisms of antiplatelet treatment against TB and co-morbidities
would also be of interest.
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Abstract: Background: Lung cancer misdiagnosed as tuberculosis (TB) is not rare, but the factors
associated with early diagnosis revision remain unclear. Methods: We screened the cases with TB
notification from 2007 to 2018 and reviewed those with misdiagnosis with a revised diagnosis to
lung cancer. We analyzed the factors associated with early diagnosis revision (≤1 months) and early
obtained pathology (≤1 months) using multivariable Cox regression. Results: During the study period,
45 (0.7%) of 6683 patients were initially notified as having TB, but later diagnosed with lung cancer.
The reasons for the original impression of TB were mostly due to image suspicion (51%) and positive
sputum acid-fast stain (AFS) (27%). Using multivariable Cox proportional regression, early diagnosis
revision was associated with obtaining the pathology early, lack of anti-TB treatment, and negative
sputum AFS. Furthermore, the predictors for early obtained pathology included large lesion size
(>3 cm), presence of a miliary radiological pattern, no anti-TB treatment, and a culture-negative
result when testing for nontuberculous mycobacteria (NTM) using multivariable Cox regression.
Conclusion: In patients who are suspected to have TB but no mycobacterial evidence is present,
lung cancer should be kept in mind and pathology needs to be obtained early, especially for those with
small lesions, radiological findings other than the miliary pattern, and a culture positive for NTM.
Keywords: tuberculosis; lung cancer; misdiagnosis; invasive procedure; revising
1. Introduction
Tuberculosis (TB) remains the most common infectious disease worldwide [1] and, according to
the World Health Organization (WHO), an estimated 10.0 million people had active TB, with 1.3 million
TB-related deaths reported in 2017 globally [2,3]. Diagnosis optimization is key to providing patient
care [4,5]. Although the diagnosis tools regarding TB have been improved in recent decades [6],
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there are still many cases diagnosed using clinical suspicion without positive culture evidence [7–10]
due to time constraints [11]. The most common reasons for a diagnosis based on clinical suspicion
are the radiographical or pathological presence of a lesion plus the difficulty and high risk of sample
collection other than sputum, or the presence of an acute illness in which TB is suspected without
improvement with broad-spectrum antibiotics [7]. In these cases, we might suggest empirical TB
treatment and closely follow-up the treatment response. Once a positive treatment response is achieved,
the diagnosis of TB can be suggested [7]. However, the accuracy of the tentative diagnosis of TB is still
imperfect, with some diagnoses inevitably being incorrect.
Among patients with misdiagnosis, lung cancer is a concern because of its increasing incidence and
high mortality [12,13]. In addition, both TB and lung cancer have similar pulmonary manifestations [14,15],
such as cavitary lesion, miliary pattern, and pleural effusion [16,17], which can be a trap for clinicians
to make a wrong diagnosis. Taiwan has an intermediate prevalence of TB. Differentiation of pulmonary
TB from lung cancer can pose a great challenge to clinicians. However, there have been few studies on
the timing of invasive diagnostic procedures for diagnosis of pulmonary TB, especially in TB-endemic
areas. In a previous study, 1.87% of initial TB notifications are finally diagnosed as lung cancer
instead [18]. The disease progression and mortality rate may be increased due to the delay in the
cancer diagnosis [19–21]. In addition, TB treatment could induce adverse events in this population
with initial misdiagnosis [7,22]. Therefore, in these situations, revising diagnoses early is important,
but unclear. We conducted this study to review the patients with an initial notification of TB and then
a revised diagnosis to lung cancer in a TB-prevalent area. We aimed to analyze the factors associated
with early revision that could improve current patient care.
2. Methods
2.1. Participant Enrollment
This retrospective study was conducted in multiple tertiary referral centers in Taiwan, with one
center located on each of the northern, middle, southern, and eastern sides of Taiwan, respectively.
Under the approval of the Institutional Review Board of Research Ethics Committee of the study
hospitals (NO. 201811047RINA), we screened patients aged ≥20 years that had been diagnosed with
tuberculosis by formal notification to Taiwan Centers for Disease Control from January 2007 to August
2018 (details are in the supplementary file). We identified the patients with a final diagnosis of non-TB
and among them, newly diagnosised lung cancer responsible for the pulmonary lesion. The patients
with pre-existing lung cancer, co-existence of TB and lung cancer, and human immunodeficiency virus
infection were excluded (Figure 1).
Figure 1. Flow chart of patient recruitment. TB, tuberculosis
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2.2. Clinical Information
We retrieved the participants’ clinical information, such as age, gender, and details of the initial
TB diagnosis from the respective hospital’s electronic records. Diagnosis date, anti-TB treatment,
and date of diagnosis revision were reviewed in the hospital’s record which was the same as that
of the Taiwan Centers for Disease Control because TB is a mandatory notification disease in Taiwan.
The reasons for initial impression and diagnosis revision were recorded. Radiographic lesions of chest
computed tomography (CT) scans were categorized as a nodule/mass, exudative lesion/consolidation,
or pleural effusion (Figure 2). In addition, the presence of cavitation and the miliary radiographic
pattern and location as well as the size of the main lesion were interpreted by pulmonologists in a
default report form. The new diagnosis of lung cancer was defined by a pathology/cytology report and
was responsible for the pulmonary lesion suspected to initially be TB. We also reviewed the methods
to obtain evidence for cancer diagnosis, the stage of lung cancer, and the mortality.
 
Figure 2. (A) Cavitary lung lesion, (B) bilateral multiple tiny lung nodules, and (C) consolidative lung
patch, which all mimicked pulmonary tuberculosis infection [18].
2.3. Outcome and Statistical Analysis
We defined revising the diagnosis early (<1 month) from TB to lung cancer as the primary
outcome and obtaining the pathology proof early (<1 month) for lung cancer as the secondary
outcome. Inter-group differences were compared using the Mann–Whitney U test or one-way
ANOVA for continuous variables, where appropriate, and the Chi square test for categorical variables.
A Kaplan–Meier (KM) curve was used for plotting the time against event curve and was compared
using the log rank test. We used Cox proportional hazard regression for analyzing time to diagnosis
revision and time to pathology proof obtainment. The clinical, radiological, and microbiological
relevant factors were included in the multivariable analysis and the final model was analyzed by
the stepwise method. All analyses were performed in SPSS version 19.0 (SPSS Inc, Chicago, IL,
USA). All Kaplan–Meier curves were plotted using the Prism software package (GraphPad Version
5.00, San Diego, CA, USA) and analyzed using the log rank test. A 2-tailed p value of <0.05 was
considered significant.
3. Results
3.1. Participant Demographics and Reasons for TB Suspicions
During the study period, a total of 6683 patients had been diagnosed in the study hospitals.
Among them, the diagnoses of 978 (14.6%) and 45 (0.7%) had been revised to non-TB causes and
lung cancer, respectively (Figure 1). The average age was 66 years and 71% were male (Table 1).
Acid-fast stain (AFS) was positive for 20% and the lesion size was around 4.7 cm. Pleural effusion
and radiological findings of cavitary and miliary patterns accounted 20%, 22%, and 11%, respectively.
The reasons for tentatively diagnosed TB included suspicion of radiological findings (n = 23, 51%),
positive AFS (n = 12, 27%), pathology suspicion for TB (n = 2, 4%), lymphocyte-predominant pleural
63
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effusion (n = 2, 4%), and other clinical suspicion (n = 8, 18%). Although all these patients were
diagnosed with TB, anti-TB treatment was only applied only in 82%. The average length of time to
obtain pathology and revise the diagnosis were 52.9 ± 74.4 days and 57.6 ± 44.7 days, respectively.






(n = 28) p Value
Age (years) 66.1 ± 13.3 69.3 ± 11.8 64.1 ± 13.9 0.242
Male sex 32 (71%) 11 (75%) 21 (75%) 0.460
Microbiology
AFS * 0.368
Positive 9 (20%) 4 (24%) 5 (18%)
Negative 35 (78%) 12 (71%) 23 (82%)
Culture * 0.147
NTM 8 (18%) 4 (24%) 4 (14%)
Negative 16 (36%) 3 (18%) 13 (46%)
Chest CT radiographic pattern 0.529
Nodular 28 (62%) 11 (65%) 17 (61%)
Consolidation 15 (33%) 6 (35%) 9 (32%)
Pleural effusion 2 (4%) 0 2 (7%)
Lesion size (cm) 4.7 ± 2.8 5.2 ± 3.0 4.4 ± 2.7 0.235
Bilateral 6 (13%) 3 (18%) 3 (11%) 0.710
Cavitation 10 (22%) 1 (6%) 9 (32%) 0.040
Miliary pattern 5 (11%) 3 (18%) 2 (7%) 0.277
Pleural effusion amount 0.388
<1/3 hemithorax 3 (7%) 2 (12%) 1 (4%)
1/3–2/3 hemithorax 5 (11%) 2 (12%) 3 (11%)
>2/3 hemithorax 1 (2%) 1 (6%) 0
The cause for TB suspicion 0.732
AFS (+) 12 (27%) 5 (29%) 7 (25%)
Pathology suspicion 2 (4%) 0 2 (7%)
Radiological suspicion 23 (51%) 9 (53%) 14 (50%)
Clinical suspicion 8 (18%) 3 (18%) 5 (18%)
Anti-TB treatment 37 (82%) 11 (65%) 26 (93%) 0.017
Days to obtain pathology 52.9 ± 74.4 46.9 ± 104.0 56.5 ± 50.7 0.009
Days to diagnosis revision 57.6 ± 44.7 15.1 ± 9.4 83.4 ± 37.0 <0.001
Abbreviations: AFS, acid-fast smear; CT, Computed Tomography; TB, tuberculosis; NTM, nontuberculous
mycobacteria. * One case and 21 cases were not tested for AFS and mycobacteria culture, respectively.
3.2. Final Diagnosis of Lung Cancer Status
The pathology proof was obtained using CT-guidance in 14 patients (31%), bronchoscopy
in 11 patients (24%), echo-guidance in 9 patients (20%), surgical procedure in 9 patients (20%),
and pleural/pericardial effusion in 2 patients (4%). In regard to the cancer stage, there were 26 patients
(58%) with metastases (stage 4) in the final diagnosis of lung cancer. In addition, 8 patients (18%) were
stage 1, 3 patients (7%) were stage 2, and 8 patients (18%) were stage 3. Regarding the cancer type,
59% of patients had adenocarcinoma, 12% had squamous cell carcinoma, 9% had small cell carcinoma,
15% had poorly-differentiated carcinoma, 1 had pleural cancer, and 1 had sarcomatoid carcinoma.
Nineteen patients (42%) died within 1 year follow-up.
3.3. The Factors Favored Early Revising Diagnosis
For patients with early diagnosis revision (n = 17, 32%) (Table 1), their age and demographics
were similar with those with late revision except they had less cavitation pattern (6% vs. 32%,
p = 0.040) and anti-TB treatment (65% vs 93%, p = 0.017) as well as lower time to obtain pathology
(46.9 days vs. 56.5 days, p = 0.009). In multivariable Cox proportion analysis, early obtaining
pathology was an independent factor associated with early diagnosis revision (Hazard ratio (HR):
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2.079 (1.041–4.154), p = 0.038). Anti-TB treatment (HR: 0.363 (0.120–1.097), p = 0.073) and positive AFS
(HR: 0.409 (0.146–1.148), 0.089) were borderline associated with diagnosis revision negatively (Table 2).
The Kaplan-Meier (KM) curve also showed that early obtaining pathology could be significantly
correlated with diagnosis revision earlier (Figure 3, p = 0.015).
Table 2. Multi-variable analysis for early diagnosis revision.
Characteristics
Multivariate
HR (95% C.I.) p Value
Early obtaining pathology vs late group 2.079 (1.041–4.154) 0.038
Empirical anti-TB treatment vs none 0.363 (0.120–1.097) 0.073
AFS positive vs negative/not done 0.409 (0.146–1.148) 0.089
Abbreviation: AFS, acid-fast smear; TB, tuberculosis. All clinical, radiological, and microbiological factors were
used for multivariable Cox proportional regression using stepwise methods.
Figure 3. Kaplan Meier curve for time to revise diagnosis to lung cancer according to time to obtain
pathology proof.
3.4. The Factors Associated with Early Obtained Pathology
We aimed to study the factors correlated with obtaining pathology proof early (n = 26, 58%).
The patients with early obtained pathology had similar age, sex, positive proportion of sputum AFS,
radiological pattern, and diagnosis evidence in comparison to those with late obtained pathology
(Table S1 in supplementary file). In contrast, larger mass size (5.8 vs. 2.7 cm, p < 0.001), more miliary
pattern (19% vs. 0%, 0.043), less anti-TB treatment (69% vs. 100%, p = 0.008), and shorter time to
diagnosis revision (42.2 vs 78.6 days, p = 0.006) were found in the early pathology group than in
late group.
We validated associated factors for early pathology by multivariable Cox proportional regression
analysis (Table 3). The analysis showed that lesion size (HR: 4.258 (1.659–10.924) per 1 cm increment,
p = 0.003), miliary radiographic pattern (HR:14.739 (4.096–53.038), p = 0.001), empirical anti-TB
treatment (HR: 0.305 (0.094–0.994), p = 0.049), and sputum culture positive for nontuberculous
mycobacteria (NTM) (HR: 0.310 (0.114–0.841), p= 0.021) were independent factors. The four independent
factors were shown to be statistically significant by KM curves (Figure 4).
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Table 3. Multi-variable analysis for early obtained pathology.
Characteristics
Multivariate
HR (95% C.I.) p Value
Miliary radiographic pattern vs. others 14.739 (4.096–53.038) <0.001
Lesion size per 1 cm increment 4.258 (1.659–10.924) 0.003
Empirical anti-TB treatment vs. no treatment 0.305 (0.094–0.994) 0.049
Culture (+) for NTM vs. negative and not done 0.310 (0.114–0.841) 0.021
Abbreviations: TB, tuberculosis; NTM, nontuberculous mycobacteria. All clinical, radiological, and microbiological
factors were used for multivariable Cox proportional regression using stepwise methods.
Figure 4. Kaplan–Meier curves for time to obtain pathology proof of lung cancer according to (A) lesion
size, (B) radiographic miliary pattern, (C) mycobacterial culture, and (D) anti-tuberculosis treatment.
NTM, nontuberculous mycobacteria; TB, tuberculosis.
4. Discussion
In the present study, the incidence of patients with misdiagnosis of TB was around 14.6% with
some revised early to obtain a diagnosis of lung cancer (0.7%). We conducted this study to review the
patients with initial notification of TB and then diagnosis revision to lung cancer in a TB-prevalent area.
This study found that obtaining pathology early could help diagnoses be revised earlier. In particular,
patients with a lesion size >3 cm, a radiologic miliary pattern, no anti-TB treatment, and cultures
negative for NTM could alert clinicians to arrange a pathology exam. In contrast, those with a lesion
size ≤3 cm, no radiologic miliary pattern, anti-TB treatment, and cultures positive for NTM are prone
to have a delayed diagnosis and our conclusion emphasizes that lung cancer should be kept in mind in
this subgroup and earlier pathology should be obtained if feasible.
The clinical and radiological manifestations of lung cancer and tuberculosis are similar in some
aspects [14,15]. For example, they are chronic and could have mass lesions, cavitation, and multiple
pulmonary lesions [16,17]. Many lung abnormalities, such as nodules or masses discovered by
chest radiography or CT scan, are considered suspicious enough to prompt immediate biopsy.
In certain clinical situations, it may be desirable to further characterize a pulmonary nodule by
imaging. Some investigations found that the CT characteristics of lung nodules or masses helped
in the differentiation of benign and malignant pulmonary lesions [19]. However, some patients
are at high risk of complications during invasive procedures, such as biopsy and bronchoscopy,
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so clinicians might try anti-TB treatment and follow the response to judge the diagnosis [7]. Therefore,
TB could be misdiagnosed in a patient actually having lung cancer. However, this could lead to a
delayed lung cancer diagnosis and late cancer treatment, which could lead to poorer outcomes [20–22].
In addition, anti-TB treatment would be unnecessary and its adverse effect and cost could be harmful
for patients [7,23]. In such a misdiagnosis, how to revise a diagnosis early is very important, especially
in a TB-prevalent area [24].
In the present study, early obtained tissue proof is a direct factor associated with shorter time to
diagnosis revision to lung cancer; it is easy to understand this causal relationship. Similar findings
have been found in our previous observation [18] but no study repeated the findings until the present
investigation. Although the misdiagnosis rate decreased, the harm is still present and needs to be
improved because it matters in delaying cancer diagnosis and influences prognosis. For patients with
positive sputum AFS, the diagnosis revision might be postponed. Because concomitant cancer and
infection is not uncommon [25,26], we would not totally exclude mycobacterial infection before we
yielded negative cultures for Mycobacterium tuberculosis, which is time consuming [11]. In regard to
patients with anti-TB treatment, the diagnosis revision is also late. This might be explained by the fact
that the overall status is highly suspected to TB, so the diagnosis revision would not be made until the
patient did not respond to the course of treatment. However, the treatment response for TB is usually
not fast [27,28].
Therefore, to obtaining pathology early would be a key step to decrease the time to revise the
diagnosis to lung cancer. There were four factors that significantly predicted early obtained pathology.
First, the size of the radiological lesion is important because large lesion always alert clinician more
and the treatment response would be easily to follow. Once it is clear the patient is unresponsive
to treatment and the lesion is huge, i.e., >3 cm, the clinician will favor further tissue proof if no
contraindications. Second, the miliary pattern can exist in both TB and lung cancer [29,30]. However,
the miliary pattern in lung cancer usually shows bigger, multiple nodules and indicates terminal
cancer with metastasis, which hints to physicians to think of cancer instead of TB. Third, no anti-TB
regimen and cultures negative for NTM indicate a low chance of mycobacterial infection, so the tie to
obtain pathology might be early in clinical practice. In fact, even if sputum culture is positive for NTM,
the clinical colonization of NTM is not low [31], so the diagnosis needs to be re-considered seriously.
In contrary, those with late obtained pathology require us to pay attention; they usually have small
lesions, receive anti-TB treatment, have cultures positive for NTM, and no miliary pattern. However,
the validation for the four-factor model is needed in the future.
Several limitations existed in this study. First, this is a retrospective study and different groups
are not identical in demographics. In addition, no standard protocol was implemented for the
procedure to obtain pathology. Among the technical part, radiology follow-up, CT acquisition protocol,
and post-processing are missing. Slice acquisition, respiratory artifacts, and dose-length product (DLP)
radiation dose all could have affected the results. All these elements would be required to determine
the potential clinical impact of this study. Third, the case number is small, although we did review the
cases from four medical referral centers. If the parent population focused on TB notification cases,
it would underestimate the percentage of lung cancer mimicking TB.
In conclusion, we found there is small proportion (0.7%), but not a rare amount, of cases of lung
cancer initially misdiagnosed as TB. Under such misdiagnosis, obtaining pathology early is a solution
to revising the diagnosis early. For those with small lesions, radiological findings other than miliary
pattern, receiving empirical anti-TB treatment, and sputum cultures positive for NTM, the time to
obtain pathology is longer and we should carefully monitor the treatment response and dynamic lesion
change in these patients. Further tissue proof is suggested, especially in patients without obvious
treatment response or definite TB evidence.
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Abstract: There has been an alarming increase in the incidence of Type 2 Diabetes Mellitus (T2DM)
worldwide. Uncontrolled T2DM can lead to alterations in the immune system, increasing the risk
of susceptibility to infections such as Mycobacterium tuberculosis (M. tb). Altered immune responses
could be attributed to factors such as the elevated glucose concentration, leading to the production of
Advanced Glycation End products (AGE) and the constant inflammation, associated with T2DM.
This production of AGE leads to the generation of reactive oxygen species (ROS), the use of the
reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) via the Polyol pathway,
and overall diminished levels of glutathione (GSH) and GSH-producing enzymes in T2DM patients,
which alters the cytokine profile and changes the immune responses within these patients. Thus,
an understanding of the intricate pathways responsible for the pathogenesis and complications in
T2DM, and the development of strategies to enhance the immune system, are both urgently needed
to prevent co-infections and co-morbidities in individuals with T2DM.
Keywords: type 2 diabetes; co-morbidities; co-infections; cytokines; inflammation; redox
imbalance; antioxidants
1. Introduction
1.1. Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus is a prevalent disease throughout the world. The World Health
Organization (WHO) reports that an estimated 422 million people all over the world are living with
diabetes. The WHO projects that diabetes will be the seventh leading cause of death in 2030 [1].
In the United States, the Center for Disease Control (CDC) reports that 30.3 million people have
diabetes, with approximately 23.1 million people diagnosed every year and a staggering 84.1 million
Americans in pre-diabetic stage [2]. Tuberculosis (TB) is a serious threat for people living with diabetes.
In 2017, 20% of people with TB in the United States also had diabetes. Currently, one third of the
population of the world is infected with latent Mycobacterium tuberculosis (M. tb) [3]. At this stage, the
individual is not infectious; however, TB can be reactivated as a result of granuloma liquefaction due
to immunodeficiency or immunocompromisation [4], as in the case with individuals suffering from
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Type 2 Diabetes Mellitus (T2DM) [5]. Due to the high prevalence of diabetes worldwide, necessary
measures must be taken to understand, prevent, and treat T2DM.
Insulin, a peptide hormone produced by beta cells within the pancreas, facilitates the absorption
of glucose into cells from blood, in order to maintain proper glucose levels [6]. T2DM is a disease
characterized by the inability of the body to produce sufficient insulin, or the development of insulin
resistance [7]. As a result, T2DM’s state of insufficient insulin production or insulin-resistance can have
detrimental complications, including macrovascular diseases such as hypertension, coronary artery
disease, heart attacks and strokes; or microvascular diseases such as neuropathy, nephropathy, and
cancer [8]. In order to effectively reduce the incidence of T2DM worldwide and prevent concurrent
infections, efforts must be undertaken to discern the etiology, to create rationale treatments for
symptomatic patients, and to develop preventive measures.
1.2. Pathogenesis in T2DM
Diabetes complications resulting from an impaired glucose metabolism have been associated with
retinopathy, nephropathy, and polyneuropathy [9]. When present, excess glucose is not oxidized and
is shunted to the polyol pathway, consisting of two enzymes—aldose reductase (AR) and sorbitol
dehydrogenase (SDH) [10]. AR reduces glucose to sorbitol in the presence of its co-factor, NADPH;
SDH, with its co-factor nicotinamide adenine dinucleotide (NAD+), converts sorbitol to fructose—a
more potent nonenzymatic glycation agent than glucose. Thus, an increase in glucose flux through the
polyol pathway (as happens in T2DM) will decrease the available NADPH and increase the production
of Advanced Glycation End products (AGE), leading to oxidative stress in a pathway we discuss
later in this review [11]. The SDH oxidation of sorbitol to fructose also causes oxidative stress due
to the co-factor conversion of NAD+ to NADH, the substrate for NADH oxidase which generates
reactive oxygen species (ROS) [12]. Elevated sorbitol levels have also been associated with cellular
and organ damage by directly depleting myoinositol (MI). This MI deficiency alters the metabolism of
phosphoinositides and reduces diacylglycerol (DAG), inositol triphosphate (IP3) and protein kinase
C (PKC) activation, resulting in a reduction in NA+/K+ ATPase pump activity. Metabolic pathway
derangement causes conductance abnormalities, resulting in neurological complications such as the
neuropathy observed in diabetic patients [10]. Additionally, SDH enzyme deficiency in nervous tissues,
the kidney, and the lens and retina of the eye lead to the elevation of sorbitol, leading to the development
and progression of retinopathy, cataracts and neuropathy observed in diabetic patients [13].
Concomitantly, the cellular antioxidant capacity of Glutathione (GSH)is diminished due to AR
activity, which depletes the NADPH required for glutathione reductase (GSR) to recycle glutathione
(GSH). A reduction in available NADPH, due to the overutilization of the Polyol Pathway, significantly
decreases GSH levels and thus limits the ROS-scavenging activity of GSH, and further increases ROS
levels [14]. A diabetic mouse model (MKR) vs. control study performed in 2010 revealed sorbitol levels
2.5 times higher in MKR when compared to a control Also found was 1.7 times lower levels of the
reduced glutathione (rGSH) in skeletal muscle [15]. Therefore, it is understood that the overutilization
of the polyol pathway due to glucose excess is a major source of oxidative stress, by limiting the
recycling of GSH via GSR induced by diabetes.
1.3. The Production of Glutathione in T2DM
GSH synthesis occurs intracellularly in a two-step enzymatic reaction. First, glutamine is joined
with cysteine via the rate-limiting enzyme glutamine–cysteine ligase (GCLC) making γ–glutamyl
cysteine. The second enzyme required for GSH synthesis is glutathione synthetase (GSS), which links
γ–glutamyl cysteine to glycine to form the functional molecule of GSH. Once formed, GSH can perform
its function by absorbing and detoxifying reactive oxygen species to prevent cellular damage. GSH can
be found in vivo in two forms—reduced, functional glutathione (rGSH/GSH), and oxidized glutathione
(GSSG). GSSG can be recycled to form rGSH/GSH via the enzyme GSR which, as previously stated,
requires NADPH [16].
72
J. Clin. Med. 2019, 8, 2219
GSH levels have been shown to be significantly compromised in individuals with T2DM, due to a
diminishment in the levels of NADPH causing the decreased ability of GSR to recycle GSSG to GSH.
Compared to healthy individuals, people with T2DM have lower levels of GCLC, the rate-limiting
catalytic unit in producing GSH [17]. These decreased amounts of GCLC correlated with increased
amounts of transforming growth factor beta (TGF-β) in patients with T2DM [17]. Furthermore,
decreased GCLC was accompanied by deceases in both GSS and gamma glutamyl transpeptidase
(GGT). Both enzymes are crucial for the synthesis and import of GSH into the cell. The results show
decreased overall levels of GSH in T2DM [17]. The rise in GSSG and decline of rGSH/GSH is due to
the excess of free radicals or ROS being produced via the AGE/Receptor for Advanced Glycation End
products (RAGE) pathway discussed in great detail below. When produced, rGSH can detoxify the
ROS by accepting the electrons and combining two molecules of rGSH/GSH to make an oxidized form
of glutathione GSSG.
GGT functions throughout the body as a transport molecule, enabling the breakdown of
extracellular GSH. The cysteine formed is then transported into the cells for GSH biosynthesis.
The mechanism by which TGF-β decreases these enzymes has not been fully elucidated; however, key
components have been found. The Antioxidant Response Element (ARE) is a regulatory enhancer
gene sequence, which upon activation induces the synthesis of basal and inducible GSH synthesizing
enzymes. Bakin et el. found signal transduction proteins intracellularly that respond to TGF-β. Once
TGF-β binds to its cellular receptor, a serine–threonine kinase, it auto-phosphorylates Smad2 and
Smad3, which then heterodimerize with Smad4 and can translocate to the nucleus and upregulate
or downregulate genes, such as GCLC and Glutamate cysteine ligase modifier protein (GCLM) [18].
It has also been shown that TGF-β, in addition to downregulating GCLC mRNA production, also
decreases the half-life of GCLC, resulting in increasing ROS intracellularly. When TGF-β interacts
with its cellular receptor, it causes an increase in caspase activity which begins the apoptosis cascade.
Inducing apoptosis cleaves proteins intracellularly, including GCLC among many others [19]. With
these enzymes decreased, it is recognized that people with T2DM produce a lower amount of functional
GSH. Another important enzyme responsible for restoring the amount of GSH is GSR, which converts
GSSG to GSH utilizing the cofactor NADPH. Contrary to the aforementioned enzymes, GSR is found in
excess in patients with T2DM, which our group postulates is a compensatory mechanism to overcome
GSH deficiency. However, with a deficiency in NADPH—a necessary co-factor for the activity of
GSR—there is no restoration of GSH despite the increased levels of GSR. Lagman et al. also found that
the amount of GSSG in T2DM was elevated in members with HbA1C over 8% [17]. They also found a
five-fold decrease in Tumor Necrosis Factor alpha (TNF-α), and a two-fold decrease in IFN-γ. The
study findings suggest that administering L-GSH will be more efficacious in patients with T2DM, than
administering N-Acetyl Cysteine (NAC), a precursor for GSH, due to the aforementioned decreased
enzymatic levels [17]. Despite abundant GSR, there are increased levels of GSSG and decreased GSH
in T2DM, and this could very well be caused by the diminished levels of NADPH in lieu of polyol
pathway utilization.
1.4. AGE-RAGE and GSH Deficiency in T2DM
The first AGE was discovered in the 1960s with the discovery of HbA1C. AGEs are destructive
in many ways, but we will focus on one we believe to be particularly important for the function of
the immune system. The binding of AGE with its counterpart Receptor for Advanced Glycation
End products (RAGE) starts a cascade, increasing the generation of ROS and activation of
Nuclear Factor-kappa-B (NF-kB) which produces proinflammatory molecules interleukin-1 (IL-1)
and interleukin-6 (IL-6). On top of the AGE-RAGE component with excess glucose in the cell, DAG
is formed, which can lead to the activation of PKC. The activation of PKC involves a plethora of
actions, including the activation of NF-kB, further increasing IL-1 and IL-6, as well as TGF-β, which,
as described previously, results in a decrease in GCLC. With the combination of TGF-β inactivating
the rate-limiting step of GSH production, and with the increase in IL-1 and IL-6 there is exacerbated
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inflammation elevating the levels of ROS in all surrounding cells. Studies have shown that this change
in the cytokine environment will lead to an altered immune response [20].
1.5. T2DM and Tuberculosis
In 2017, tuberculosis (TB) caused an estimated 1.6 million deaths and an incidence of 10 million
cases of TB developed worldwide [21]. TB has been on the rise since the 1980s, in part due to the
HIV pandemic, multidrug resistance, and increased numbers of highly susceptible individuals with
suppressed/altered immune systems, such as those with T2DM [8]. Currently, one-quarter of the
population of the world is latently infected with M. tb [21]. Individuals with latent tuberculosis
Infection (LTBI) are not infectious; however, active TB can occur due to the reactivation of a dormant
infection as a consequence of granuloma liquefaction in immunodeficient or immunocompromised
individuals, such as individuals with HIV or T2DM [5]. Several studies have looked at the correlation
between the prevalence of T2DM and TB. In 2012, it was found that 50% of patients studied who tested
positive for M. tb infection had either diabetes or pre-diabetes. Other studies which found similar
accounts of diabetes and TB in India found that, in Mexico, 35% of patients testing positive for M. tb
infection had diabetes. Furthermore, in 2011, an article found that with uncontrolled diabetes and TB
infection there were more cavitary lesions, and a higher incidence of positive sputum cultures, even two
months after initiation treatment. Thus, careful monitoring of the progression of M. tb infection and
glucose control should be top priorities of physicians with patients with both illnesses [22]. According
to the CDC, 20% of patients with TB have diabetes in the US.
In patients with T2DM, the depletion of GSH is extremely prevalent, which may result in additional
pathogenesis. Discussed later are the effects of GSH depletion in altering levels of cytokine production
and the immune consequence. One cytokine that is extremely important for restricting and containing
M. tb infection is TNF-α. This cytokine aids in the formation of granuloma to prevent the spread and
wall off the pathogen. It has been shown that, in the absence of TNF-α, there will be an impairment in
the formation of the granuloma, leading to the dissemination of the pathogen [23]. IFN-γ, another
cytokine responsible for augmenting the effector functions of macrophages, was found to be decreased
in patients with T2DM [17]. In a systematic review, patients with diabetes who were infected with M.
tb had a risk ratio of 1.69 for treatment failure and death. The study also found an increased risk of
relapse in patients with diabetes vs. non-diabetic individuals. The conclusion of the study found that
improved glucose control and close monitoring in patients with the comorbidity of M. tb and Diabetes
should be implemented to assist in the recovery process [23]. M. tb infection in healthy subjects
will result in robust immune responses mediated by the competent immune system resulting in the
formation of granuloma, which suppresses the spread of the pathogen. However, in patients with
weakened immune systems, a reactivation of M. tb occurring in those with LTBI or primary infection
can lead to active TB. We were able to find links between cytokine imbalance, as a consequence of
diminished GSH levels due to decreases in the level of GSH synthesis and ability of the recycling
enzymes. Increased TGF-β can be a major contributing factor to the decreasing levels of GSH synthesis
enzymes. The inability of GSR in diabetic patients to restore in order to recycle GSSG to GSH is due
to the depletion of NADPH by the Polyol pathway. With all these factors, it forms a sort of circle of
perpetuation. (Visualized in Figure 1) M. tb has been a successful pathogen capable of evading the
immune system, and those with a compromised immune system are at increased risk for both the
reactivation of LTBI and development of active TB after initial exposure. While M. tb is not the only
pathogen to cause an active disease in individuals with diabetes, we focused mainly on this pathogen
due to the long-standing prevalence, as well as the global burden, of TB. Two cytokines—IFN- γ and
TNF- α —which are imperative to the control and prevention of the spread of M. tb, respectively,
are significantly compromised in individuals with T2DM (discussed below in the next section). We
therefore believe that cytokine dysregulation in individuals with T2DM causes impaired immune
responses against M. tb, resulting in active TB.
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Figure 1. For oxidative stress and glutathione (GSH) deficiency in individuals with Type 2 Diabetes
Mellitus (T2DM).
1.6. Cytokine Production and Immune Responses against M. tb Infection
Efficient communication between cells is necessary to modulate an adequate immune response
in individuals for cell migration and specific instruction. This is a critical role for cytokines and
chemokines. Cytokines are small, soluble proteins that are produced by the host immune cells
which influence the activity of other cells by acting in a paracrine manner [24]. Different immune
cells, such as macrophages and neutrophils, initiate cytokine production when interacting with a
pathogen. Multiple pattern recognition receptors (PRR) on these cells recognize various bacterial
factors, such as mycobacterial cell wall components, secreted molecules, and nucleic acids derived
from mycobacteria, which promote cytokine production [19,20]. The cytokines discharged by these
cells have essential regulatory properties, and contribute to the host defense against M. tb through
the formation of a granuloma which leads to the containment and extermination of bacteria [25,26].
Granulomas are composed of macrophages, multinucleated giant cells, CD4+ and CD8+ T-cells,
B-cells and neutrophils [27]. Within an immunocompetent individual, the interaction between M.
tb and granulomatous cells of the immune system results in the constant secretion of cytokines;
particularly, TNF-α, (formation of the granuloma), interleukin-10 (IL-10)(immune modulation), IL-6
(inflammatory cytokine), interleukin-2 (IL-2)(T-cell growth factor), interleukin-12 (IL-12)(stimulation
of cells to produce IFN-γ), and IFN-γ (macrophage stimulation) [28].
TNF-α secreted by macrophages, dendritic cells (DC), and T-cells augments effector immune
responses against M. tb infection [26,29]. Additionally, upon infection, pulmonary epithelium and
lung fibroblasts produce chemokine (C-X-C motif) ligand 8 (CXCL8), which promotes the rapid
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recruitment of neutrophils [30]. It was previously shown, that after the ingestion of dead or dying M.
tb-infected apoptotic neutrophils at the infection site, a proinflammatory response is triggered and
macrophages become activated, releasing TNF-α [31]. Thus, it was demonstrated that TNF-α promotes
the production of chemokines and chemokine receptors, and also an expression of adhesion molecules,
which affect the formation of granulomas in M. tb-infected tissues [32]. TNF-α also works in synergy
with IFN-γ to induce nitric oxide production [33].
Another important modulator of the immune response is the neutrophil-mediated release of
IL-10, which is known to decrease inflammation. IL-10 is produced by phagocytes of lung lesions
and reduces expression of TNF-α and IL-12 [34]. IL-10 also blocks phagosome maturation and allows
the pathogen to survive in alveolar macrophages, and through reduction of T-cell responses, it may
affect the integrity of the granulomas, thus promoting the transmission of M. tb by predisposing the
host to lung cavitation [35]. IL-10 possesses macrophage-deactivating properties and reduces IL-12
production, which in turn decreases IFN-γ production by T-cells [36]. These findings indicate that
IL-10 plays an anti-inflammatory role and may counter the macrophage-activating properties of IFN-γ.
Therefore, the balance between TNF-α with antagonistic IL-10 and synergistic IFN-γ cytokines plays a
role in fine-tuning the tissue damage in the granulomas, as well as its bactericidal effects [37].
When M. tb or apoptotic macrophages and neutrophils containing M. tb interact with DCs, it
causes the DCs to mature and become able to stimulate T-cells through the expression of major
histocompatibility complex (MHC) and co-stimulatory molecules, with the aid of the secretion of IL-12
and IFN-γ [38]. IL-12 inducers can polarize CD4+ T-cells toward a T-helper (TH1) phenotype [39].
TH1cells produce IFN-γ, IL-2, IL-12 and TNF-α—cytokines important for the suppression of M. tb
growth and replication [40]. On the other hand, Type-2 T-helper phenotype (TH2) responses lead to the
production of IL-4, IL-5, and IL-10, which exert anti-inflammatory effects [41].
CD4+ and CD8+ T-cells are important in maintaining specific immunity against M. tb, and
protective immunity is associated with antigen presentation by DC to T-cells [42]. Although MHC class
II restricted CD4+ T-cells play an important role in protection against M. tb, MHC Class I restricted
T-cells act later in the infectious cycle by killing M. tb-infected cells through the secretion of cytotoxic
molecules, such as perforin, granzymes, and granulysin [43].
IL-2, also called T-cell growth factor, is produced by TH1 cells. IL-2 is responsible for maintaining
the CD4 and CD8 T-cell viability, and thereby amplifies T-cell responses against M. tb infection [37].
IL-6 is another cytokine involved in the immune response against M. tb which has multiple roles,
including inflammation and T-cell differentiation [44]. During infection, IL-6 and TGF-β control the
relative levels of expression of the transcription factor FoxP3. These T-regs have multiple inhibitory
effects, and by limiting the intensity of the T-cell response to M. tb, they attempt to balance potentially
harmful immune responses [38,39]. IL-17 mediates the cellular recruitment of neutrophils via CXCL8 in
order to form lung lymphoid follicles, providing optimal macrophage activation and bacterial control
during M. tb. infection. However, the hyperactivity of TH17 cells can lead to an increased pathological
state through the IL-17 mediated influx of neutrophils, which can cause tissue damage [41,42].
TB is a complex disease, and as such, the role of any particular cytokine cannot be categorized
so easily as either “beneficial” or “harmful”. However, based on the amount produced and the
circumstances, these cytokines can cause either defensive or pathologic effects, by either working
synergistically or antagonistically to the immune system in order to control the infection.
1.7. Why GSH Is Important in a Functioning Immune System
In 2003, Venketaraman et al. established the importance of GSH in the immune response controlling
the infection of M. tb [45]. GSH levels were found to be decreased in red blood cells and peripheral
blood mononuclear cells isolated from patients with active pulmonary TB. Dr. Venketaraman’s group
also found that the administration of a precursor of GSH—N-acetyl cysteine (NAC)—to isolated
immune cells improved the control of M. tb, as well as decreased the levels of pro-inflammatory
cytokines such as IL-6, TNF-α and IL-1 [45]. Furthermore, through its role as a Nitric Oxide (NO) carrier,
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the addition of S-Nitrosoglutathione (GSNO) to M. tb cultures was found to be mycobactericidal [46].
Moreover, the addition of NAC, along with cytokines IL-2, and IL-12 caused a significant enhancement
in the effector functions of natural killer (NK) cells, which in turn caused an increased production of
IFN-γ, a macrophage-activating cytokine [44,47–49]. The immune system requires different cytokines
present to mount the proper responses. The TH1 response, for example, which requires IL-12 and
IFN-γ produced by the TH1 cells, can further activate macrophage effector response [50]. With the
infection present, ROS are produced to assist in the killing of bacteria; however, they can be harmful
to the host system if not absorbed via GSH and other antioxidants to prevent cellular damage. It
has been shown that ROS and GSH levels can alter the cytokine release of T-cells [51]. Depletion of
GSH due to ROS production will lead to NF-kB binding to the DNA, resulting in the production of
IL-1, IL-6 and TNF-α. In contrast, GSH repletion will suppress the production of the aforementioned
cytokines [51–53]. With a depletion of GSH during infection or T2DM, this could cause NF-kB release
and upregulate the production of IL-1, TNF-α, and IL-6—all inflammatory cytokines. Although IL-6
is necessary for proper macrophage activity, Van Heyningen’s group found that the overproduction
of IL-6 can lead to macrophages’ inability to respond properly to the infection [48]. With this being
said, TNF-α is an extremely important cytokine for the formation of granulomas in M. tb infection. A
cytokine cannot be classified as “beneficial” or “detrimental”; rather, in order to produce intended
effect it should be in the right site at the right time, but, as stated previously, overproduction can cause
disarray, desensitization and malfunction. With each of these studies, it should now be apparent that
GSH is extremely important for the proper function of the immune system, whether assisting as an NO
carrier, as GSNO to assist in the killing of the infection, or scavenging excess ROS to control cytokine
levels to mount a proper response. We believe the augmented immune system in diabetic patients is
primarily due to the decrease in GSH, which leads to a depletion in IL-12. Deficiency of this cytokine
has been shown in several studies to lead to recurrent infections, while the addition of NAC or L-GSH
restored the IL-12 and IFN-γ, which in turn enhanced mycobacterial killing [44,47,54–56]. Studies have
also found that when there is an increase in IL-4 and IL-5, the cytokines responsible for polarizing the
helper T-cells to a TH2 response [57,58]. Thus, further proving that the levels of ROS or GSH are a
crucial deciding factor when creating an immune response.
1.8. Vitamin D and Macrophage Activation
Vitamin D is a secosteroid which can be ingested (vitamin D3 and vitamin D2) into the body or
endogenously produced in the skin upon sun exposure (vitamin D3) [59,60]. Vitamin D has displayed
anti-inflammatory effects, as supplementation with vitamin D results in decreased radical oxygen
species (ROS) and pro-inflammatory cytokines [61,62].
GSH plays a role in maintaining vitamin D regulatory genes; GSH deficiency hinders the expression
of vitamin D-binding proteins and receptors [63,64]. Furthermore, supplementation with L-cystine, a
precursor for GSH, increases levels of vitamin D and its binding proteins [63,65].
Thus, we postulate that a decrease in GSH indirectly affects the immune system via decreasing
the concentrations of vitamin D. However, further studies are needed to confirm at what hemoglobin
A1c the deficiency of Vitamin D—due to decreases in GSH—occurs. The mechanism underlying this
phenomenon can be attributed to the role of vitamin D in adaptive immunity [64]. Vitamin D assists
macrophages to inhibit the proliferation of M. tb [59,60,66]. M. tb binds to the toll-like receptors seen
on the cell surface of macrophages, upon which the expression of the vitamin D receptors and 1-alpha
hydroxylase is upregulated [67]. The activated vitamin D then induces the transcription of human
cathelicidin (hCAP18) and beta-defensin 4 (DEFB4), both of which are crucial to antimycobacterial
function including the auto-lysosomal elimination of M. tb [59,66–69]. The importance of this intracrine
pathway was demonstrated by Zhao’s study in which the cellular ability to eradicate M. tb in DM
patients improved upon vitamin D supplementation [65].
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2. Summary
It has been shown in previous studies, that an excess of glucose in systemic circulation can cause an
increase in ROS and the proinflammatory cytokines IL-1 and IL-6, which at high enough concentrations
can inhibit the function of macrophages. Due to excess glucose, TGF-β becomes increased through the
activation of AGE and its receptor RAGE, through PKC, which inhibits the manufacturing of GSH. The
oxidized form of glutathione—GSSG—can be recycled if the body has enough NADPH utilizing the
enzyme GSR. However, in diabetic patients, NADPH is being utilized heavily on the polyol pathway,
leading to an overall decrease in GSH levels and an increase in ROS, which can alter the cytokine
levels in the body [55]. GSH increase has been shown to upregulate the production of IFN-γ and IL-12,
favoring the host immune response against M. tb infection.
The peripheral neuropathy and altered immune system can be traced back to a common metabolic
pathway, but for different reasons. One of the complications of T2DM, peripheral neuropathy, was
linked to the Polyol pathway and the build-up of sorbitol due to an SDH deficiency in the nervous tissue.
The complications involving the immune system are not due to products from the Polyol pathway
but rather from the overutilization of NADPH. The depletion of NADPH leads to the inability of GSR
to recycle GSH, causing decreased GSH, increased ROS, differing cytokine profiles and, ultimately,
immune system compromise.
Author Contributions: S.F., A.Y., N.N., G.L., T.N., and K.T. have contributed to drafting this review. V.V. conceived
the frame work, provided guidance and assistance, and made edits to the draft.
Funding: The authors appreciate the funding support from National Heart Blood Lung Institute at the National
Institutes of Health (NIH) award 1R15HL143545-01A1.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. World Health Organization. Diabetes Facts (Infographics); WHO: Geneva, Switzerland, 2016.
2. Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report, 2017 Estimates of Diabetes
and Its Burden in the United States Background; CDC: Atlanta, GA, USA, 2018.
3. World Health Organization. Tuberculosis. Available online: https://www.who.int/news-room/fact-sheets/
detail/tuberculosis (accessed on 13 November 2019).
4. Frieden, T.R.; Sterling, T.R.; Munsiff, S.S.; Watt, C.J.; Dye, C. Tuberculosis. Lancet 2003, 362, 887–899.
[CrossRef]
5. Ai, J.-W.; Ruan, Q.-L.; Liu, Q.-H.; Zhang, W.-H. Updates on the risk factors for latent tuberculosis reactivation
and their managements. Emerg. Microbes Infect. 2016, 5, 1–8. [CrossRef] [PubMed]
6. Wilcox, G. Insulin and insulin resistance. Clin. Biochem. Rev. 2005, 26, 19–39. [PubMed]
7. Nowotny, K.; Jung, T.; Höhn, A.; Weber, D.; Grune, T. Advanced Glycation End Products and Oxidative
Stress in Type 2 Diabetes Mellitus. Biomolecules 2015, 5, 194–222. [CrossRef]
8. Wu, Y.; Ding, Y.; Tanaka, Y.; Zhang, W. Risk factors contributing to type 2 diabetes and recent advances in the
treatment and prevention. Int. J. Med. Sci. 2014, 11, 1185–1200. [CrossRef] [PubMed]
9. Schemmel, K.E.; Padiyara, R.S.; D’Souza, J.J. Aldose reductase inhibitors in the treatment of diabetic
peripheral neuropathy: A review. J. Diabetes Complicat. 2010, 24, 354–360. [CrossRef] [PubMed]
10. Oka, M.; Kato, N. Aldose Reductase Inhibitors. J. Enzyme Inhib. 2001, 16, 465–473. [CrossRef]
11. Oates, P.J. Aldose reductase, still a compelling target for diabetic neuropathy. Curr. Drug Targets 2008, 9,
14–36. [CrossRef] [PubMed]
12. Morré, D.M.; Lenaz, G.; Morré, D.J. Surface oxidase and oxidative stress propagation in aging. J. Exp. Biol.
2000, 203 Pt 10, 1513–1521.
13. Pollreisz, A.; Schmidt-Erfurth, U. Diabetic Cataract—Pathogenesis, Epidemiology and Treatment. J.
Ophthalmol. 2010, 2010, 1–8. [CrossRef]
14. Cheng, H.-M.; González, R.G. The effect of high glucose and oxidative stress on lens metabolism, aldose
reductase, and senile cataractogenesis. Metabolism 1986, 35, 10–14. [CrossRef]
78
J. Clin. Med. 2019, 8, 2219
15. Gallagher, E.J.; LeRoith, D.; Stasinopoulos, M.; Zelenko, Z.; Shiloach, J. Polyol accumulation in muscle and
liver in a mouse model of type 2 diabetes. J. Diabetes Complicat. 2016, 30, 999–1007. [CrossRef] [PubMed]
16. Griffith, O.W. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic. Biol.
Med. 1999, 27, 922–935. [CrossRef]
17. Lagman, M.; Ly, J.; Saing, T.; Singh, M.K.; Tudela, E.V.; Morris, D.; Chi, P.-T.; Ochoa, C.; Sathananthan, A.;
Venketaraman, V. Investigating the causes for decreased levels of glutathione in individuals with type II
diabetes. PLoS ONE 2015, 10, e0118436. [CrossRef]
18. Bakin, A.V.; Stourman, N.V.; Sekhar, K.R.; Rinehart, C.; Yan, X.; Meredith, M.J.; Arteaga, C.L.; Freeman, M.L.
Smad3-ATF3 signaling mediates TGF-β suppression of genes encoding Phase II detoxifying proteins. Free
Radic. Biol. Med. 2005, 38, 375–387. [CrossRef]
19. Franklin, C.C.; Rosenfeld-Franklin, M.E.; White, C.; Kavanagh, T.J.; Fausto, N. TGFbeta1-induced
suppression of glutathione antioxidant defenses in hepatocytes: Caspase-dependent post-translational and
caspase-independent transcriptional regulatory mechanisms. FASEB J. 2003, 17, 1535–1537. [CrossRef]
20. Yan, Z.; Garg, S.K.; Kipnis, J.; Banerjee, R. Extracellular redox modulation by regulatory T cells. Nat. Chem.
Biol. 2009, 5, 721–723. [CrossRef]
21. World Health Organization. ‘Tuberculosis’ Fact Sheet; WHO: Geneva, Switzerland, 2010; Volume 104.
22. Park, S.W.; Shin, J.W.; Kim, J.Y.; Park, I.W.; Choi, B.W.; Choi, J.C.; Kim, Y.S. The effect of diabetic control status
on the clinical features of pulmonary tuberculosis. Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31, 1305–1310.
[CrossRef]
23. Baker, M.A.; Harries, A.D.; Jeon, C.Y.; Hart, J.E.; Kapur, A.; Lönnroth, K.; Ottmani, S.-E.; Goonesekera, S.D.;
Murray, M.B. The impact of diabetes on tuberculosis treatment outcomes: A systematic review. BMC Med.
2011, 9, 81. [CrossRef]
24. Dinarello, C.A. Historical insights into cytokines. Eur. J. Immunol. 2007, 37 (Suppl. 1), 34–45. [CrossRef]
25. Domingo-Gonzalez, R.; Prince, O.; Cooper, A. Cytokines and Chemokines in Mycobacterium tuberculosis
Infection. In Tuberculosis and the Tubercle Bacillus, 2nd ed.; American Society of Microbiology: Washington,
DC, USA, 2016; pp. 33–72.
26. Kaufmann, S.H.E. Protection against tuberculosis: Cytokines, T cells, and macrophages. Ann. Rheum. Dis.
2002, 61 (Suppl. 2), ii54–ii58. [CrossRef] [PubMed]
27. Lin, P.L.; Plessner, H.L.; Voitenok, N.N.; Flynn, J.L. Tumor Necrosis Factor and Tuberculosis. J. Investig.
Dermatol. Symp. Proc. 2007, 12, 22–25. [CrossRef] [PubMed]
28. Cooper, A.M.; Mayer-Barber, K.D.; Sher, A. Role of innate cytokines in mycobacterial infection. Mucosal
Immunol. 2011, 4, 252–260. [CrossRef] [PubMed]
29. Philips, J.A.; Ernst, J.D. Tuberculosis Pathogenesis and Immunity. Annu. Rev. Pathol. Mech. Dis. 2012, 7,
353–384. [CrossRef] [PubMed]
30. Wickremasinghe, M.I.; Thomas, L.H.; Friedland, J.S. Pulmonary epithelial cells are a source of IL-8 in the
response to Mycobacterium tuberculosis: Essential role of IL-1 from infected monocytes in a NF-κB-dependent
network. J. Immunol. 1999, 163, 3936–3947. [PubMed]
31. Alexander, Y.; Persson, Z.; Blomgran-Julinder, R.; Rahman, S.; Zheng, L.; Stendahl, O. Mycobacterium
tuberculosis-induced apoptotic neutrophils trigger a pro-inflammatory response in macrophages through
release of heat shock protein 72, acting in synergy with the bacteria. Microbes Infect. 2008, 10, 233–240.
32. Flynn, J.L.; Chan, J. I Mmunology of T Uberculosis. Annu. Rev. Immunol. 2001, 19, 93–129. [CrossRef]
33. Liew, F.Y.; Li, Y.; Millott, S. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of
Leishmania major through the induction of nitric oxide. J. Immunol. 1990, 145, 4306–4310.
34. Beamer, G.L.; Flaherty, D.K.; Assogba, B.D.; Stromberg, P.; Gonzalez-Juarrero, M.; de Waal Malefyt, R.;
Vesosky, B.; Turner, J. Interleukin-10 promotes Mycobacterium tuberculosis disease progression in CBA/J
mice. J. Immunol. 2008, 181, 5545–5550. [CrossRef]
35. O’Leary, S.; O’Sullivan, M.P.; Keane, J. IL-10 Blocks Phagosome Maturation in Mycobacterium tuberculosis–
Infected Human Macrophages. Am. J. Respir. Cell Mol. Biol. 2011, 45, 172–180. [CrossRef]
36. Gong, J.H.; Zhang, M.; Modlin, R.L.; Linsley, P.S.; Iyer, D.; Lin, Y.; Barnes, P.F. Interleukin-10 downregulates
Mycobacterium tuberculosis-induced Th1 responses and CTLA-4 expression. Infect. Immun. 1996, 64,
913–918. [PubMed]
37. Lowe, D.M.; Redford, P.S.; Wilkinson, R.J.; O’Garra, A.; Martineau, A.R. Neutrophils in tuberculosis: Friend
or foe? Trends Immunol. 2012, 33, 14–25. [CrossRef] [PubMed]
79
J. Clin. Med. 2019, 8, 2219
38. Giacomini, E.; Iona, E.; Ferroni, L.; Miettinen, M.; Fattorini, L.; Orefici, G.; Julkunen, I.; Coccia, E.M. Infection
of Human Macrophages and Dendritic Cells with Mycobacterium tuberculosis Induces a Differential Cytokine
Gene Expression That Modulates T Cell Response. J. Immunol. 2001, 166, 7033–7041. [CrossRef] [PubMed]
39. Sano, K.; Haneda, K.; Tamura, G.; Shirato, K. Ovalbumin (OVA) and Mycobacterium tuberculosis Bacilli
Cooperatively Polarize Anti-OVA T-helper (Th) Cells toward a Th1-Dominant Phenotype and Ameliorate
Murine Tracheal Eosinophilia. Am. J. Respir. Cell Mol. Biol. 1999, 20, 1260–1267. [CrossRef]
40. Boom, W.H.; Canaday, D.H.; Fulton, S.A.; Gehring, A.J.; Rojas, R.E.; Torres, M. Human immunity to M.
tuberculosis: T cell subsets and antigen processing. Tuberculosis (Edinb) 2003, 83, 98–106. [CrossRef]
41. Mosmann, T.R.; Coffman, R.L. TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to
Different Functional Properties. Annu. Rev. Immunol. 1989, 7, 145–173. [CrossRef] [PubMed]
42. Cooper, A.M. T cells in mycobacterial infection and disease. Curr. Opin. Immunol. 2009, 21, 378–384.
[CrossRef] [PubMed]
43. Ottenhoff, T.H.M.; Kaufmann, S.H.E. Vaccines against Tuberculosis: Where Are We and Where Do We Need
to Go? PLoS Pathog. 2012, 8, e1002607. [CrossRef]
44. VanHeyningen, T.K.; Collins, H.L.; Russell, D.G. IL-6 produced by macrophages infected with Mycobacterium
species suppresses T cell responses. J. Immunol. 1997, 158, 330–337.
45. Venketaraman, V.; Millman, A.; Salman, M.; Swaminathan, S.; Goetz, M.; Lardizabal, A.; Hom, D.;
Connell, N.D. Glutathione levels and immune responses in tuberculosis patients. Microb. Pathog. 2008, 44,
255–261. [CrossRef]
46. Venketaraman, V.; Dayaram, Y.K.; Talaue, M.T.; Connell, N.D. Glutathione and Nitrosoglutathione in
Macrophage Defense against Mycobacterium tuberculosis. Infect. Immun. 2005, 73, 1886–1889. [CrossRef]
[PubMed]
47. Afzali, B.; Mitchell, P.; Lechler, R.I.; John, S.; Lombardi, G. Translational Mini-Review Series on Th17 Cells:
Induction of interleukin-17 production by regulatory T cells. Clin. Exp. Immunol. 2010, 159, 120–130.
[CrossRef] [PubMed]
48. Millman, A.C.; Salman, M.; Dayaram, Y.K.; Connell, N.D.; Venketaraman, V. Natural Killer Cells, Glutathione,
Cytokines, and Innate Immunity Against Mycobacterium tuberculosis. J. Interf. Cytokine Res. 2008, 28, 153–165.
[CrossRef] [PubMed]
49. Kasai, M.; Yoneda, T.; Habu, S.; Maruyama, Y.; Okumura, K.; Tokunaga, T. In vivo effect of anti-asialo GM1
antibody on natural killer activity. Nature 1981, 291, 334–335. [CrossRef]
50. Janeway, C.A., Jr.; Travers, P.; Walport, M. Immunobiology: The Immune System in Health and Disease, 5th ed.;
Garland Science: New York, NY, USA, 2001.
51. Garg, S.K.; Yan, Z.; Vitvitsky, V.; Banerjee, R. Differential dependence on cysteine from transsulfuration
versus transport during T cell activation. Antioxid. Redox Signal. 2011, 15, 39–47. [CrossRef]
52. Verhasselt, V.; Berghe, W.V.; Vanderheyde, N.; Willems, F.; Haegeman, G.; Goldman, M. N-acetyl-L-cysteine
inhibits primary human T cell responses at the dendritic cell level: Association with NF-kappaB inhibition. J.
Immunol. 1999, 162, 2569–2574.
53. Bernal-Fernandez, G.; Espinosa-Cueto, P.; Leyva-Meza, R.; Mancilla, N.; Mancilla, R. Decreased Expression
of T-Cell Costimulatory Molecule CD28 on CD4 and CD8 T Cells of Mexican Patients with Pulmonary
Tuberculosis. Tuberc. Res. Treat. 2010, 2010, 1–8. [CrossRef]
54. Haraguchi, S.; Day, N.K.; Nelson, R.P.; Emmanuel, P.; Duplantier, J.E.; Christodoulou, C.S.; Good, R.A.
Interleukin 12 deficiency associated with recurrent infections. Proc. Natl. Acad. Sci. USA 1998, 95,
13125–13129. [CrossRef]
55. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev.
Immunol. 2003, 3, 133–146. [CrossRef]
56. Tan, K.S.; Lee, K.O.; Low, K.C.; Gamage, A.M.; Liu, Y.; Tan, G.Y.G.; Koh, H.Q.V.; Alonso, S.; Gan, Y.H.
Glutathione deficiency in type 2 diabetes impairs cytokine responses and control of intracellular bacteria. J.
Clin. Investig. 2012, 122, 2289–2300. [CrossRef]
57. Kumar, N.P.; Sridhar, R.; Banurekha, V.V.; Jawahar, M.S.; Fay, M.P.; Nutman, T.B.; Babu, S. Type 2 diabetes
mellitus coincident with pulmonary tuberculosis is associated with heightened systemic type 1, type 17, and
other proinflammatory cytokines. Ann. Am. Thorac. Soc. 2013, 10, 441–449. [CrossRef] [PubMed]
58. Chen, H.; Wen, F.; Zhang, X.; Su, S.B. Expression of T-helper-associated cytokines in patients with type 2
diabetes mellitus with retinopathy. Mol. Vis. 2012, 18, 219–226. [PubMed]
80
J. Clin. Med. 2019, 8, 2219
59. Sutaria, N.; Liu, C.-T.; Chen, T.C. Vitamin D Status, Receptor Gene Polymorphisms, and Supplementation
on Tuberculosis: A Systematic Review of Case-Control Studies and Randomized Controlled Trials. J. Clin.
Transl. Endocrinol. 2014, 1, 151–160. [CrossRef] [PubMed]
60. Zhao, X.; Yuan, Y.; Lin, Y.; Zhang, T.; Bai, Y.; Kang, D.; Li, X.; Kang, W.; Dlodlo, R.A.; Harries, A.D. Vitamin D
status of tuberculosis patients with diabetes mellitus in different economic areas and associated factors in
China. PLoS ONE 2018, 13, e0206372. [CrossRef]
61. Jain, S.K.; Micinski, D. Vitamin D upregulates glutamate cysteine ligase and glutathione reductase, and
GSH formation, and decreases ROS and MCP-1 and IL-8 secretion in high-glucose exposed U937 monocytes.
Biochem. Biophys. Res. Commun. 2013, 437, 7–11. [CrossRef]
62. Farrokhian, A.; Raygan, F.; Bahmani, F.; Talari, H.R.; Esfandiari, R.; Esmaillzadeh, A.; Asemi, Z. Long-Term
Vitamin D Supplementation Affects Metabolic Status in Vitamin D–Deficient Type 2 Diabetic Patients with
Coronary Artery Disease. J. Nutr. 2017, 147, 384–389. [CrossRef]
63. Parsanathan, R.; Jain, S.K. Glutathione deficiency alters the vitamin D-metabolizing enzymes CYP27B1 and
CYP24A1 in human renal proximal tubule epithelial cells and kidney of HFD-fed mice. Free Radic. Biol. Med.
2019, 131, 376–381. [CrossRef]
64. Jain, S.K.; Parsanathan, R.; Achari, A.E.; Kanikarla-Marie, P.; Bocchini, J.A. Glutathione Stimulates Vitamin
D Regulatory and Glucose-Metabolism Genes, Lowers Oxidative Stress and Inflammation, and Increases
25-Hydroxy-Vitamin D Levels in Blood: A Novel Approach to Treat 25-Hydroxyvitamin D Deficiency.
Antioxidants Redox Signal. 2018, 29, 1792–1807. [CrossRef]
65. Jain, S.K.; Kahlon, G.; Bass, P.; Levine, S.N.; Warden, C. Can l-cysteine and Vitamin D rescue Vitamin D and
Vitamin D binding protein levels in blood Plasma of African American type 2 diabetic patients? Antioxid.
Redox Signal. 2015, 23, 688–693. [CrossRef]
66. Chesdachai, S.; Zughaier, S.M.; Hao, L.; Kempker, R.R.; Blumberg, H.M.; Ziegler, T.R.; Tangpricha, V. The
effects of first-line anti-tuberculosis drugs on the actions of vitamin D in human macrophages. J. Clin. Transl.
Endocrinol. 2016, 6, 23–29. [CrossRef]
67. Hewison, M. Vitamin D and the intracrinology of innate immunity. Mol. Cell. Endocrinol. 2010, 321, 103–111.
[CrossRef] [PubMed]
68. Ashenafi, S.; Mazurek, J.; Rehn, A.; Lemma, B.; Aderaye, G.; Bekele, A.; Assefa, G.; Chanyalew, M.; Aseffa, A.;
Andersson, J.; et al. Vitamin D3 status and the association with human cathelicidin expression in patients
with different clinical forms of active tuberculosis. Nutrients 2018, 10, 721. [CrossRef] [PubMed]
69. Herrera, M.T.; Gonzalez, Y.; Hernández-Sánchez, F.; Miguel, G.F.; Torres, M. Low serum vitamin D levels in
type 2 diabetes patients are associated with decreased mycobacterial activity. BMC Infect. Dis. 2017, 17, 1–9.
[CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution






Potentials of Host-Directed Therapies in
Tuberculosis Management
Yash Dara †, Doron Volcani †, Kush Shah †, Kevin Shin † and Vishwanath Venketaraman *
Department of Basic Medical Sciences, College of Osteopathic Medicine of the Pacific, Western University of
Health Sciences, Pomona, CA 91766, USA
* Correspondence: vvenketaraman@westernu.edu; Tel.: +1-909-706-3736
† All of these authors contributed equally to the presented review.
Received: 27 June 2019; Accepted: 2 August 2019; Published: 3 August 2019
	

Abstract: Tuberculosis (TB) remains as a leading cause of mortality in developing countries, persisting
as a major threat to the global public health. Current treatment involving a long antibiotic regimen
brings concern to the topic of patient compliance, contributing to the emergence of drug resistant TB.
The current review will provide an updated outlook on novel anti-TB therapies that can be given
as adjunctive agents to current anti-TB treatments, with a particular focus on modulating the host
immune response to effectively target all forms of TB. Additional potential therapeutic pathway
targets, including lipid metabolism alteration and vascular endothelial growth factor (VEGF)-directed
therapies, are discussed.
Keywords: Mycobacterium tuberculosis; host-directed therapies; autophagy; immune responses
1. Introduction
Tuberculosis (TB), caused by the bacterial pathogen Mycobacterium tuberculosis (M. tb), remains
a leading cause of mortality in developing countries, with approximately one-third of the global
population remaining infected and 10 million new cases reported officially to the World Health
Organization (WHO) in 2017 [1]. Currently, the best first-line curative therapy strategy for TB is the
Directly Observed Treatment, Short Course (DOTS), comprising of an antibiotic regimen of isoniazid,
rifampicin, pyrazinamide, and ethambutol for six to nine months, and additional patient monitoring
during the first two initial months. However, due to its long duration and adverse side effects,
patient compliance greatly decreases, leading to discontinuation of DOTS. This has contributed to the
emergence of multidrug-resistant TB (MDR-TB), representing the continuous threat it possesses to
public health and economic growth, globally [2]. As antimicrobial resistance against M. tb increases,
it has become an international priority to develop effective, novel therapeutic approaches.
Recent improvements in the field of genomics have provided insight into various pathways
that can be exploited as targets of possible emerging therapies. Along with the relatively successful
treatment methodology of the pre-chemotherapy era, which demonstrated a capacity of ‘self-cure’
against TB, a shift in focus towards modulating the host immune response as adjunctive therapy,
namely host-directed therapies (HDTs), to meet the needs for nearly all forms of M. tb infections,
including MDR-TB, is underway. The emerging and existing HDT agents and their potentials will be
the subject of the current review.
2. mTOR Inhibition
In recent years, there is an interest in exploiting autophagy pathways via HDTs as an approach
to manage TB [3,4]. This cellular process, involving lysosomal degradation, is essential in the
removal of protein aggregates and damaged cellular organelles that may damage the integrity of
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the cell [3]. A summary of the autophagy pathway is described in the following: as autophagy
begins, a double-membrane bound vesicle containing cytoplasmic material, namely an autophagosome,
is formed. These autophagosomes will fuse with lysosomes to form autophagolyosomes, resulting in
degradation of cellular debris [4]. While this process is complex, there are three required components,
Unc-51-like Kinase 1 complex (ULK1), focal adhesion kinase family interacting protein of 200 kd
(FIP200), and autophagy related protein 13 (ATG13) [4].
Mammalian target of rapamycin (mTOR) is a multi-process regulator, specifically involved in
numerous anabolic pathways, thus being most active when nutrients are readily available, aiding in
cell survivability [4,5]. Typically, mTOR is inactivated in conditions of cellular stress (i.e., hypoxia
and starvation), inducing autophagy. One proposed mechanism of mTOR interaction in autophagy
via phosphorylation of ATG13 to inhibit the actions of the ULK complex [5]. Additionally, another
discussed mechanism is the inhibition of the active form of Beclin-1-regulated autophagy protein [5].
Downstream metabolic effects after mTOR activation have been previously described: mTOR-1 complex
activates SREBP-1 and PPAR-gamma to promote lipogenesis and activates S6K1 to promote glucose
transporter 1 (GLUT-1) synthesis to increase glycolysis and lipogenesis. Additionally, mTOR-1 complex
activates S6K1 to promote protein synthesis [5].
In the case of TB, the key role of autophagy is to restrict M. tb growth and can be triggered to do so
via numerous intracellular cues (i.e., IFN-gamma and vitamin D) [5]. However, it has been observed
that in the presence of M. tb, mTOR activity is continuously expressed, and thus, will promote the
aerobic glycolytic pathway [5]. This shift in metabolism, being similar to the Warburg effect in cancer
cells, is thought to be essential in mounting an immune response against M. tb [6]. Because mTOR
is a negative regulator of autophagy, it can be noted that M. tb survivability is correlated with the
inhibition of autophagolysosome fusion [6]. As such, stimulating autophagy via various pathways
will increase the ability to fight M. tb infection [5–7]. One of the main strategies to tackle M. tb is
through direct inhibition of the mTOR via rapamycin analogs, with greater focus on everolimus due to
its greater bioavailability and lower side effect profile [7]. While the beneficial effects of everolimus
has been demonstrated over the years, it is important to note high doses of everolimus is also an
effective immunosuppressant and has applications in cases of organ transplants and cancer therapies.
There have been discussions of utilizing various drug delivery systems to target M. tb specific cell [4].
Looking at in vivo effects of rapamycin and everolimus reiterates the potential yet further
investigation needed when using mTOR inhibition for treating M. tb infection. In a Zebrafish
model with M. marinum infection, mTOR-deficient Zebrafish cleared infection earlier [8]. In mice
models, rapamycin given to mice at an early age did not significantly change life expectancy or
susceptibility to disease; however, when given at a later age, the mice had better survival expectancy [9].
When rapamycin was given to BCG-vaccinated mice, there was an increase in the vaccination efficacy
against M. tb infection associated with autophagy, increased antigen presentation, and increased
Th1-type immune response [10]. However, when investigating rapamycin efficiency in cells pre-infected
with HIV, the mTOR inhibition was advantageous for M. tb [11]. The rapamycin derivative, everolimus,
also shows promise in vivo. In healthy elderly volunteers given low doses of everolimus, there was a
20% improvement in protection after the influenza vaccination, with low doses showing the lowest
number of adverse events [12]. In contrast, when looking at organ-transplant patients given everolimus,
there was a higher risk of TB and reactivation of latent TB [13]. The doses in this study were higher
than that of the influenza study, and the higher risk associated with higher doses of everolimus could
be overcome with Rifampicin [14]. Overall, more needs to be done to understand the dose-response of
everolimus. Alternatively, enhancing the delivery of such drugs could have better potential against
M. tb. For example, an in vitro study looking at inhalable rapamycin in particles showed “macrophages
exposed to the particles or rapamycin in solution at a concentration of 100 μg/mL over a 24 h period
maintained 79.37 ± 0.72% and 58.33 ± 1.39% viability, respectively” [15]. They further concluded
inhalable rapamycin to be better at clearing M. tb than rapamycin in solution in vitro [15].
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3. Cathelicidin (LL37) Inducers
Cathelicidins are part of the antimicrobial peptide class, with LL37 being the only known human
cathelicidin [16]. They kill mycobacteria, regulate the innate immune system through cytokines
and chemokines, and participate in autophagy [17]. LL37 is 37 amino acids long, alpha-helical,
and cationic making it have a higher affinity to DNA, and aggregates in solution [16]. It penetrates
the bacterial membrane, causing pores and bacterial lysis, but it does not affect mammalian cells
with cholesterol in their membranes [16]. LL37 is described to have both proinflammatory and
anti-inflammatory effects depending on its environment [16]. Cathelicidins are expressed in neutrophils,
monocytes, keratinocytes, lymphocytes, and epithelial cells of the skin, testis, gastrointestinal system,
and respiratory tract [17].
LL37 produced by alveolar macrophages and neutrophils significantly contributes to the growth
inhibition of intracellular pathogens [17]. Specifically, M. tb is shown to induce synthesis of LL37
in epithelial cells, neutrophils, monocyte-derived macrophages, and in alveolar macrophages [17].
However, LL37 levels were undetectable in TB granulomas, indicative of its absence during late stages
of M. tb infection. M. tb increases the amount of LL37 by activating Toll-Like Receptors (TLRs) 2,
and especially 9 [18]. In this proinflammatory pathway, the activated TLR9 will induce the synthesis of
Type I IFN, LL37 and thereby forming M1 macrophages, NETosis (neutrophil extracellular traps) with
DNA complexes, and increased inflammatory cells [16]. When LL37 produced during M. tb infection
triggers formation of NETs, the NET: LL37complexes containing M. tb will then be internalized by the
macrophages, followed by the killing of the pathogen inside the lysosomes [19].
The importance of cathelicidins and their protection against TB are seen in the animal studies
below [20,21]. It has been shown that mycobacterial infection can increase the levels of cAMP,
which inhibits cathelicidins and therefore promotes intracellular M. tb growth. This was demonstrated
in mice lacking the cathelicidin-producing gene. This study used Cramp-knocked out mice (the
gene equivalent to human LL37 gene), to see if it was required for regulating protective immunity
against M. tb in vivo. They describe the experiment as using “Cramp−/−mice in a validated model of
pulmonary tuberculosis and conducted cell-based assays with macrophages from these mice” [20].
The results showed “macrophages from Cramp−/−mice were unable to control M. tuberculosis growth
in an in vitro infection model, were deficient in intracellular calcium influx and were defective in
stimulating T-cells [20]. Additionally, CD4 and CD8 T-cells from Cramp−/−mice produced less IFNβ
upon stimulation. Furthermore, bacterial-derived cyclic-AMP modulated cathelicidin expression
in macrophages” [20]. Thus, it is necessary to have cathelicidins for the innate response to protect
against M. tb infections [20]. In another study, treatment of immunocompromised mice that are latently
infected with M. tb with combination of TNF-alpha, beta-defensin, and LL37 resulted in protection and
prevented reactivation of latent M. tb infection. This further confirms the ability of LL37 in protecting
against reactivation of latent M. tb infection. Still, there is some caution needed when considering LL37
as a therapeutic, as it has been shown that in people who were resistance to Colistin (an antibiotic
usually given as a last line of defense to drug resistant bacteria), were also resistant to LL37 [21].
Recent studies have demonstrated the potential of vitamin D administration to induce LL37
production via activation of TLR2/1 on human macrophages [22,23]. Vitamin D causes increase in
cathelicidin release, which upregulates transcription of Beclin-1 and Atg5, which help in autophagy [24].
It is important to note that without LL37, vitamin D does not decrease M. tb growth, as demonstrated
by using siRNA to knockout LL37 gene [25]. In addition, Vitamin D may also inhibit M. tb growth by
enhancing the ability of monocytes to respond to IFN-gamma [26]. It then seems promising to use
Vitamin D supplementation for individuals more susceptible to M. tb infection, such as HIV patients [27].
However, there are conflicting reports regarding the effectiveness of serum-25 hydroxyvitamin D in
cases of active pulmonary tuberculosis. In one cross-sectional study, it was determined that HIV
patients, testing positive for pulmonary TB, still had greater serum levels of 25-hydroxyvitamin D [27].
While this is at variance with other reports, there are still clinical trials demonstrating beneficial
potential of adjunctive vitamin D supplementation. Since vitamin D, as well as 4-phenylbutyrate
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(PBA), have been shown to induce LL37 release, one study found giving either vitamin D, PBA, or both
in conjunction with chemotherapy to adults with active TB provided beneficial effects towards clinical
recovery [28]. Currently, there is an ongoing clinical trial looking at the effectiveness of vitamin
D supplementation in adjunct to antiretroviral therapy for HIV-infected adults with low serum-25
hydroxyvitamin D since these individuals are at higher risk for mortality, HIV progress, and incidence
of TB [29]. This study’s findings are expected to lead to larger vitamin D supplementation trials for
preventing pulmonary TB in other populations as well [29].
4. Adjunctive Defensin Therapy
Defensins are another group of antimicrobial peptides that are part of the innate immune
system [30]. They are arginine rich, cationic, 16–50 amino acids long, that form beta-sheets held by
three disulfide bonds. Defensins have pharmaceutical potential due to their low molecular weight,
non-specific and broad activity, and are resistant to proteolysis. There are three subfamilies: alpha,
beta, and theta. They differ based on their length, disulfide bond locations, and structure of their
precursor. Alpha and beta are more similar as compared to theta in amino acid sequence, tertiary
structures, and location of their genes on the same chromosome [30]. Defensins are stored in the
granules and lysosomes of innate immune and are released into the environment. They help against
many pathogens, including gram positive and negative bacteria, mycobacteria, fungi, and viruses [30].
There are six subtypes of human alpha defensins. They are stored in neutrophils, as well as
tracheal epithelial cells, saliva, mucosa of the cheeks, submandibular glands, and the Paneth cells of the
small intestines [30]. Alpha defensins work against gram positive and negative bacteria, mycobacteria,
fungi, and viruses. There are 11 subtypes of human beta defensins, which are seen in the intestines,
reproductive system, epithelial cells of the trachea and bronchi, mucous, and macrophages [30].
They have antimicrobial effects on gram positive and negative bacteria, multi-resistant bacteria,
and yeast. As for the theta defensins, they have not been found in humans, and while they have shown
antimicrobial activity, they have not been shown to be effective against mycobacteria [30].
Besides their antimicrobial effects, defensins also increase histamine release by activating mast cells,
increase cytokines, act as ligands, help in wound healing, and beta defensins increase bone growth [30].
More specifically, M. tb infection is frequently associated with the production of human beta
defensin-2 (HBD-2) [31]. It has been shown that M. tb induces HBD-2 mRNA expression in lung
epithelial cells, and alveolar macrophages. HBD-2 peptides are seen in lung epithelial cells and are
more concentrated where there are M. tb clusters [31]. During progressive pulmonary TB, there is
an initial rise in HBD-2, which inhibits bacilli proliferation. During latent TB, there is a continuous
increase in HBD-2, however when TB is reactivated, there is low amounts of defensin [18]. There are
also correlations with alpha defensins and TB, as seen when comparing patients with TB and healthy
individuals who previously had TB both showing an increase in alpha 1, 3, and 4 defensins, seen in
eosinophils [17].
More specific to the subtypes of beta defensins, HBD-1 is constitutively released, whereas 2-4 are
induced by pathogens. HBD-1 and 2 are important for permeabilizing M. tb., and HBD-2 is especially
seen in the respiratory tract where they are induced by bacteria and cytokines, go to macrophages or
phagosomes, and are activated when LPS reacts with TLR4 [17,32]. HBD-4 has shown to be released in
infected macrophages by TLR2/1 stimulation induced by IL-1B and vitamin D [17,32]. L-isoleucine has
also shown to upregulate gene expression of HBD-3 and 4, which lowers the bacilli load [32].
One mechanism as to how defensins work was shown in vitro, where they used 50 mg/mL to
inhibit M. tb growth, independent of calcium and magnesium [33]. Lesions were seen on the surface of
the bacteria [33]. This means there is an increase in permeabilizing the cell membranes of the bacteria,
which was further shown to occur extracellularly or during phagocytosis. Defensins are also attracted
to glycoproteins to kill viruses with envelopes, and polyanionic structures such as DNA. The cationic
properties of defensins also enable them to be attracted towards the anionic phospholipids of bacteria
and viruses, in addition to DNA [32].
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Another mechanism of defensins is their chemotactic effects [32]. Alpha defensins recruit
macrophages, while beta defensins recruit immature T-cells and dendritic cells through CCR6 receptors.
Theta defensins have no chemotactic effects [32]. M. tb causes macrophages to release HBD-2 through
TLR and recognizing pathogen-associated molecular patterns such as peptidoglycan and lipoteichoic
acid. This is done through MAPK or NF-kB, which further causes proinflammation and cytokines to
be released [32].
Looking from a future pharmaceutical and therapeutic perspective, some of the challenges include
the excessive cost, increase in concentration causing cytotoxicity, and being less stable in vivo [30,32].
Still, there have been positive signs in using defensins at much lower concentrations in vivo. In this
study, mice infected with M. tb needed 5 μg of HNP-1 given subcutaneously to have a significant
decrease in CFU from the lungs in a matter of 1 week. Even further, “therapy with 1 μg of HNP-1 also
resulted in a significant decrease in CFU from lungs after 2 and 4 weeks (P < 0.01 for both time points)
compared to controls” [34]. Alternatively, another in vivo study successfully used L-isoleucine to
induce beta-defensins. Mice were infected with M. tb for 60 days were then given 250 μg of intratracheal
L-isoleucine every 48 h. The results showed “administration of l-isoleucine induced a significant
increase of beta-defensins 3 and 4 which was associated with decreased bacillary loads and tissue
damage” [35]. However, another challenge to be aware of is how bacteria resistant to antibiotics with
the mprF gene seem also to be resistant to antimicrobial peptides. This is because that gene makes
the pathogen less negatively charged. However, because defensins are non-specific, there is overall
fewer resistant bacteria to this anti-microbial peptide (AMP) compared to antibiotics [32]. There have
been few reports of administering defensins as therapy. Most promising is their synergistic effects with
anti-Tb drugs, by increasing the permeability of the bacteria, allowing the drugs to interact with its
intracellular target more easily [32]. More research should investigate the effects of L-isoleucine and
vitamin D as well.
5. Metformin
Metformin, a widely known diabetes drug, is one of the front-line medications in the management
of type 2 diabetes. Metformin promotes autophagy by altering the AKT-mTOR signaling pathway [36].
It increases phosphorylation of AMPK and decreases the production of various cytokines [36].
Experimental TB mice model studies demonstrated the potential benefits metformin has in improving
pulmonary pathology and reducing bacterial load. However, modest effects were shown when
metformin was used as an adjunctive therapy with isoniazid, a common anti-TB drug [37]. With recent
cohort studies performed in India and Taiwan, there is increasing evidence suggesting metformin
usage being associated with a lower risk of incident TB [38,39]. Further clinical research is needed in
thoroughly understanding the role of metformin in diabetic patients infected with TB.
6. Statins
Altering lipid metabolism via statin therapy is another potential target for novel TB
management therapies [7]. Statins (HMG-CoA reductase inhibitors) are utilized to lower serum
LDL cholesterol to prevent issues like atherosclerosis. In addition, statins are also known to
have anti-inflammatory effects mediated by transforming growth factor-beta and peroxisome
proliferator-activated receptor-gamma [40]. In the case of TB, statins promote phagosome maturation
and induce autophagy through reductions in cholesterol levels since mycobacteria preferentially
utilizes lipid carbon sources as nutrients [41]. Experimental studies using the statin simvastatin as an
adjunctive therapy in conjunction with rifampicin, isoniazid, and pyrazinamide resulted in significant
reduction in the bacterial burden [42]. Despite being very promising, a large retrospective analysis of
statin usage for diabetic patients infected with M. tb were not associated with a protective effect [43].
Therefore, it is essential to perform additional research in this area to determine optimal statin agents,
including repurposing current FDA-approved drugs, with appropriate dosing schedules for the most
effective results.
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7. Additional Approaches
Additional emerging approaches that have not been discussed extensively in the literature include
nanoparticles, vitamin A supplementation, and anti-VEGF inhibitors.
Nanoparticles show high promise as an innovative drug delivery platform by providing a
controlled environment in which various drugs can be continuously released to improve treatment
outcomes [44]. Numerous studies have demonstrated enhanced intracellular accumulation of
three anti-TB drugs, namely isoniazid, rifampin, and streptomycin [44]. Antimicrobial activity
of isoniazid and streptomycin was enhanced, while there was no notable change in rifampin activity
while encapsulated in nanoparticle [44]. As improvements in stability of these nanoparticles
system progress, it is highly possible that novel adjunctive therapies can be administered via
nanoparticle encapsulation [44]. The other potential with using nanoparticles is lowering cytotoxicity,
as demonstrated in a Zebrafish model of tuberculosis study, when thioridazine was encapsulated in
a nanoparticle, no toxicity was detected compared to free thioridazine. This study also found the
thioridazine nanoparticle therapy improved rifampicin’s effect against M. tb in vivo [45].
Vitamin A deficiency has been observed in patients with TB. The deficiency of vitamin A in
patients with TB might be a contributor to the development of TB [46]. Alternatively, deficiency
could be the result of loss of appetite, poor intestinal absorption, increased urinary loss of vitamin A
due to TB [46]. Vitamin A deficiency lowers immunity whilst vitamin A supplementation reduces
morbidity and mortality, particularly from measles and diarrhea. Vitamin A supplementation also
decreases the mortality rate in HIV-infected children and delays the progression to AIDS in HIV
infected subjects [46]. A higher incidence of lung cancer and increased mortality have been observed
in smokers after beta-carotene supplementation. It is thought that multiple micronutrients rather than
vitamin A alone may be more beneficial in patients with TB. However, further research is needed to
be conclusive.
Since TB granulomas feature abnormal vasculature, there is discussion of administering anti-TB
drugs in conjunction with antiangiogenic (anti-VEGF) agents, such as bevacizumab [47]. This has the
potential to improve delivery of antimicrobial drugs into granulomas and stimulate sensitivity to drug
treatment through improved oxygen delivery into the lesions during the window of normalization [47].
Furthermore, this type of ‘host-directed therapy’ that targets the abnormal granuloma vasculature
and reduces hypoxia may lead to a more robust immune response again the bacteria. Through this
mechanism, vessel normalization has the potential to reduce the overall duration of TB chemotherapies
and possibly avoid localized exposure of the bacterium to monotherapy, thereby avoiding the
development of drug resistance, which is one of the main issues in the global control of TB [47].
8. Conclusions
A current review of the developing HDT agents presents as a challenge due to the broad spectrum
of research within the field. Current data, both pre- and clinical, is insufficient to draw major conclusions
regarding the efficacy and potency of these developing therapy strategies (summary of recent studies
has been summarized in Table 1). In addition, it is important to note that most of these agents still
need to be researched in clinical settings. At the time of writing this review article, there are three
phase 2 clinical trials, NCT0296892 (everolimus, auranofin, vitamin D, CC-11050), NCT03160638
(azithromycin), and NCT03281226 (N-acetylcysteine), that are active, with two of them recruiting
patients to demonstrate the efficacies of these various HDT therapy strategies. These data sets can
potentially change current anti-TB protocols and induce a shift in direction for anti-TB therapies.
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Table 1. Host-Directed Therapies against TB: Recent Clinical and Additional Studies.
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By modulating key host proteins, there remains the possibility of adverse unintended consequences.
Nonetheless, novel approaches using HDTs can also provide with benefits in additional contexts,
including immune responses to other organisms that may not pertain to TB infections. Additionally,
it is just as important to identify new biomarkers to diagnose TB earlier with the hopes of preventing
disease progression. Current TB diagnostic methods present with serious limitations in either precision
or efficacy. This delays the diagnosis of TB significantly, further aiding in the complexity of the disease.
With current advancements in biosensing technologies and point-of-care diagnostic tools, there is large
potential to improve detection of TB. These approaches to managing and diagnosing TB, along with
advancements in genomics and technology, can result in precise and effective novel therapies with the
hopes of mitigating the global burden mycobacterial infections present. From a clinical perspective,
these approaches are still in a relative infancy.
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Zwierzchowski, L.; Bagnicka, E. Defensins: Natural component of human innate immunity. Hum. Immunol.
2013, 74, 1069–1079. [CrossRef]
31. Rivas-Santiago, B.; Schwander, S.K.; Sarabia, C.; Diamond, G.; Klein-Patel, M.E.; Hernández-Pando, R.;
Ellner, J.J.; Sada, E. Human β-Defensin 2 Is Expressed and Associated with Mycobacterium tuberculosis
during Infection of Human Alveolar Epithelial Cells. Infect. Immun. 2005, 73, 4505–4511. [CrossRef]
32. Miyakawa, Y.; Ratnakar, P.; Rao, A.G.; Costello, M.L.; Mathieu-Costello, O.; Lehrer, R.I.; Catanzaro, A. In vitro
activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against
Mycobacterium tuberculosis. Infect. Immun. 1996, 64, 926–932. [PubMed]
33. Dong, H.; Lv, Y.; Zhao, D.; Barrow, P.; Zhou, X. Defensins: The Case for Their Use against Mycobacterial
Infections. J. Immunol. Res. 2016, 2016, 1–9. [CrossRef] [PubMed]
34. Sharma, S.; Verma, I.; Khuller, G.K. Therapeutic Potential of Human Neutrophil Peptide 1 against Experimental
Tuberculosis. Antimicrob. Agents Chemother. 2001, 45, 639–640. [CrossRef] [PubMed]
35. Rivas-Santiago, C.E.; Rivas-Santiago, B.; Leon, D.A.; Castañeda-Delgado, J.; Pando, R.H. Induction of
β-defensins by l-isoleucine as novel immunotherapy in experimental murine tuberculosis. Clin. Exp. Immunol.
2011, 164, 80–89. [CrossRef] [PubMed]
36. Lachmandas, E.; Eckold, C.; Böhme, J.; Koeken, V.A.C.M.; Marzuki, M.B.; Blok, B.; Arts, R.J.W.; Chen, J.;
Teng, K.W.W.; Ratter, J.; et al. Metformin Alters Human Host Responses to Mycobacterium tuberculosis in
Healthy Subjects. J. Infect. Dis. 2019, 220, 139–150. [CrossRef]
37. Singhal, A.; Jie, L.; Kumar, P.; Hong, G.S.; Leow, M.K.-S.; Paleja, B.; Tsenova, L.; Kurepina, N.; Chen, J.;
Zolezzi, F.; et al. Metformin as adjunct antituberculosis therapy. Sci. Transl. Med. 2014, 6, 263. [CrossRef]
[PubMed]
38. Marupuru, S.; Senapati, P.; Pathadka, S.; Miraj, S.S.; Unnikrishnan, M.K.; Manu, M.K. Protective effect of
metformin against tuberculosis infections in diabetic patients: An observational study of south Indian
tertiary healthcare facility. Braz. J. Infect. Dis. 2017, 21, 312–316. [CrossRef]
39. Lee, M.-C.; Chiang, C.-Y.; Lee, C.-H.; Ho, C.-M.; Chang, C.-H.; Wang, J.-Y.; Chen, S.-M. Metformin use is
associated with a low risk of tuberculosis among newly diagnosed diabetes mellitus patients with normal
renal function: A nationwide cohort study with validated diagnostic criteria. PLoS ONE 2018, 13, e0205807.
[CrossRef]
92
J. Clin. Med. 2019, 8, 1166
40. Ma, S.; Ma, C.C.-H. Recent development in pleiotropic effects of statins on cardiovascular disease through
regulation of transforming growth factor-beta superfamily. Cytokine Growth Factor Rev. 2011, 22, 167–175.
[CrossRef]
41. Parihar, S.P.; Guler, R.; Khutlang, R.; Lang, D.M.; Hurdayal, R.; Mhlanga, M.M.; Suzuki, H.; Marais, A.D.;
Brombacher, F. Statin Therapy Reduces the Mycobacterium tuberculosis Burden in Human Macrophages and
in Mice by Enhancing Autophagy and Phagosome Maturation. J. Infect. Dis. 2013, 209, 754–763. [CrossRef]
42. Skerry, C.; Pinn, M.L.; Bruiners, N.; Pine, R.; Gennaro, M.L.; Karakousis, P.C. Simvastatin increases the in vivo
activity of the first-line tuberculosis regimen. J. Antimicrob. Chemother. 2014, 69, 2453–2457. [CrossRef]
43. Kang, Y.A.; Choi, N.-K.; Seong, J.-M.; Heo, E.Y.; Koo, B.K.; Hwang, S.-S.; Park, B.-J.; Yim, J.-J.; Lee, C.-H.
The effects of statin use on the development of tuberculosis among patients with diabetes mellitus. Int. J.
Tuberc. Lung Dis. 2014, 18, 717–724. [CrossRef]
44. Anisimova, Y.; Gelperina, S.; Peloquin, C.; Heifets, L. Nanoparticles as Antituberculosis Drugs Carriers: Effect
on Activity Against Mycobacterium tuberculosis in Human Monocyte-Derived Macrophages. J. Nanopart. Res.
2000, 2, 165–171. [CrossRef]
45. Vibe, C.B.; Fenaroli, F.; Pires, D.; Wilson, S.R.; Bogoeva, V.; Kalluru, R.; Speth, M.; Anes, E.; Griffiths, G.;
Hildahl, J. Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against
mycobacterial infection in zebrafish. Nanotoxicology 2015, 10, 680–688. [CrossRef]
46. Mathur, M.L. Role of vitamin A supplementation in the treatment of tuberculosis. Natl. Med. J. India 2007,
20, 16–21.
47. Polena, H.; Boudou, F.; Tilleul, S.; Dubois-Colas, N.; Lecointe, C.; Rakotosamimanana, N.; Pelizzola, M.;
Andriamandimby, S.F.; Raharimanga, V.; Charles, P.; et al. Mycobacterium tuberculosis exploits the formation
of new blood vessels for its dissemination. Sci. Rep. 2016, 6, 33162. [CrossRef]
48. Harbut, M.B.; Vilchèze, C.; Luo, X.; Hensler, M.E.; Guo, H.; Yang, B.; Chatterjee, A.K.; Nizet, V.; Jacobs, W.R.;
Schultz, P.G.; et al. Auranofin Exerts Broad-Spectrum Bactericidal Activities by Targeting Thiol-Redox
Homeostasis. Proc. Natl. Acad. Sci. USA 2015, 112, 4453–4458. [CrossRef]
49. Lin, K.; Obrien, K.M.; Trujillo, C.; Wang, R.; Wallach, J.B.; Schnappinger, D.; Ehrt, S. Mycobacterium
Tuberculosis Thioredoxin Reductase Is Essential for Thiol Redox Homeostasis but Plays a Minor Role in
Antioxidant Defense. PLoS Pathog. 2016, 12, e1005675. [CrossRef]
50. Martineau, A.R.; Timms, P.M.; Bothamley, G.H.; Hanifa, Y.; Islam, K.; Claxton, A.P.; Packe, G.E.;
Moore-Gillon, J.C.; Darmalingam, M.; Davidson, R.N.; et al. High-Dose Vitamin D3 during Intensive-Phase
Antimicrobial Treatment of Pulmonary Tuberculosis: A Double-Blind Randomised Controlled Trial. Lancet
2011, 377, 242–250. [CrossRef]
51. Daley, P.; Jagannathan, V.; John, K.R.; Sarojini, J.; Latha, A.; Vieth, R.; Suzana, S.; Jeyaseelan, L.; Christopher, D.J.;
Smieja, M.; et al. Adjunctive Vitamin D for Treatment of Active Tuberculosis in India: A Randomised,
Double-Blind, Placebo-Controlled Trial. Lancet Infect. Dis. 2015, 15, 528–534. [CrossRef]
52. Tukvadze, N.; Sanikidze, E.; Kipiani, M.; Hebbar, G.; Easley, K.A.; Shenvi, N.; Kempker, R.R.; Frediani, J.K.;
Mirtskhulava, V.; Alvarez, J.A.; et al. High-Dose Vitamin D3 in Adults with Pulmonary Tuberculosis: A
Double-Blind Randomized Controlled Trial. Am. J. Clin. Nutr. 2015, 102, 1059–1069. [CrossRef]
53. Hasan, Z.; Salahuddin, N.; Rao, N.; Aqeel, M.; Mahmood, F.; Ali, F.; Ashraf, M.; Rahman, F.; Mahmood, S.;
Islam, M.; et al. Change in serum CXCL10 levels during anti-tuberculosis treatment depends on vitamin D
status [Short Communication]. Int. J. Tuberc. Lung Dis. 2014, 18, 466–469. [CrossRef]
54. Salahuddin, N.; Ali, F.; Hasan, Z.; Rao, N.; Aqeel, M.; Mahmood, F. Vitamin D Accelerates Clinical Recovery
from Tuberculosis: Results of the SUCCINCT Study [Supplementary Cholecalciferol in Recovery from
Tuberculosis]. A Randomized, Placebo-Controlled, Clinical Trial of Vitamin D Supplementation in Patients
with Pulmonary Tuberculosis’. BMC Infect. Dis. 2013, 13, 22.
55. Ralph, A.P.; Waramori, G.; Pontororing, G.J.; Kenangalem, E.; Wiguna, A.; Tjitra, E.; Sandjaja; Lolong, D.B.;
Yeo, T.W.; Chatfield, M.D.; et al. L-Arginine and Vitamin D Adjunctive Therapies in Pulmonary Tuberculosis:
A Randomised, Double-Blind, Placebo-Controlled Trial. PLoS ONE 2013, 8, e70032. [CrossRef]
56. Ma, Y.; Pang, Y.; Shu, W.; Liu, Y.-H.; Ge, Q.-P.; Du, J.; Li, L.; Gao, W.-W. Metformin Reduces the Relapse Rate
of Tuberculosis Patients with Diabetes Mellitus: Experiences from 3-Year Follow-Up. Eur. J. Clin. Microbiol.
Infect. Dis. 2018, 37, 1259–1263. [CrossRef]
93
J. Clin. Med. 2019, 8, 1166
57. Novita, B.D.; Soediono, E.I.; Nugraha, J. Metformin associated inflammation levels regulation in type
2 diabetes mellitus-tuberculosis coinfection patients—A case report. Indian J. Tuberc. 2018, 65, 345–349.
[CrossRef]
58. Novita, B.D.; Ali, M.; Pranoto, A.; Soediono, E.I.; Mertaniasih, N.M. Metformin induced autophagy in diabetes
mellitus—Tuberculosis co-infection patients: A case study. Indian J. Tuberc. 2019, 66, 64–69. [CrossRef]
59. Degner, N.R.; Wang, J.-Y.; Golub, J.E.; Karakousis, P.C. Metformin Use Reverses the Increased Mortality
Associated With Diabetes Mellitus During Tuberculosis Treatment. Clin. Infect. Dis. 2017, 66, 198–205.
[CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





Investigating the Role of Everolimus in mTOR
Inhibition and Autophagy Promotion as a
Potential Host-Directed Therapeutic Target in
Mycobacterium tuberculosis Infection
Stephen Cerni 1,†, Dylan Shafer 1,†, Kimberly To 2 and Vishwanath Venketaraman 1,2,*
1 Department of Basic Medical Sciences, College of Osteopathic Medicine of the Pacific, Western University of
Health Sciences, Pomona, CA 91766-1854, USA; stephen.cerni@westernu.edu (S.C.)
dylan.shafer@westernu.edu (D.S.)
2 Graduate College of Biomedical Sciences, Western University of Health Sciences,
Pomona, CA 91766-1854, USA; kimberly.to@westernu.edu
* Correspondence: vvenketaraman@westernu.edu; Tel.: +1-909-706-3736
† These authors contributed equally to this work.
Received: 13 January 2019; Accepted: 8 February 2019; Published: 11 February 2019
	

Abstract: Tuberculosis (TB) is a serious infectious disease caused by the pathogen Mycobacterium
tuberculosis (Mtb). The current therapy consists of a combination of antibiotics over the course of
four months. Current treatment protocols run into problems due to the growing antibiotic resistance
of Mtb and poor compliance to the multi-drug-resistant TB treatment protocol. New treatments
are being investigated that target host intracellular processes that could be effective in fighting Mtb
infections. Autophagy is an intracellular process that is involved in eliminating cellular debris,
as well as intracellular pathogens. Mammalian target of rapamycin (mTOR) is an enzyme involved
in inhibiting this pathway. Modulation of mTOR and the autophagy cellular machinery are being
investigated as potential therapeutic targets for novel Mtb treatments. In this review, we discuss the
background of Mtb pathogenesis, including its interaction with the innate and adaptive immune
systems, the mTOR and autophagy pathways, the interaction of Mtb with these pathways, and finally,
the drug everolimus, which targets these pathways and is a potential novel therapy for TB treatment.
Keywords: Mycobacterium tuberculosis; host-directed therapies; immune responses
1. Introduction
Tuberculosis (TB) is an ancient infectious disease caused by Mycobacterium tuberculosis (Mtb)
that still plagues the modern world. Mtb has survived over 70,000 years, and today actively infects
around 10 million people annually and lies latent in 1.7 billion people worldwide (23% of the global
population) [1]. Claiming over a million lives a year, TB is the leading cause of death by an infectious
agent over human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS).
Additionally, immunocompromised individuals, such as those with HIV and type 2 diabetes (T2DM)
are at a greater risk of developing active TB. The common treatment for drug-sensitive pulmonary TB
by the World Health Organization (WHO) is the Directly Observed Treatment, Short Course (DOTS).
DOTS is comprised of an antibiotic regimen of isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA),
and ethambutol (ETH) in the initial phase for 2 months, followed by INH and RIF in the continuation
phase for 4 months. DOTS therapy is currently the best curative treatment for TB, but the long duration
and potential adverse side-effects cause a high non-compliance/drop-out rate. Patient non-compliance
increases the risks for development of drug-resistant TB and contributes to TB’s status as one of the
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top ten causes of death globally [2]. TB’s continuous threat to public health warrants investigation into
more effective treatments.
A relatively new modality of TB treatment is called Host Directed Therapy (HDT). HDT aims
to augment the endogenous host immune system to battle TB infection, through the use of
pharmacology [3]. One target of interest for HDT in TB treatment is autophagy. Autophagy is an
intracellular homeostatic process that degrades damaged cellular components and organelles during
times of cellular stress via lysosomal degradation [4]. This process is also part of innate immunity and
is involved in eliminating intracellular pathogens. Autophagy is also involved in adaptive immunity
and might facilitate antigen presentation, which eventually leads to granuloma formation. Mtb is able
to hinder the host cells’ ability to complete autophagy, through the modulation of mammalian target of
rapamycin (mTOR). Everolimus, a potential HDT, might be able to modulate this effect on mTOR and
could be a novel treatment for Mtb. Here, we have investigated the role of mTOR in the intracellular
autophagy of Mtb and its implication as a target for future treatment.
2. Autophagy Overview
Autophagy is a homeostatic cellular process that involves removing protein aggregates and
damaged organelles via lysosomal degradation. This process is crucial for cells to survive under
stressful conditions and involves eliminating unnecessary or damaged elements from the cell [5].
It is also a key process for removing invading pathogens, making it a potential target for directed
therapies [4,6]. Autophagy has many different subtypes based on the target of degradation and
can be selective (for a particular organelle or pathogen) or non-selective (also referred to as macro
autophagy or bulk autophagy). For the purposes of this review, we will focus on xenophagy, which is
a type of selective autophagy that specifically targets intracellular pathogens [5]. We will review the
general process of autophagy as well as specific autophagic processes as they pertain to Mtb, including
interactions with the innate and adaptive immune systems. An investigation of the relationship
between autophagy and Mtb is critical in understanding the potential targets of HDT.
Autophagy begins with the formation of an autophagosome, which is a double-membrane-bound
vesicle that contains cytoplasmic material [4]. These autophagosomes are non-degradative until
they come in contact with lysosomes, forming an autolysosome, which enables them to degrade
their contents [4,7]. The induction of autophagy is complex but involves three main components,
the phosphoinositide 3-kinase complex 3 (PI3KC3), Unc-51-like Kinase 1 complex (ULK1), and the
autophagy-related protein (ATG) complex [6]. The process of autophagy is inhibited by the mTOR
complex [6], which is a focus for potential Mtb therapeutics. The specific mechanisms of this interaction
will be discussed later in this review. Autophagy is not a single pathway and has many effects, both,
with the innate immune system and the adaptive immune system. In this review, three autophagy
pathways will be discussed: direct pathogen degradation (also referred to as xenophagy), interaction
with the innate immune system, and interactions with the adaptive immune system [7].
Xenophagy is a specific type of autophagy that describes the process of delivering intracellular
pathogens to lysosomes via autophagic mechanisms [4]. The precise mechanisms of xenophagy are
not well understood; however, there are several proposed hypotheses [7]. An overview of xenophagy
can be seen in Figure 1. There are three general steps in the autophagy pathway: initiation, elongation
of the autophagosome, and maturation of the autophagolysosome and degradation of its contents.
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Figure 1. Xenophagy Pathway Overview. Cellular stress including starvation or hypoxia can trigger
the autophagy pathway by relieving inhibition by mammalian target of rapamycin 1 (mTOR1).
In the case of xenophagy, autophagic mechanisms are triggered by an intracellular pathogen.
The pathway begins with phosphorylation of the Unc-51-like Kinase 1 (ULK1) complex, which activates
the phosphoinositide 3-kinase complex 3 (PI3KC3) complex. This begins the double-membraned
autophagosome formation, which is derived from the endoplasmic reticulum (ER). The next step is
elongation and closure of the autophagosome. An autophagy-related protein (ATG) complex comprised
of ATG5, ATG12, and ATG16 is involved in this next step. Microtubule-associated protein 1A/1B-light
chain 3 (LC3) is also conjugated to the membrane, at this step. Phosphatidylinositol 3 phosphate (PI3P)
produced by the PI3KC3 complex is necessary for autophagosome closure, as well. The final step is
fusion with a lysosome forming an autolysosome, degrading its contents. VMP1: vacuole membrane
protein 1, FIP200: focal adhesion kinase family interacting protein of 200kd, WIPI: WD repeat domain
phosphoinositide-interacting protein 1, DFCP1: double FYVE domain-containing protein 1.
Before the autophagy mechanisms begin, the intracellular pathogen is tagged with ubiquitin.
The process of tagging intracellular bacteria is similar to that of tagging endogenous proteins or
organelles for destruction via ubiquitination [6]. Autophagy receptors play an important role in target
recognition and delivery to the autophagosome [8]. These specific mechanisms will be discussed
in the innate immune system section. The next step is the initiation of autophagosome formation.
Generally, autophagy begins with inhibition of mTOR, which results in translocation of the mTOR to
the endoplasmic reticulum (ER) and the subsequent phosphorylation of the ULK1 complex, inducing
autophagy [9]. This leads to the recruitment of PI3KC3, which produces phosphatidylinositol 3
phosphate (PI3P); this is essential for the autophagosome formation via the double FYVE-containing
protein 1 (DFCP1) and the beta transducin (WD)-repeat domain phosphoinositide-interacting (WIPI)
proteins [8,10]. Vacuole Membrane Protein 1(VMP1) also appears to play a role in the autophagosome
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formation, via interaction with beclin 1 and the ULK1 complex [4,8]. The last step of the autophagosome
formation requires an ATG12–ATG5 complex and a Microtubule-associated protein 1A/1B-light
chain 3 (LC3). The final step of autophagy is the fusion of the autophagosome with the lysosomal
compartment [4]. This leads to the formation of the autophagolysosome, which ultimately degrades
the pathogen.
In addition to pathogen degradation via xenophagy, autophagy may modulate the innate and
adaptive immune systems [4]. With respect to the innate immune system, autophagy can both
enhance interferon production and prevent excessive innate immune system activity from being
detrimental [4]. With respect to adaptive immunity, autophagy is reportedly involved with both the
delivery of exogenous and endogenous antigens to major histocompatibility complex (MHC) class II
antigen-presenting molecules and the presentation of viral antigens by MHC class I antigen presenting
molecules [4].
3. Autophagy and TB in the Innate Immune System
There appear to be two autophagy pathways involved in an Mtb infection, which ultimately
lead to the formation of an autolysosome. These pathways are illustrated in Figure 2. The first
classical pathway is xenophagy, which is triggered by a mycobacterial infection via activation of the
bacterial early secretory antigenic target (ESAT)-6 secretion system (ESX-1), leading to a disruption
of the phagosome membrane [11,12]. The bacterial DNA is next recognized via the stimulator of
interferon genes (STING)-dependent pathway which recognizes DNA on the surface of the bacteria [11].
This STING pathway then leads to the direct ubiquitination of the bacteria, which involves activity
by the parkin ligase, the Smurf1 ligase, and the TRIM3 ligase [13–16]. The parkin ligase specifically
mediates the linkage of K63 ubiquitin chains [14] and the Smurf1 ligase mediates the linkage of K48
ubiquitin chains [15]. Next, the ubiquitin LC3-binding autophagy adaptors p62 and NPD52 bind
ubiquitin, leading to the recruitment of autophagic components, which create a phagophore around
the bacteria [11].
An offshoot of this classical pathway involves the murine immunity-related p47 guanosine
triphosphatase family M protein 1 (IRGM1). IRGM1 is thought to contribute to this pathway through
stabilization of autophagy factors and adenosine monophosphate (AMP)-activated protein kinase
(AMPK) [17]. IRGM1 is induced by similar factors that induce general autophagy, including starvation
and IFN-γ [17].
The second pathway involved is called the LC3 associated phagocytosis (LAP) pathway [13].
This pathway differs from the classical autophagy pathway in that it does not involve a double
membrane autophagosome, but rather a single membrane LAPsome [18]. The pathway begins
with Toll-like receptor (TLR) activation by Mtb, which leads to phagocytosis of the pathogen [19].
The phagocytosed pathogen is now in a single-membrane LAPsome, which has PI3P attached to it
(produced by PI3KC3) and includes key LAP proteins, such as Beclin 1 and Rubicon [13]. This leads
to the generation of reactive oxygen species (ROS) via the stabilization of the nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase-2 (NOX2) complex [20]. The combination of PI3P, ROS,
and several other ATGs lead to LC3 being conjugated to the single phagosome membrane [20,21].
This eventually leads to fusion with cellular lysosomes and the destruction of the pathogen [20].
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Figure 2. Autophagy and Mycobacterium tuberculosis (Mtb). The first pathway illustrated in the
classic xenophagy pathway. The phagosome is disrupted by bacterial early secretory antigenic target
(ESAT)-6 secretion system (ESX1). This allows for recognition of bacterial DNA by the stimulator
of interferon genes (STING) pathway, which triggers autophagy. Several ligases are involved in
the ubiquitination of the bacteria, including Tripartite motif-containing protein 3 (TRIM3), Parkin,
and Smurf1. This ubiquitination facilitates recognition of the bacteria by autophagic mechanisms,
leading to the formation of a double-membraned autophagosome. This autophagosome fuses with
a lysosome leading to the formation of an autolysosome and the degradation of bacteria. A second
pathway, and an offshoot of the first xenophagy pathway, involves immunity-related p47 guanosine
triphosphatase family M protein 1 (IRGM1). IRGM1 is triggered by interferon-gamma (IFN-γ) and
leads to the activation of autophagic mechanisms. The specifics of this pathway are unclear, but it
might involve activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK),
which relieves the autophagy pathway of its inhibition by mTOR1. The third and final pathway
is also referred to as the 1A/1B-light chain 3 (LC3) associated phagocytosis (LAP) pathway. Bacteria is
recognized by a toll-like receptor (TLR) and phagocytosed. This process triggers the phosphoinositide
3-kinase (PI3K) complex, leading to the production of PI3P. PI3P leads to the production of reactive
oxygen species (ROS), via stabilization of the nicotinamide adenine dinucleotide phosphate hydrogen
(NADPH) oxidase-2 (NOX) complex. Phosphatidylinositol 3 phosphate (PI3P), ROS, and other
autophagy related proteins (ATGs) lead to the formation of a LAPsome, which is a single-membraned
compartment. Microtubule-associated protein 1A/1B-light chain 3 (LC3) is conjugated to the LAPsome,
which triggers fusion with a lysosome, leading to degradation of the bacteria. NDP52: nuclear domain
10, protein 2.
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The LAP pathway of autophagy can prevent Mtb from inhibiting the maturation of lysosomes.
Mtb is phagocytosed by an actin-mediated membrane that engulfs the bacterium into a phagosome.
Ideally, Rab GTPases activate within the phagosomal membrane to recruit vacuolar ATPases that
acidify the phagosomal contents. Then, the phagosome proceeds to fuse with the lysosome which
further acidifies and degrades bacteria via enzymatic processes. However, Mtb alters the phagosome
trafficking pathway through numerous methods, preventing its own elimination by this process [22,23].
Mtb uses phosphatidylinositol mannoside (PIM) to stimulate Rab14, promoting phagosome fusion
with an early endosome, resulting in the prevention of phagosomal maturation and acidification [24].
Other studies have found Mtb uses Lipoarabinomannan Mannosylated (ManLAM) to interfere with
the calmodulin complex formation with PI3KC3 and the production of PI3P, which is responsible for
the recruitment of vacuolar GTPases to the phagosome, preventing its maturation and fusion with the
lysosome [25]. Mtb also prevents phagosomal maturation by preventing the phagosome from acquiring
Rab5 due to the presence of tryptophan aspartate coat protein (TACO). Through these processes Mtb
resides in the phagosome at a pH of 6.2 rather than the normal physiologic levels, which can reach a
pH of <5.0 [26]. However, when autophagy is induced stronger PI3KC3 and PI3P activation occurs
and Mtb’s inhibition of lysosomal maturation is overcome [27].
4. Autophagy and TB in the Adaptive Immune System
An adaptive cellular immune response is needed to effectively control an Mtb infection. After the
initial innate immune responses, adaptive immunity develops to control the dividing bacteria.
Development of adaptive immune responses occur between 3 to 8 weeks after the initial exposure to
Mtb. Impaired adaptive immunity often results in clinical TB. Effective host immune responses against
Mtb infection are dependent on the optimal interactions between the appropriate T cell subsets and
infected macrophages.
4.1. Type 1 T helper (TH1)
Immunity to Mtb infection is associated with the emergence of protective CD4+ T cells that
secrete cytokines, resulting in the activation of macrophages and recruitment of monocytes for
granuloma formation. Studies in human and animals have demonstrated that acquired immunity
to Mtb involved multiple T cell subsets with a dominant role of CD4+ T helper cells and aid from
the CD8+ T cells [28]. Type 1 T helper (Th1) cells produce interferon-gamma (IFN-γ), interleukin,
(IL)-2, and tumor necrosis factor (TNF)-beta, which activate macrophages and are responsible for
cell-mediated immunity and phagocyte-dependent protective responses. These CD4+ Th1 cells may
recognize mycobacterial fragments by the presence of MHC II class molecules on the antigen-presenting
cells, such as macrophages, although this concept is debated in recent literature as Mtb may have some
mechanisms for inhibiting MHC II presentation [29]. Mice with deleted genes for CD4+ or MHC class
II molecules are significantly susceptible to Mtb infection, strongly establishing the central protective
role of the CD4+ T cells [30,31]. Additionally, loss of the CD4+ cell number and function, during the
advanced stages of HIV infection, results in progressive primary infection, reactivation of endogenous
Mtb, and increased susceptibility to re-infection [32].
Following phagocytosis of Mtb by macrophages and dendritic cells, IL-12 secretion is induced,
driving the development of a Th1 response with the production of IFN-γ. IFN-γ is involved in the
recruitment of T-cells, in the induction of expression of the MHC class II molecules, in the augmentation
of antigen presenting cells (APCs), and in the control of Mtb growth [33]. Additionally, IFN-γ promotes
cellular proliferation, cell adhesion, apoptosis, and autophagy [34]. IL-12 is crucial for generation of a
protective immunity, with its main function being the induction of expression of IFN-γ and activation
of antigen-specific lymphocytes. Mice with deleted IL-12p40 gene were more susceptible to infection,
had increased bacterial burden, and decreased survival time compared to control mice [35]. IFN-γ has
been established as the principal mediator for a protective immune response to Mtb infection. IFN-γ
100
J. Clin. Med. 2019, 8, 232
knockout (GKO) mice formed defective granulomas and failed to produce nitrogen intermediates [36].
CD8+ cells also secrete IFN-γ but to a lesser extent than that of the CD4+ T cells [34].
4.2. Granuloma Formation
Granuloma formation is the hallmark immunopathology of TB, providing a microenvironment
for the T cell activation of infected macrophages, to the inhibition of bacterial growth, and localization
of the inflammatory and immune responses to the site of infection. Granuloma formation is largely
dependent on T cell-mediated immune responses and macrophage-derived cytokines, such as IFN-γ
and members of the TNF superfamily [37]. Immediate and sustained secretion of chemokines is
essential for the recruitment, migration, and aggregation of monocytes and lymphocytes to form
granulomas at the sites of Mtb infection [38]. Granulomas are composed of various immune
cells, including macrophages, dendritic cells, T cell, fibroblasts, epithelioid histiocytes, giant cells,
and natural killer cells [37]. The granuloma provides a physical barrier which encapsulates and
prevents bacteria from spreading. This local environment allows these immune cells to interact and
to effectively kill Mtb, which is achieved by macrophage activation and creating an oxygen and
nutrient-deprived environment [39]. Critical to granuloma formation is tumor necrosis factor-alpha
(TNF-α). Mice deficient in TNF-α or the 55 kDa TNF receptor, died a rapid death, and with a sustainably
higher bacterial burden, compared to control mice [40]. Another study showed structural deficiencies
in granulation formation in the TNF-α gene-targeted mice. Therefore, TNF-α has a central role in
anti-TB immunity, through generation of structurally effective granulomatous response [41].
The failure of the macrophages to acquire mycobactericidal function is likely is due to the
host’s inability to generate a sufficient Th1 cell-mediated response. Individuals with compromised
cell-mediated immunity, such as HIV-positive patients and diabetic patients, are highly susceptible to
Mtb infection. A mechanism of immunosuppression is attributed to decreased levels of GSH, which has
been shown in HIV and in individuals with T2DM [42,43]. Supplementation with GSH can help restore
cytokine balance and enhanced granulomatous response [42–44]. GSH is an essential component of
intracellular antioxidant systems and functions in the protection of cells against oxidative stress and in
maintaining redox homeostasis [45]. GSH could be a potential adjunct therapy to antibiotics and new
host-directed therapies in helping relieve oxidative stress in cells.
4.3. Autophagy and Adaptive Immunity
Autophagy contributes to the crosstalk between the innate and adaptive immune response in Mtb
infection by enhancing antigen presentation. Autophagy is reportedly involved in both the delivery of
exogenous and endogenous antigens to MHC class II antigen presenting molecules, along with the
presentation of viral antigens by MHC class I antigen presenting molecules [46]. Various authors have
shown how autophagy can contribute to the MHC class II presentation, which is particularly important
in Mtb defense [47,48]. The antigenic contents of the autophagosomes are degraded when they fuse
with lysosomes. Then, within the multi-vesicular MHC-II loading compartments (MIICs), the antigenic
peptides are fashioned into MHC-II binding groves by the HLA-DM. Autophagy increases the MIIC
turnover and strongly improves the MHC class II presentation to CD4+ T cells [7]. A study conducted
by Jagannath C. et al., 2009 showed autophagy augmented the efficacy of the BCG vaccine in mice,
by improving antigen presentation by antigen presenting cells [49].
In addition to antigen presentation, the adaptive immune system and autophagy maintain a
synergistic relationship through the production of cytokines in the defense of Mtb. IFN-γ produced by
Th1 cells induces autophagy [28,29]. In turn, autophagy has been shown to increase the production
of TNF-α, IL-6, and IL-8 [7]. In mice, IFN-γ produced by Th1 cells promotes the expression of a p47
resistance GTPase, called IFN-γ-inducible protein (LRG-47) [30,31]. It is suspected that LRG-47 prompts
the creation of autophagolysosomes in the defense of Mtb [30]. Multiple experiments have shown that
inhibition of certain ATGs, like Beclin-1, and treatment with autophagy inhibitor 3-MA in both murine
and human models showed reduction of TNF-α, IL-6, and IL-8 [32]. Each of these cytokines play an
101
J. Clin. Med. 2019, 8, 232
important role in the inflammatory response against Mtb: IL-8 helps recruit neutrophils, IL-6 stimulates
production of acute phase reaction, and TNF-α is essential in the production of granuloma formation.
These findings point towards autophagy as a potent regulator of host defense against Mtb.
5. mTOR
The mammalian target of rapamycin (mTOR) is a regulator of many cellular processes involved
in growth and differentiation. It is involved in many anabolic pathways and blocks catabolic processes,
such as autophagy [50]. mTOR is active when nutrients are readily available to the cell, and is
inactivated during times of starvation, leading to the induction of autophagy, which helps the cell
survive under these unfavorable conditions [51]. The pathway discussed in this review is also referred
to as the Protein kinase B (AKT)/mTOR pathway; illustrated in Figure 3.
Figure 3. Mammalian target of rapamycin (mTOR) pathway. mTOR1 is triggered by certain growth
factors and is generally anabolic, making it an important enzyme in both cancer and processes related
to autophagy. Cellular stressors, such as hypoxia or cellular starvation, lead to the inhibition of
mTOR, thus, activating the autophagy pathway. mTOR1 inhibits specific enzyme subunits in the
autophagy pathway, including Unc-51-like Kinase 1 complex (ULK1), autophagy related protein
13 (ATG13), and activating molecule in Beclin 1-regulated autophagy protein 1 (AMBRA). mTOR1
activation has several metabolic downstream effects, including increased lipogenesis, increased
glycolysis, and increased protein synthesis. mTOR is inhibited by compounds in the rapamycin
pathway, including everolimus. PI3K: phosphoinositide 3-kinase, AKT: Protein kinase B, PRAS 40:
proline-rich AKT substrate of 40kd, PRR5: proline-rich protein 5, AMPK: adenosine monophosphate
(AMP)-activated protein kinase, SREBP1: sterol regulatory element-binding protein 1, PPAR γ:
peroxisome proliferatory-activated receptor γ, GLUT1: glucose transporter 1, FIP200: focal adhesion
kinase family interacting protein of 200 kd.
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mTOR’s specific interaction with autophagic mechanisms has been clarified recently. mTOR
interacts with the ULK complex, consisting of the ULK1, FIP200, and ATG13 [52]. mTOR
phosphorylates ATG 13, inhibiting the function of the ULK complex [53]. There has also been another
proposed mechanism of mTOR autophagy regulation that involves the beclin1 complex. mTOR may
inhibit activating molecule in Beclin 1-regulated autophagy protein (AMBRA1), a component of the
beclin1 complex [54]. AMBRA1 activity is thought to enhance the ULK1 complex kinase activity [54].
In this way, autophagy is regulated at several points by mTOR, in response to cellular energy demands.
As stated earlier, autophagy is induced by cellular stressors, such as starvation. In a low nutrient
or hypoxic environment, mTOR is inactivated, leading to the induction of autophagy [51]. In addition
to inhibiting autophagy, mTOR leads to the activation of many metabolic processes, such as glucose
metabolism and protein and lipid synthesis [6]. Namely, mTORC1 and mTORC2 increase glycolysis
and increase glucose transporter 1 (GLUT1) expression [55]. mTOR is also thought to regulate
lipogenesis, via regulation of the activity of peroxisome proliferatory-activated receptor (PPAR) γ [56].
6. mTOR in TB
mTOR’s activity can be modulated by Mtb infection [57]. Mtb increases mTOR activity as measured
by increased activity in downstream mTOR targets [57]. This is thought to be why there is an increase
in cellular aerobic glycolysis [57]. This increase in glucose metabolism is also thought to be a key step
in mounting a sufficient immune response against Mtb [57]. This metabolic shift during a Mtb infection
is similar to that of the Warburg effect in cancer cells [58]. The Warburg effect occurs when cancer cells
preferentially metabolize glucose by glycolysis, producing lactate, despite having adequate oxygen to
undergo oxidative phosphorylation [59].
Another defense mechanism that could be effective in fighting an Mtb infection, is the induction
of autophagy in granulomas. As discussed earlier, granulomas are a key process in walling off and
fighting an Mtb infection, due to their ability to foster a beneficial environment for immune cells,
as well as provide a physical barrier that prevents the infection from spreading. Additionally, however,
granulomas may also provide an environment that fosters autophagic mechanisms. The hypoxic
environment in specific types of granulomas has been shown to inhibit mTOR, inducing autophagy, as
measured by increased levels of key autophagic enzymes [60].
7. Treatment
Several promising HDT strategies exist for the fight against Mtb. Strategies that specifically
enhance autophagy can be divided into two categories—those involved in inhibiting the mTOR
pathway and those that are not. Several points in the AKT/mTOR pathway might be targeted
to promote autophagy, such as mTOR itself or AMPK. Direct inhibition of the mTOR complex by
rapamycin and its analogs, also referred to as “rapalogs,” is a well-established mechanism to promote
autophagy [61]. Activation of AMPK by Metformin also promotes autophagy, via inhibition of mTOR1
(although its role in Mtb therapy needs further research) [62]. Drugs that inhibit ATGs and PIK3C3 are
also being developed, although inhibition of these enzymes may not completely stop autophagy from
occurring [4].
There are also several mTOR-independent targets which can promote autophagy. Ca+ channel
blockers, such as Clonidine and Minoxidil, have been found to induce autophagy by increasing the
levels of LC3 [63]. Several antipsychotics, such as lithium and valproic acid, also act to increase
autophagy by decreasing levels of myo-inositol-1,4,5-triphosphate (IP3), which is thought to promote
autophagy, although this mechanism is poorly understood [64]. Lithium has been shown to inhibit
the growth of other mycobacterium species, but further studies need to be performed to establish
its role in the pathogenesis of Mtb [65]. Numerous other drugs have proposed autophagy inducing
mechanisms, such as resveratrol, spermidine, EGFR antagonists, vitamin D, and drugs that affect
Beclin1 or nitrous oxide (NO) [3,4], although more investigation needs to be done on their therapeutic
effect, specifically for Mtb. Further discussion of these drugs is outside of the scope of this review,
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but it is worth mentioning the numerous potential targets of HDT in the search of better, more effective
treatments of Mtb.
This review will focus specifically on mTOR inhibitors as a potential therapeutic for Mtb treatment.
Inhibition of mTOR by rapamycin analogs promotes autophagy, increasing the macrophages’ ability
to fight Mtb infection. Rapamycin analogs include sirolimus, temsirolimus, and everolimus [61].
These drugs have traditionally been used as anti-cancer treatments, due to their growth-suppressing
effects, however, they are being investigated for the treatment of TB, due to their effect on the
AKT/mTOR pathway and their autophagy. Of these three drugs, everolimus presents as a good
candidate for further investigation as therapy for Mtb infection. Everolimus is a novel inhibitor of
mTOR that could potentially be used as a therapy for Mtb infection and has been shown to decrease
Mtb growth [6]. Everolimus is administered as an oral tablet and has a lower side effect profile than its
injectable counterpart temsirolimus [66]. Additionally, everolimus has a greater bioavailability than
sirolimus and it decreases vascular inflammation, more so than sirolimus [67].
The beneficial effects of everolimus on autophagy must be carefully weighed against its effects on
the immune system, when treating Mtb. At high doses, everolimus is an effective immunosuppressant
and is FDA approved for organ transplant recipients and cancer patients, but at lower doses it has
shown to have an augmentative effect on host immune response [68–70]. A study conducted in
2014 showed that a group of healthy elderly individuals, treated with everolimus, showed a 20%
improvement in their protective response after an influenza vaccination. This response included
the reduced expression of programmed cell death-1 receptor on CD8+ and CD4+ T-cells via the
inhibition of mTOR [69]. The subjects in this study were treated at a lower dose of everolimus than the
transplant patients who are conversely at an increased risk of Mtb infection when using everolimus [6].
A proposed mechanism for delivery of everolimus to target cells infected with Mtb, without causing
systemic immunosuppression, is through an inhaled nanoparticle preparation [71]. An in vitro study of
inhalable rapamycin showed a more effective intracellular clearing of mycobacterium than rapamycin
in solution [72]. These findings suggest that rapalogs, such as everolimus, might have a promising
future as an HDT against TB.
8. Conclusions
Mtb infections pose a major global public health threat. Current treatments still revolve around
antibiotic DOTS therapy. As antibiotic resistance grows other therapeutic targets will become more
and more essential. HDT is a novel treatment strategy, aimed at using host immune mechanisms to
battle infection. In this paper, we investigated the current literature on the AKT/mTOR pathway
and autophagy, and their role in the pathogenesis of Mtb. We also investigated the current literature
on everolimus as a novel therapy for Mtb infection, modulating cellular autophagic mechanisms via
the inhibition of mTOR. The benefits of everolimus include less dependence on the use of DOTS
therapy and the growing threat of resistant Mtb. These benefits must be carefully weighed against the
immunosuppressive effect of everolimus. Novel drug delivery systems, such as inhaled nanoparticles
might address this, although understanding the risks of treatment with each individual patient must
also be carefully considered. Continued investigation of these novel therapeutic targets is crucial to
addressing the global threat of Mtb.
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